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Medication use in the older population
Our western population is ageing, as not only the number of older people is increasing, but 
also the life expectancy.1 In 2012, the Netherlands counted 2.7 million people aged ≥65 
years – corresponding to 16% of the total population –, and this is expected to increase to 
4.7 million in 2041 – corresponding to ~26% of the total population –.2 With respect to health, 
the ageing process is accompanied by morbidities, such as cardiovascular, musculoskeletal, 
and airway conditions, but also cognitive decline, cancer and diabetes.1 In older individuals, 
multiple conditions are regularly present at the same time, of those aged ≥65 years ~65% has 
two or more conditions, which are often treated or managed with medication regimens.3-6 
Improvements in healthcare, disease management and treatment are additive factors 
that facilitate the ageing of the western population.1 On the other hand, use of multiple 
medications for various conditions increases the risk of adverse drug reactions and drug-
drug interactions.3,4 Especially for older individuals this is of importance as – compared to 
younger individuals – they not only use more medicines, they are also more prone to adverse 
drug reactions due to physiological changes, including changes in body composition, blood 
flow, and liver and kidney function.7,8 So, decisions on treatment – medication use – need to 
take into account this precarious balance in order to optimize the health effect. Therefore, 
insight into the potential risks and negative effects are needed. This thesis especially focuses 
on older individuals and fall incidents. Falls can have many causes but may also occur as an 
unintended consequence of medication use, and they are considered as a major health care 
problem in this age group9. Medication-related falls have gained more attention in the recent 
decades, though literature is inconclusive on the medication groups that are associated 
with an increased fall risk.10-15 Moreover, the pathways underlying the association between 
medication use and fall incidents need to be further examined. Therefore, in this thesis we 
addressed medication-related falls and their potential underlying pathways. We examined 
the role of genetic variants in medication-related falls, and whether more knowledge on this 
subject could help to determine individuals at risk for medication-related falls. Furthermore, 
it could provide insight into the biological mechanism involved in medication-related falls. 
In addition to medication-related falls, we investigated homocysteine and bone mineral 
density (BMD). Homocysteine is a risk indicator for various age-related diseases and may be 
related to falls via physical function.16,17 BMD is an indicator for bone health and fracture risk, 
which is of major importance for those at risk for falls.18,19 
Medication use and fall incidents 
As previously indicated, fall incidents are a major health problem in older individuals. Of all 
falls, 5 to 12%20,21 result in serious injuries or fractures requiring medical attention, which lead 
to reduced quality of life and substantial health care costs.22,23 Moreover, approximately one 
third of the older individuals (≥65 y) encounters at least one fall yearly.9 There are multiple 
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risk factors for falling, including; a history of falling, muscle weakness, impaired balance, 
gait, vision and cognition, but also environmental hazards, and medication use.20,24,25 
Medication use is one of the potentially modifiable risk factors for falls.26,27 Psychotropic10-14 
and cardiovascular10,11,13-15 medication have been indicated as the main medication groups 
contributing to an increased fall risk. They may affect fall risk by inducing dizziness, sedation, 
instability, and hypotension.10-15 However, evidence for the association between medication 
use and fall risk is mainly based on observational studies, which have applied varying 
methods for recording fall incidents and medication use. Only a limited number of the 
studies recorded falls prospectively and ascertained medication use at the time of the fall.10 
Therefore, new insight into potential associations between medication use and fall incidents, 
using prospectively gathered medication and fall data are of clinical value (Chapter 2.1). 
Potential pathways of medication-related falls, including genetic 
variation
As described above, older individuals frequently use medication which could next to their 
intended effects, also have unintended effects – including falls –.3,4 On the other hand, 
individuals might not respond to the given medication, which is also an undesired outcome. 
So, overall pharmacological effects of medications vary between individuals, which 
complicates attaining the desired outcome.28-33 There are multiple factors that may play a role 
in medication response, including age, gender, health status, and lifestyle. Genetic variation 
is another factor that may explain interindividual variation and therefore may influence 
medication response. When we are able to identify genetic variants with substantial effects, 
individuals at increased – medication-related fall – risk could be identified based on their 
genetic makeup and treatment could be more targeted.30-33
Benzodiazepine-related falls
Use of benzodiazepines has most strongly and consistently been associated with an increased 
fall risk.10,13,34,35 And, pharmacological effects of benzodiazepines have been observed to be 
influenced by genetic variation.36,37 Nevertheless, limited information is available about the 
role of genetic variation in benzodiazepine-related falls.38 So, more research is needed and 
various approaches can be used.30,31 We chose to follow two approaches: a candidate gene 
study and a genome wide association study (GWAS). The first approach has previously been 
used in a pilot study.38 The authors selected genetic variants in genes encoding medication 
metabolising enzymes, thereby plasma drug concentrations may be influenced and might 
subsequently affect fall risk. Two genetic polymorphisms were identified that modified 
benzodiazepine-related fall risk.38 To confirm this finding, a replication study was performed 
(Chapter 2.2). Nevertheless, a candidate gene approach is restricted to prior knowledge on 
genetic variants that influence a pathway, which may affect the outcome – medication-
related falls –.30,31 The second approach is hypothesis free and can identify genetic variants 
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– out of millions of variants –30,31,39 that significantly modified the association between 
medication use and fall risk (Chapter 2.3). 
Beta-blocker-related falls
Use of beta-blockers has been associated with fall risk, but literature is contradictory.10,40-42 
Pharmacological effects and occurrence of adverse effects may vary between different beta-
blocking agents. Differences between beta-blocking agents relate, for example, to their 
selectivity for adrenergic receptors, lipid solubility, intrinsic sympathetic activity (ISA), and 
their elimination route.43,44 Some beta-blockers are eliminated through liver metabolism – 
e.g., metoprolol and propranolol –,43,44 in which the Cytochrome P450 (CYP) 2D6 enzyme 
plays an important role.45,46 Genetic variation in the CYP2D6 gene might thereby influence 
the elimination of beta-blockers, and potentially subsequent fall risk. In this thesis the 
association between use of beta-blockers and beta-blocker characteristics – selectivity, lipid 
solubility, intrinsic sympathetic activity (ISA), and CYP2D6 enzyme metabolism – and fall risk 
was analysed (Chapter 2.4).
Medication, homocysteine and falls
Homocysteine is an amino acid formed from methionine, an essential amino acid that is 
present in our diet.47 Hyperhomocysteinemia, >15 µmol/L, is prevalent in 10-30% of Dutch 
older individuals48 and is associated with cardiovascular disease,49,50 cognitive decline,51,52 
and fractures.53-55 Furthermore, homocysteine has been related to physical function,16,17 
and thereby it might be related to falls. We did not investigate the association between 
homocysteine and falls, as this was done by Swart et al in the B-PROOF study.16,17 Instead, we 
were interested whether there was an association between medication use and homocysteine 
levels, as potential precursor to an association with falls. In addition to a reduced intake or 
absorption of vitamin B12 and/or folic acid,
47 medication use could, unintentionally, influence 
homocysteine levels.56-58 However, evidence is limited per medication group and results are 
contradictory and inconclusive. More insight into possible medication-related changes in 
homocysteine levels could help to create clinical awareness, and might suggest monitoring 
these levels during the use of specific medications (Chapter 3.1).
Medication, bone mineral density and fractures
Fractures are another important problem in the elderly population, and are related to falls 
and osteoporosis.18,19 Osteoporosis is characterized by loss of bone mass and structure, 
and is currently determined by assessing bone mineral density (BMD).18,19 Use of selective 
serotonin reuptake inhibitors (SSRIs) has been associated with an increased fracture risk, 
potentially because of an underlying association with falls and/or BMD.59-61 The association 
between SSRIs and falls has consistently been reported in literature,11,62,63 while there 
are conflicting results regarding the association between SSRIs and BMD, and change in 
BMD.64-66 In previous studies, use of SSRIs was assessed through interview data and limited 
information was available regarding the duration of use at the study visit or in between the 
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study visits.64-66 Since bone remodeling is a slow process,67 we expected that the duration of 
SSRI use is of importance when examining the association with BMD. Therefore, longitudinal 
studies investigating the association between use of SSRIs and duration of treatment, with 
BMD and change in BMD are of clinical relevance (Chapter 3.2).
Study populations
For this thesis, data from three Dutch studies were used, the Rotterdam Study, B-PROOF, and 
LASA. 
 The B-PROOF study population formed a basis for investigating the research questions 
within this thesis. B-PROOF is an acronym for ‘B-vitamins for the PRevention Of Osteoporotic 
Fractures’. It is a multi-centre, randomized, placebo-controlled, double-blind trial investigating 
the efficacy of vitamin B12 and folic acid supplementation on the prevention of fractures in 
persons aged ≥65 years, with mildly elevated homocysteine levels (12-50 μmol/L).68 
The Rotterdam Study is an ongoing prospective population-based cohort, executed within 
Rotterdam.69 The study aims to investigate the incidence of, and risk factors for various age-
related diseases. The study was initiated in 1989 and in total 7,983 participants, aged ≥55 years, 
were included (78% response rate, cohort I). In 2000, the study was extended with a second 
cohort of 3,011 participants, aged ≥55 years (67% response rate, cohort II). Additionally, in 
2006 a second extension of the cohort was initiated, including 3,923 participants aged 45 
years or older (65% response rate, cohort III). From baseline onwards, follow-up examinations 
were conducted every 4-5 years including interviews and an extensive set of examinations.
 LASA, Longitudinal Aging Study Amsterdam, is also an ongoing prospective population-
based cohort study and started in 1991.70 The study was executed in the surrounding of 
three Dutch cities; Amsterdam, Zwolle and Oss, and aims to examine determinants and 
consequences of physical, cognitive and social aspects in an ageing population. From 
baseline onwards, data was collected approximately every 3 years on these aspects, using 
interviews, questionnaires and examinations.
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Objectives of this thesis
In this thesis, we addressed the association between medication use and fall incidents, and 
their potential underlying pathways. Thereby, we examined the role of genetic variants, 
homocysteine and bone mineral density. The following objectives were addressed:
Objective 1: Which medication is associated with fall risk in the B-PROOF study populations? 
(Chapter 2.1)
Objective 2: Are there genetic variants that modify the association between medication use 
and fall risk? (Chapter 2.2, 2.3 and 2.4)
Objective 3: Is medication use associated with homocysteine levels? (Chapter 3.1)
Objective 4: Is use of SSRIs associated with BMD and change in BMD over time? (Chapter 3.2)
Author contributions
In chapter 2.1 the study concept and design was done by: BHS, AGU, and NvdV. Data analyses 
and interpretation was done by: ACH, BHS, AGU, and NvdV. Drafting the manuscript was 
done by: ACH and NvdV. Revising the manuscript was done by: all authors. The study 
was supervised by: BHS, AGU, and NvdV. In chapter 2.2 the study concept and design was 
done by: BHS, GZ, AGU, and NvdV. Data analyses and interpretation was done by: ACH, GZ, 
BHS, AGU, and NvdV. Drafting the manuscript was done by: ACH and NvdV. Revising the 
manuscript was done by: all authors. The study was supervised by: BHS, AGU, and NvdV. In 
chapter 2.3 the study concept and design was done by: BHS, AGU, and NvdV. Data analyses 
and interpretation was done by: ACH, BHS, AGU, and NvdV. Drafting the manuscript was 
done by: ACH, SCvD, and NvdV. Revising the manuscript was done by: all authors. The study 
was supervised by: BHS, AGU, SCvD, and NvdV. In chapter 2.4 the study concept and design 
was done by: BHS, AGU, LB, NvdV. Data analyses and interpretation was done by: LB, ACH, 
BHS, AGU, and NvdV. Drafting the manuscript was done by: ACH, LB, BHS, AGU, and NvdV. 
Revising the manuscript was done by: all authors. The study was supervised by: LB, BHS, 
AGU, and NvdV. In chapter 3.1 the study concept and design was done by: BHS, AGU, and 
NvdV. Data analyses and interpretation was done by: ACH, BHS, AGU, and NvdV. Drafting the 
manuscript was done by: ACH and NvdV. Revising the manuscript was done by: all authors. 
The study was supervised by: BHS, AGU, and NvdV. In chapter 3.2 the study concept and 
design was done by: FR, GZ, BHS, AGU, LEV, NA, and ACH. Data analyses and interpretation 
was done by: NA, ACH, FR, BHS, MCZ, and LEV. Drafting manuscript was done by: NA, ACH, 
FR, and RN. Revising manuscript was done by: all authors. The study was supervised by: BHS, 
FR, MCZ, LEV, and AGU.
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Abstract 
Background 
Medication use is a potentially modifiable risk factor for falling; psychotropic and 
cardiovascular drugs have been indicated as main drug groups that increase fall risk. 
However, evidence is mainly based on studies that recorded falls retrospectively and/or 
did not determine medication use at the time of the fall. Therefore, we investigated the 
associations indicated in literature between medication use and falls, using prospectively 
recorded falls and medication use determined at the time of the fall.
Methods
Data from the B-PROOF (B-vitamins for the prevention of osteoporotic fractures) study were 
used, concerning community-dwelling elderly aged ≥65 years. We included 2,407 participants 
with pharmacy dispensing records. During the 2- to 3-year follow-up, participants recorded 
falls using a fall calendar. Cox proportional hazard models were applied, adjusting for potential 
confounders including age, sex, health status variables and concomitant medication use.
Results 
During follow-up, 1,147 participants experienced at least one fall. Users of anti-arrhythmic 
medication had an increased fall risk (hazard ratio [HR]= 1.61; 95% confidence interval [CI] 
1.12-2.32) compared with non-users. Similarly, non-selective beta-blocker use was associated 
with an increased fall risk (HR 1.41 [95% CI 1.12; 1.78]), while statin use was associated with a 
lower risk (HR=0.81 [95% CI 0.71; 0.94]). Benzodiazepine use (HR 1.32 [95% CI 1.02-1.71]), and 
antidepressant use (HR 1.40 [95% CI 1.07; 1.82]) were associated with an increased fall risk. 
Use of other cardiovascular and psychotropic medication was not associated with fall risk.
Conclusion 
Our results strengthen the evidence for an increased fall risk in community-dwelling elderly 
during the use of anti-arrhythmics, non-selective beta-blockers, benzodiazepines, and 
antidepressant medication. Clinicians should prescribe these drugs cautiously and if possible 
choose safer alternatives for older patients.
Key points
 • In a prospective setting including a community-dwelling population, aged ≥65 years, 
the use of antiarrhythmic medication, non-selective beta-blockers, benzodiazepines, and 
antidepressant medication was associated with an increased fall risk.
 • Statin use was associated with a decreased fall risk.
 • Clinicians should prescribe the fall-risk increasing drugs with caution and if possible 
choose safer alternatives for older patients.
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Introduction
Fall incidents are a major problem in older individuals, as one in every three experiences at 
least one fall per year.1 Of all falls, 5 to 12%2,3 result in serious injuries or fractures requiring 
medical attention, which leads to reduced quality of life and substantial health care costs.4,5 
A potentially modifiable risk factor for falls is medication use.6,7 Over the last decade, 
medication-related falls have received more and more attention. Psychotropic8-10 and 
cardiovascular8,9,11 medications have been indicated as the main drug groups contributing 
to an increased fall risk. However, evidence for these associations is mainly based on 
observational studies, which have applied varying methods for recording fall incidents 
and medication use. The most recent meta-analysis showed that only 6 out of 22 studies 
included recorded falls prospectively and ascertained medication use at the time of the fall.8 
In addition, current evidence is based on studies in community-dwelling older individuals 
as well as in those living in long-term care facilities, while these populations clearly differ 
in clinical characteristics. Therefore, the question arises whether these results can be validly 
combined. Although overall results point in a similar direction, only psychotropic drug 
use is consistently associated with an increased fall-risk.8,9,12-14 Therefore, our objective is 
to investigate associations previously indicated in literature between medication use and 
fall incidents, using prospectively recorded fall incidents and pharmacy dispensing records 
to determine medication use at the time of the fall. The study setting concerns a large 
population of community-dwelling older individuals, with a follow-up period of 2-3 years. 
Methods 
Study population and setting
Data from the B-PROOF study were used. B-PROOF is an acronym for ‘B-vitamins for the 
prevention of osteoporotic fractures’, a study whose design has been described elsewhere in 
more detail.15 Briefly, it is a multi-centre, randomized, placebo-controlled, double-blind trial 
investigating the efficacy of vitamin B12 and folic acid supplementation on the prevention of 
fracture incidence in individuals aged ≥65 years. In total, 2,919 participants were included 
from the area of three Dutch cities: Wageningen, Rotterdam and Amsterdam. All participants 
had mildly elevated homocysteine levels (12-50 μmol/L), sufficient renal function (creatinine 
≤150 μmol/L), and did not report malignancies in the past 5 years. Participants were randomly 
selected to receive daily the intervention tablet containing 500 μg vitamin B12, 400 μg folic 
acid and 600 IU vitamin D, or the placebo tablet containing only 600 IU of vitamin D. In total, 
the intervention period comprised 2-3 years. The Medical Ethics Committee of Wageningen 
University approved the study protocol, and the Medical Ethics Committees of Erasmus 
Medical Centre and VU University Medical Center gave approval for local feasibility. Before 
entering the study, all participants gave written informed consent.
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Previous results indicated that the intervention had no effect on the time to the first or 
second fall or the number of falls experienced during the follow-up.16 Therefore, in the 
current study, we treated the study population as a cohort and, to rule out potential residual 
confounding that might relate to the intervention, we adjusted for the intervention status. 
The intervention status indicated whether a participant received the intervention or the 
placebo tablet during follow-up. 
Outcome
Fall incidents were prospectively recorded during the study period. Participants reported fall 
incidents each week on a fall and fracture calendar, which was returned to the research team 
every 3 months. When a calendar was incomplete or unclear, the participant was contacted 
by telephone. A fall incident was defined as an unintentional change in position resulting in 
coming to a rest at a lower level or on the ground.17 Participants were followed until their first 
fall incident. The Thursday in that particular week was defined as the index date. Participants 
who encountered more than one fall during the follow-up period were censored after their 
first fall incident. Drop-outs (of the intervention study) without further calendar information 
after drop-out were censored at their drop-out date. Participants who kept filling out the 
calendar after their drop-out were followed until their last calendar. Therefore, a participant’s 
follow-up time ended at the date of their first fall-incident, their drop-out date or the date of 
their last calendar, date of death, or the end of the study, whichever came first.
Medication use
Medication use was determined on the basis of pharmacy dispensing records. These records 
contain information regarding the product name, the anatomical therapeutic chemical 
code,18 the administration route, the dispensing date, the total amount of drug units per 
prescription and the prescribed daily number of units. Electronic pharmacy dispensing 
records were obtained from the Dutch Foundation for Pharmaceutical Statistics (SFK). This 
foundation gathers data of all the pharmacies in their panel, which is approximately 95% of 
all Dutch community pharmacies.19 Dispensing records were only obtained for participants 
who gave written informed consent for gathering these data. Additionally, the pharmacists 
approved the use of the data. The pharmacy dispensing data of a participant were defined as 
complete when all participant pharmacies were in the SFK panel and data could be obtained. 
Data were available for the participants throughout their follow-up period.
 Medication usage periods were calculated from the dispensing date, the number of 
tablets prescribed, and the prescribed daily number of tablets. A participant was considered 
a current user of a medication group when the time of the fall (index date) fell within a 
prescription episode. The average prescribed daily dose was expressed in standardized 
defined daily doses (DDDs).18
 The medication groups from Table 1, covering previously suggested fall-risk increasing 
drugs (FRID),8-11,20,21 were used as potential exposure determinants. Medication groups with 
<1% users at baseline were not included in the analyses. 
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 23
23Medication-related falls | 
1
2
3
4
5
Covariates
Baseline demographic characteristics were ascertained using a questionnaire that gathered 
data on age, sex, use of a walking aid, history of falls and fractures, and health status variables 
(which included smoking habits, alcohol consumption, prevalent cardiovascular disease 
parameters, diabetes and hypercholesterolemia). A history of cardiovascular disease was 
defined as having a history of at least one of the following disorders: myocardial infarction, 
angina pectoris, heart failure, percutaneous coronary intervention, intermittent claudication, 
transient ischaemic attack, stroke, thrombosis or embolism. During the baseline study visit, 
various characteristics were measured, including weight, height, blood pressure, physical 
performance, handgrip strength, depressive symptoms and cognitive status. Weight was 
measured with a calibrated scale, and height was measured using a stadiometer. From this, 
the body mass index (BMI, kg/m2) was calculated. Blood pressure was measured twice, using 
an Omron M1 plus device (Omron Healthcare Europe, Hoofddorp, The Netherlands), and 
the lowest diastolic and corresponding systolic blood pressure reading were included in the 
analyses. Hypertension was defined as systolic blood pressure >140mmHg and/or diastolic 
blood pressure >90 mmHg.22 A physical performance score was calculated from the results 
of three physical function tests: walking test, chair stand test, and the tandem stand test.23 
For every test, a maximum score of 4 could be obtained, resulting in a physical performance 
score ranging from 0 to 12 (low physical performance – high physical performance).24 
Handgrip strength (kg) was assessed by performing two maximum trials per hand using a 
dynamometer (Takei TKK 5401, Takei Scientific Instrument CO. Ltd., Tokyo, Japan). The highest 
result of the four trials was used as the maximum handgrip strength. Depressive symptoms 
were measured using the 15-item version of the Geriatric Depression Scale (GDS),25 and 
cognitive status was measured by using the Mini-Mental State Examination (MMSE).26
 Blood was drawn when the participants had fasted or had consumed a light restricted 
breakfast. Plasma homocysteine levels were assessed from blood collected in an tube 
containing EDTA (ethylenediaminetetraacetic acid), which was stored on ice after blood 
collection and processed within 4 h. To determine homocysteine, Wageningen University 
used high-performance liquid chromatography (intra assay coefficient of variation 
[CV]= 3.1%, inter assay CV= 5.9%), Erasmus Medical Centre used liquid chromatography-mass 
spectrometry/mass spectrometry (LC-MS/MS) (intra assay CV= 5.5%, inter assay CV= 1.3%), 
and VU Medical Centre used the Architect i2000 RS analyser (intra assay CV= 2%, inter assay 
CV= 4%). Cross calibration of the assays indicated no significant difference between the 
outcomes. 
 Serum creatinine was measured using the enzymatic colorimetric Roche CREA plus assay 
(CV= 2%). It was used to calculate an age- and sex-adjusted estimate of the glomerular 
filtration rate (GFR) according to the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation.27 For men, it was calculated when their creatinine was ≤80 μmol/L using 
the formula 141 x [serum creatinine (μmol/L) / 80]-0.411 x [0.993age (years)], and if their creatinine 
was >80 μmol/L using the formula 141 x [serum creatinine (μmol/L) / 80]-1.209 x [0.993age (years)] 
in ml/min/1.73m2. For women, it was calculated when their creatinine levels were ≤62 μmol/L 
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 24
24 | Chapter 2.1
using the formula 144 x [serum creatinine (μmol/L) / 62]-0.329 x [0.993age (years)], and if their 
creatinine was >62 μmol/L using the formula 144 x [serum creatinine (μmol/L) / 62]-1.209 x 
[0.993age (years)] in ml/min/1.73m2. 
 Serum 25-hydroxy vitamin D [25(OH)D], was used as marker for vitamin D status and 
determined by isotope dilution-online solid phase extraction liquid chromatography-
tandem mass spectrometry (ID-XLS-MS/MS), which is described elsewhere in detail.28
Table 1. Drug categories of potentially fall-risk increasing drugs.8-11,20,21
Drug categories Drug sub-categories
Cardiovascular 
Anti-arrhythmics class 1A anti-arrhythmic, digitalis glycosides
Vasodilators
Antihypertensives α-blockers
β-blockers selective, non-selective, α & β-blockers
Diuretics thiazides, loop diuretics
Calcium antagonist
Renin-angiotensin agents ACE-inhibitors, angiotensin II antagonist
Lipid-lowering drugs statins
Nervous system
Analgesics opioids, and others
Anticonvulsants
Anti-Parkinson
Antipsychotics
Sedatives & hypnotics benzodiazepines
Antidepressants TCAs, SSRIs, others
Dementia drugs cholinesterase inhibitors, others
Antivertigo drugs
Respiratory system sympathomimetics, antihistaminics
Miscellaneous
Diabetic drugs insulin, oral glucose-lowering
Antacids H2-receptor antagonist, proton pump inhibitors
Urological spasmolytic
Muscle-skeletal muscle relaxants
Anti-inflammatory NSAIDs
ACE-inhibitors= angiotensin-converting-enzyme inhibitors, TCAs= tricyclic antidepressants, SSRIs= selective serotonin reuptake inhibitors 
NSAIDs= non-steroidal anti-inflammatory drugs. 
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Statistical analyses
Baseline characteristics were determined for the overall group and for fallers and non-fallers 
separately. These characteristics were also assessed for the whole B-PROOF population, 
including those without electronic pharmacy dispensing records. Differences between 
groups were tested using a t test for continuous variables and a Chi-squared test for 
categorical variables. If a variable was non-normally distributed, a Mann-Whitney U test was 
used. 
 Cox proportional hazards models were used to calculate hazard ratios (HR). The model 
compares the prevalence of exposure to the medication group in the incident fall cases on the 
index date with the exposure prevalence in all other participants in the cohort on that date.29 
The models were adjusted for age, sex and intervention status. The variables that differed at 
baseline between fallers and non-fallers (p<0.2) were added to the model using the forward 
selection methods (model 2). Medication groups that resulted in significant HRs were added 
to the other significant medication groups, thereby adjusting for concomitant medication 
use (model 3). The effect of handgrip strength and physical performance was investigated 
separately by adding them separately as well as combined to the model. Physical function 
parameters are known fall-risk factors, but they might also be affected by medication use 
itself, and thereby might act as an intermediate. In addition, the effect of fall history was 
examined by adding it to the model. When the HR was changed >5%, the parameter was 
regarded to influence the association. Interaction with CKD-EPI was tested for medication 
groups with renal clearance, since associations may be different in those with reduced renal 
function. When the p-value of the interaction term was <0.1 the results were stratified. 
 To further investigate the robustness of our findings, we investigated the dose-response 
relationship for the medication groups that were significantly associated with fall risk. 
The categories for dose were created based on the median number of prescribed DDDs. 
Furthermore, additional analyses were conducted for non-selective β-blockers, diuretics, 
statins and antidepressants. Non-selective β-blocker use was subdivided in timolol use 
– administered as eye drops with potential systemic effects – and other non-selective 
β-blocker use, to investigate whether the association was driven by timolol use. For thiazide 
and loop diuretics, duration periods were investigated, since previous research indicated 
an increased fall risk on initiation of treatment.30-32 The duration periods were defined as 
the first 21 days of use, 22-45 days and longer than 45 days of use, taking non-users as the 
reference.30-32 In addition, the association between past use of statins and antidepressants 
with fall incidents was assessed. This reason for this was that the association between statins 
and antidepressants might have been confounded by the indication for their use. Past use 
was defined as use prior to the index date. All statistical analyses were carried out using the 
statistical software package SPSS version 21.0 (IBM, Armonk, NY, USA) and p values <0.05 
were considered to be statistically significant.
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Results
Study population characteristics
The study population with pharmacy dispensing records consisted of 2,407 participants. 
Their baseline characteristics, also subdivided into those who did and did not experience 
fall during follow-up, are presented in Table 2. Participants who experienced a fall during 
follow-up were slightly older, more likely to be women and to have a positive fall history. 
Furthermore, fallers were more likely to use a walking aid, have lower handgrip strength and 
lower physical performance score, while their MMSE and GDS score was slightly higher than 
those who did not fall during the follow-up.
 Characteristics of the subgroup with pharmacy dispensing data were very similar to 
the overall B-PROOF population (n= 2,919, data not shown). The only significant difference 
was a slightly lower percentage of women (49.1 vs. 50.0, p= 0.026) and participants using a 
walking aid (13.6 vs. 14.6, p= 0.001) in the pharmacy dispensing data group. Furthermore, 
the representation of study centres was slightly altered and the physical performance score 
was slightly higher in those with pharmacy dispensing data than the whole B-PROOF study 
population, although the difference in physical performance score did not result in different 
median and interquartile range (IQR) values: 9 [6-11] vs. 9 [6-11], p= 0.017.
Fall risk-increasing drugs (FRID)
Of the cardiovascular drugs, the use of anti-arrhythmic medication was associated with 
an increased risk for falls compared with non-users (HR 1.61; 95% confidence interval [CI] 
1.12; 2.32; p= 0.010) (Table 3, model 3). Similarly, use of non-selective beta-blockers was 
associated with an increased fall risk (HR 1.41 [95% CI 1.12; 1.78] p= 0.004), while statin use 
was associated with a lower fall risk (HR 0.81 [95% CI 0.71; 0.94] p= 0.004) (Table 3, model 3). 
Use of antihypertensive medication overall or any of the other cardiovascular medication 
groups was not significantly associated with fall incidents (Table 3, model 2). In addition, 
the use of ‘other’ analgesics was associated with an increased fall risk, HR= 1.45 (95% CI 1.00; 
2.11) p= 0.049) (Table 3, model 3). This ‘other’ analgesics group included the non-opioid 
analgesics, covering the Anatomical Therapeutic Chemical (ATC) codes N02B and N02C. With 
regard to psychotropic drugs, the use of benzodiazepines was associated with an increased 
risk (HR 1.32 [95% CI 1.02; 1.71] p= 0.034) (Table 3, model 3). Likewise, antidepressant use was 
associated with an increased risk (HR 1.31 [95% CI 1.00; 1.70] p= 0.046) (Table 3, model 3). No 
other significant associations were observed between the use of psychotropic mediation or 
any of the other medication groups and fall incidents (Table 3, model 2 and 3).
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Table 2. Baseline characteristics of the study population and subdivided in those who did and did not 
encountered a fall during follow-up.
Characteristic A. 
Study cohort  
(N= 2,407)
B. 
Fall cases 
(N=1,147)
C. 
Non- fallers 
(N=1,260)
Comparison  
B vs. C  
p-value
Age (years)a 74.0 (6.4) 74.4 (6.7) 73.7 (6.1) 0.003*
Sex (women, %) 49.1 53.8 44.8 <0.001*
Study centre (%)
Erasmus MC
VUmc
Wageningen UR
47.1
27.0
25.8
43.8
30.3
26.0
50.2
24.1
25.7
0.001*
History of falls (% yes)
No falls
1 fall
>1 fall
67.9
20.4
11.7
55.8
25.6
18.6
78.6
15.8
5.5
<0.001*
Walking aid (% yes) 13.6 15.1 12.2 0.040*
BMI (kg/m2)a 27.1 (4.0) 26.9 (4.0) 27.3 (4.0) 0.400
Smoking (%)
Never
Past
Current
33.9
56.8
9.3
35.3
56.6
8.1
32.7
57.0
10.3
0.112
Alcohol use (%)
Light
Moderate
Excessive
Very excessive
67.3
29.0
3.3
0.3
67.8
28.5
3.4
0.3
66.9
29.5
3.3
0.4
0.887
MMSE scoreb 28 [27-29] 29 [27-29] 28 [27-29] 0.005*
GDS scoreb 1[0-2] 1[0-2] 1[0-2] 0.010*
Diabetes (% yes) 10.5 10.3 10.7 0.779
Hypertension (% yes) 63.8 64.0 63.6 0.865
Cardiovascular history (% yes) 38.3 38.9 37.9 0.643
Handgrip strength (kg)a 32.6 (10.7) 31.6 (10.7) 33.6 (10.6) <0.001*
Physical performance (0-12) 9 [6-11] 9 [6-11] 9 [7-11] 0.012*
Homocysteine levels (µmol/L)b 14 [13-16] 14 [13-17] 14 [13-16] 0.620
Vitamin D, 25(OH)D 53 [37-71] 54 [36-72] 53 [37-70] 0.260
CKD-EPI GFR (ml/min/1.73m2)b 71.4 [61.4-81.7] 70.8 [60.7-80.8] 72.2[61.7-82.4] 0.024*
Received intervention (%) 50.4 50.0 50.7 0.710
a Presented as mean (± standard deviation [SD]). b Presented as median and interquartile range [IQR]. *P-value <0.05. 
Erasmus MC= Erasmus Medical Centre, VUmc= Vrije Universiteit Medical Centre, Wageningen UR= Wageningen University and Research 
centre, BMI= body mass index, MMSE= Mini-Mental State Examination, GDS= Geriatric Depression Scale , 25(OH)D= 25-hydroxyvitamin D, 
CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration, GFR= glomerular filtration rate.
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Table 3. Associations between the use of fall-risk increasing drugs and fall risk.
Number of users 
(%) a
Model 1 b 
(HR [95% CI])
Model 2 c 
(HR [95% CI])
Model 3 d 
(HR [95% CI]) 
p-value
Cardiovascular
Cardiac Glycosides 42 (1.7) 0.68 (0.42; 1.09) 0.62 (0.38; 1.00)
Anti-arrhythmic 36 (1.5) 1.59 (1.11; 2.83) 1.59 (1.10; 2.29) 1.61 (1.12; 2.32) 0.010*
Vasodilators 66(2.7) 0.98 (0.70; 1.36) 0.90 (0.64; 1.25)
Other cardiac drugs 1 (<0.1) ; ; 
Antihypertensive overall 1224 (50.9) 0.93 (0.83; 1.04) 0.92 (0.82; 1.04)
α- blockers 149 (6.2) 0.77 (0.60; 0.98) 0.83 (0.64; 1.07)
β- blockers 612 (25.5) 1.01 (0.88; 1.15) 1.00 (0.88; 1.13)
Non-selective 130 (5.4) 1.37 (1.09; 1.72) 1.36 (1.08; 1.71) 1.41 (1.12; 1.78) 0.004*
Selective 486 (20.2) 0.93 (0.80; 1.07) 0.91 (0.79; 1.05)
α- & β-blockers 13 (0.5) ; ; 
Diuretics 574 (23.9) 1.02 (0.90; 1.17) 0.99 (0.87; 1.13)
Thiazides 430 (17.9) 0.99 (0.86; 1.15) 0.99 (0.86; 1.15)
Loop diuretics 96 (4.0) 1.25 (0.96; 1.61) 1.13 (0.87; 1.47)
Calcium antagonist 300 (12.5) 0.94 (0.79; 1.10) 0.93 (0.78; 1.09)
Renin-angiotensin agents 731 (30.4) 0.91 (0.81; 1.03) 0.93 (0.83; 1.06)
ACE-inhibitors 349 (14.5) 0.86 (0.73; 1.00) 0.90 (0.76; 1.06)
Angiotensin II 
antagonist
393 (16.4) 1.01 (0.87; 1.18) 1.00 (0.86; 1.16)
Lipid-lowering
Statins 527 (21.9) 0.80 (0.70; 0.92) 0.83 (0.72; 0.95) 0.81 (0.71; 0.94) 0.004*
Nervous system
Analgesics
Opioids 45(1.9) 1.35 (0.97; 1.90) 1.26 (0.90; 1.77)
Others 38 (1.6) 1.65 (1.14; 2.38) 1.47 (1.01; 2.13) 1.45 (1.00; 2.11) 0.049*
Anticonvulsants 42 (1.7) 1.44 (0.95; 2.18) 1.31 (0.87; 1.98)
Anti-Parkinson 31 (1.3) 1.26 (0.81; 1.96) 1.25 (0.80; 1.95)
Antipsychotics 13 (0.5) ; ; 
Sedatives & hypnotics 76(3.2) 1.47 (1.11; 1.94) 1.31 (0.99; 1.74)
Benzodiazepines 100 (4.2) 1.46 (1.14; 1.89) 1.30 (1.01; 1.69) 1.32 (1.02; 1.71) 0.034*
Antidepressants 95 (4.0) 1.39 (1.07; 1.80) 1.30 (1.00; 1.69) 1.31 (1.01; 1.70) 0.046*
TCAs 26 (1.1) 1.56 (0.98; 2.49) 1.50 (0.94; 2.40)
SSRIs 45 (1.9) 1.39 (0.96; 1.99) 1.28 (0.89; 1.85)
Others 25 (1.0) 1.09 (0.63; 1.90) 1.00 (0.58; 1.74)
Cholinesterase inhibitors 4 (0.2) ; ; 
Other dementia 6 (0.2) ; ; 
Antivertigo 22 (0.9) ; ; 
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Table 3. (Continued)
Number of users 
(%) a
Model 1 b 
(HR [95% CI])
Model 2 c 
(HR [95% CI])
Model 3 d 
(HR [95% CI]) 
p-value
Respiratory system
Sympathomimetics 154 (6.4) 1.20 (0.97; 1.49) 1.16 (0.93; 1.44)
Antihistaminics 52(2.2) 1.44 (1.01; 2.05) 1.39 (0.98; 1.98)
Miscellaneous
Diabetic
Insulin 52 (2.2) 1.19 (0.83; 1.71) 1.18 (0.82; 1.70)
Oral glucose-lowering 180 (7.5) 0.94 (0.76; 1.16) 0.95 (0.77; 1.17)
Antacids 488 (20.3) 1.11 (0.97; 1.28) 1.07 (0.93; 1.22)
H2-receptor antagonists 28 (1.2) 0.60 (0.31; 1.16) 0.62 (0.32; 1.19)
Proton pump inhibitors 458 (19.1) 1.15 (1.00; 1.32) 1.10 (0.96; 1.26)
Urologicals 185 (7.7) 0.87 (0.70; 1.08) 0.94 (0.75; 1.17)
Spasmolytics 38 (1.6) 1.52 (1.00; 2.29) 1.43 (0.95; 2.17)
Muscle-skeletal
Muscle relaxants 3 (0.1) ; ; 
Anti-inflammatory
NSAIDs 70 (2.9) 1.31 (0.97; 1.78) 1.26 (0.93; 1.71)
a The number of users (%) at baseline. b Model 1: crude model. c Model 2: adjusted for age, sex, intervention status, MMSE, GDS, and study centre. 
d  Model 3: confounders model 2, plus the other significantly associated drugs from model 2. *P-value <0.05. 
HR= hazard ratio, CI= confidence interval, ACE-inhibitors= angiotensin-converting-enzyme inhibitors, TCAs= tricyclic antidepressants, 
SSRIs= selective serotonin reuptake inhibitors, NSAIDs= non-steroidal anti-inflammatory drugs, MMSE= Mini-Mental State Examination, 
GDS= Geriatric Depression Scale
The role of physical performance, fall history and renal function parameters
Adding handgrip strength, physical performance, or both parameters to the model did 
not change most of the HRs substantially; only the association with non-opioid analgesics 
and antidepressants was affected. After adding the physical performance score to the 
model, the association with non-opioid analgesics lost significance (HR 1.39 [95% CI 0.95; 
2.05] p= 0.093). Conversely, when physical performance was added to the antidepressant 
model, the association became stronger (HR 1.40 [95% CI 1.07; 1.82] p= 0.013), indicating a 
potentially protective effect of physical performance. 
 Adding fall history to the model did not substantially change the HR of any of the 
medication groups that were significantly associated with fall risk (supplementary Table 
1). The interaction term for renal function with a medication group did not suggest effect 
modification for any of the medication groups (data not shown). 
Additional analyses
No clear dose-response association was observed for any of the medication groups that were 
significantly associated with fall risk (supplementary Table 2). 
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The use of non-selective β-blockers – excluding timolol use – was associated with an increased 
fall risk (HR 1.41 [95% CI 1.03; 1.95] p= 0.034), while timolol use was borderline significantly 
associated (HR 1.37 [95% CI 0.99; 1.90] p= 0.060). Both associations were adjusted for age, 
sex, intervention status, study centre, MMSE and GDS score, and the other medication groups 
that were significantly associated with fall risk (data not shown). 
 The first 21 days of thiazide use (HR 0.89 [95% CI 0.59; 1.35] p= 0.588), and loop diuretic 
use, (HR 1.36 [95% CI 0.74; 2.48] p= 0.321) were not associated with an increased fall risk; both 
associations were adjusted for age, sex, intervention, study centre, and MMSE and GDS score. 
 Past use of statins was not associated with fall risk (HR 1.07 [95% CI 0.78; 1.46] p= 0.690). 
Likewise, past use of antidepressants was not associated with fall risk (HR 1.37 [95% CI 0.88; 
2.14] p= 0.161). Both associations were adjusted for age, sex, intervention status, study centre, 
MMSE and GDS score, and the other medication groups that were significantly associated 
with fall risk (data not shown).
Discussion
Our results indicate an increased fall risk in community-dwelling older adults during the 
use of anti-arrhythmic medication, non-selective beta-blockers, benzodiazepines and 
antidepressant medication. Additionally, a decreased fall risk was observed for statin use, 
whereas no significant association was observed for other antihypertensive medication, 
including diuretics, and for non-steroidal anti-inflammatory drugs (NSAIDs).
 In concordance with our results, the meta-analysis by Leipzig et al.11 indicated an increased 
fall risk from anti-arrhythmic class IA drug use. However, our exposure category, was slightly 
different because we combined all classes of anti-arrhythmic medication. Potential adverse 
effects of anti-arrhythmics that may contribute to fall risk are bradycardia, hypotension or 
torsade de pointes.33
 The meta-analysis by Woolcott et al.8 did not indicate an increased fall risk for beta-blocker 
use, whereas two recent self-controlled case series studies did observe an increased risk.30,31 
Our results indicated an increased risk for use of non-selective beta-blocker. Previous studies 
did not distinguish between different types of beta-blockers, and it is unclear whether eye 
drops such as timolol were included. Timolol is a non-selective beta-blocker known to be 
able to cause systemic – adverse – effects.34,35 Its use has been associated with syncope.36 
Timolol is regularly used in the elderly population, including our population, mainly for 
glaucoma or ocular hypertension.34,35 Although timolol by itself was borderline significantly 
associated with an increased fall risk, the HR was similar to that for non-selective beta-
blocker use, excluding timolol. Furthermore, the combination of non-selective beta-blocker 
use and timolol has a higher level of significance than when separated. An increased fall risk 
by beta-blockers may be a result of bradycardia and hypotension. However, non-selective 
beta-blocker use might have additional adverse effects by which they may increase the fall 
risk. For example, sotalol also exhibits class III anti-arrhythmic properties, which is associated 
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 31
31Medication-related falls | 
1
2
3
4
5
with torsade de pointes,33 and propranolol use may result in central nervous system adverse 
effects, such as dizziness and insomnia, due to its lipophilic properties.37 
 The use of antihypertensive medication overall has been indicated to increase fall 
risk.8,30 Similarly, diuretic use overall has been associated with increased fall risk,11 but not 
consistently.8 Recent results indicated that initiation of antihypertensives30 and especially 
thiazide diuretics30-32 increased fall risk, which is potentially attributed to an initially induced 
hypotensive effect that stabilizes over time.30,32 Nevertheless, according to our additional 
analyses, initiation of thiazides or loop diuretics was not associated with fall risk. This 
discrepancy in findings might be due to our low number of users who initiated thiazides or 
loop diuretics. 
 Remarkably, our results indicated a decreased fall risk during statin use, while previously 
an increased risk has been proposed due to potential negative effects on muscle strength 
and balance. Nevertheless, no significant associations were observed.38 A beneficial effect on 
fall risk might be due to the cardioprotective effects of statin use.38-40 An opposite explanation 
might be confounding by indication. It is possible that more frail older individuals may not 
have received a statin prescription, and therefore the non-statin users had an increased fall 
risk. However, this is speculative, and our additional analyses investigating the association 
with past use of statins did not support this speculation. Because our finding is new and 
potential mechanisms are lacking, more research is required before firm conclusions can be 
drawn.
 Analyses with use of ‘other’ analgesics, covering the non-opioids, indicated a significant 
association with fall risk in the first analysis, but lost significance after including physical 
performance. For this particular drug group, a confounding effect is more likely than a 
mediating effect. Use of non-opioid analgesics may reflect an impaired overall health status, 
including physical performance state, and may thereby be related to fall risk. Previously, 
Leipzig et al.11 also did not observe an association between use of non-opioid analgesics and 
fall risk. 
 The use of sedatives and hypnotics, and especially benzodiazepines, has been 
consistently shown to increase fall risk.8,9,12-14 Benzodiazepine use could influence fall risk in 
several ways, by negatively affecting balance, gait and cognition.9 In addition, it may induce 
hyponatremia,41 which is also associated with falls.42,43
 In line with previous findings,8,9,32,44 we observed an increased fall risk for antidepressant 
medication use overall, while no significant association with its subgroups were seen. This 
may be due to low numbers of users in the subgroups. Antidepressant use has been proposed 
to affect fall risk in several ways including by inducing sedation, impaired sleep and balance, 
slower gait speed and reaction time, and orthostatic hypotension.44-46 Nevertheless, it is 
difficult to separate the effect from depression itself, as that could result in falls via similar 
mechanisms.44-46 However, our additional analyses did not indicate an increased fall risk 
for past users of antidepressants. In addition, two self-controlled case-series studies also 
reported an increased risk, and this method is less subject to confounding by indication.46,47 
Furthermore, a cohort study investigating the association with both depression and 
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antidepressants concluded that both aspects contributed to fall risk.44 Thus, our result 
strengthens the evidence for an increased fall risk during antidepressant use.
 This study has several limitations. First, the studied population included participants 
with slightly elevated homocysteine levels at baseline. Therefore, our results cannot be 
extrapolated to the general ambulant older population. Nevertheless, it is questionable 
whether the observed association would be different in populations that also included 
participants with lower homocysteine levels, as there is, to our knowledge, no association 
between homocysteine levels and medication-related falls. Second, half of the participants 
received folic acid and vitamin B12, and all participants received vitamin D supplementation 
during their follow-up. However, no differences were observed between the intervention 
and placebo groups regarding the time to the first fall or second fall and the number of 
falls experienced during follow-up.16 With respect to the vitamin D supplementation, this has 
been suggested to reduce fall risk, though evidence is inconsistent.48 Because all participants 
received supplementation, and we do not expect interference with medication-related falls, 
we do not think this affected our results. Third, falls were self-reported in a weekly fashion, 
thereby the fall week was known instead of the exact fall date. However, we do not think 
that this minimal random misclassification in timeframe has altered the results. Fourth, 
confounding by indication or contra-indication could not be investigated thoroughly in 
our study and could have affected our results. Finally, based on the number of medication 
groups investigated, a chance finding could have occurred. Although there are limitations, 
our study has major strengths. It investigated a large community-dwelling population in 
which a wide range of health status determinants were assessed. Furthermore, falls were 
recorded prospectively, and medication use was determined using pharmacy dispensing 
records, making it possible to determine medication use at time of the fall. Thereby, we 
could more closely approach the true association between medication use and fall incidents, 
compared with cross-sectional studies.
Conclusion and perspective 
Overall, our results strengthen the evidence for an increased fall risk in community-dwelling 
older individuals during the use of anti-arrhythmic medication, non-selective beta-blockers, 
benzodiazepines and antidepressant medication. Although medication use is a potentially 
modifiable fall-risk factor, single interventions targeting reductions in the number or doses 
of medications are limited, though more studies focused on fall prevention using medication 
reviews to modify prescription. Fall rate could be reduced by such interventions, but results 
regarding fall risk reduction are modest,48,49 which is partly attributed to the complexity of 
dose reduction or stopping medication and the possible reintroduction of medication use 
after stopping.49 Nevertheless, clinicians should be aware of drugs associated with fall risk 
during prescription, and consider the risk-benefit balance. If available, safer alternatives 
should be recommended.
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Table 2. Dose-response relationships for medication groups that were significantly associated with fall risk.
Number  
of users a
Model 1 b 
(HR [95% CI])
Model 2 c 
(HR [95% CI])
Model 3 d 
(HR [95% CI]) 
p-value
Antiarrhythmic
 ≤ median (0.75 DDD)
 > median (0.75 DDD)
15 
15
1.60 (0.96; 2.66)
1.58 (0.95; 2.63)
1.49 (0.89; 2.48)
1.70 (1.02; 2.84)
1.47 (0.88; 2.46) 
1.78 (1.07; 2.97)
0.137
0.027*
Non-selective β-blocker
 ≤ median (0.50 DDD)
 > median (0.50 DDD)
20
20
1.34 (0.86; 2.08)
1.35 (0.86; 2.13)
1.38 (0.89; 2.15)
1.35 (0.85; 2.12)
1.45 (0.93; 2.26)
1.40 (0.89; 2.22)
0.103
0.144
Statins
 < median (1.00 DDD)
 ≥ median (1.00 DDD)
110
143
0.80 (0.66; 0.97)
0.80 (0.67; 0.96)
0.82 (0.67; 0.99)
0.83 (0.70; 0.99)
0.80 (0.66; 0.98)
0.82 (0.69; 0.99)
0.029
0.033
Benzodiazepines 
 ≤ median (0.50 DDD)
 > median (0.50 DDD)
38
24
1.48 (0.11; 2.04)
1.40 (0.93; 2.09)
1.30 (0.94; 1.80)
1.27 (0.85; 1.91)
1.30 (0.94; 1.81) 
1.32 (0.88; 1.98) 
0.116
0.186
Antidepressants
 < median (1.00 DDD)
 ≥ median (1.00 DDD)
33
29
1.61 (1.13; 2.29)
1.21 (0.84; 1.75)
1.52 (1.06; 2.16)
1.12 (0.77; 1.63)
1.59 (1.11; 2.26) 
1.23 (0.85; 1.79)
0.011 e*
0.272 e
a The number of cases using the medication group. b Model 1: crude model. c Model 2: adjusted for age, sex, intervention status, MMSE, GDS, 
and study centre. d Model 3: confounders model 2, plus the other significantly associated drugs from model 2. e Model 3: confounders model 
2, plus physical performance. *P-value <0.05.
HR= hazard ratio, CI= confidence interval, DDD= defined daily dose, MMSE= Mini-Mental State Examination, GDS= Geriatric Depression Scale.
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Abstract 
Objective 
To investigate whether the CYP2C9*2 and *3 variants modify benzodiazepine-related fall risk.
Design 
Three prospective studies; the Rotterdam Study, B-PROOF and LASA.
Setting
Community-dwelling individuals living in or near five Dutch cities.
Participants 
There were 11,485 participants aged ≥55 years.
Measurements 
Fall incidents were recorded prospectively. Benzodiazepine use was determined using 
pharmacy dispensing records or interviews. Cox proportional hazard models adjusted for 
age and sex were applied to determine the association between benzodiazepine use and fall 
risk stratified for CYP2C9 genotype and comparing benzodiazepine users to non-users. The 
results of the three studies were combined applying meta-analysis. Within benzodiazepine 
users the association between genotypes and fall risk was also assessed.
Results 
Three thousand seven hundred five participants (32%) encountered a fall during 91,996 
follow-up years, and 4-15% – depending on the study population – used benzodiazepines. 
CYP2C9 variants had frequencies of 13% for the *2 allele and 6% for the *3 allele. Compared 
to non-users, current benzodiazepine use was associated with an 18% to 36% increased 
fall risk across studies with a combined hazard ratio (HR)= 1.26 (95% confidence interval 
[CI], 1.13; 1.40). CYP2C9*2 or *3 allele variants modified benzodiazepine-related fall risk. 
Compared to non-users, those carrying a CYP2C9*2 or *3 allele and using benzodiazepines 
had a 45% increased fall risk (HR, 1.45 (95% CI 1.21; 1.73)), whereas CYP2C9*1 homozygotes 
using benzodiazepines had no increased fall risk (HR, 1.14 (95% CI 0.90; 1.45)). Within 
benzodiazepine users, having a CYP2C9*2 or *3 allele was associated with an increased fall 
risk, HR, 1.35 (95% CI 1.06; 1.72). Additionally, we observed an allele dose effect, heterozygous 
allele carriers had a fall risk of (HR= 1.30 95% CI 1.05; 1.61), and homozygous allele carriers of 
(HR= 1.91 95% CI 1.23; 2.96).
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Conclusions 
CYP2C9*2 and *3 allele variants modify benzodiazepine-related fall risk. Those using 
benzodiazepines and having reduced CYP2C9 enzyme activity – based on their genotype 
– are at increased fall risk. In clinical practice, genotyping might be considered for elderly 
patients with an indication for benzodiazepine use. However, since the exact role of CYP2C9 
in benzodiazepine metabolism is still unclear, additional research is warranted.
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Introduction
In older adults, fall incidents form a significant health problem, as approximately one third 
yearly encounters at least one fall.1 Fall incidents frequently result in morbidity and mortality, 
and they are associated with reduced quality of life and increased health care costs.2-5 
There are multiple risk factors for falling, including benzodiazepine use.6-8 Benzodiazepine 
use may affect fall risk by inducing sedation, dizziness and balance problems.9,10 However, 
pharmacological effects of benzodiazepines vary between individuals. This may be due to 
varying plasma drug concentrations, which are potentially influenced by genetic variation.11 
Moreover, previous studies observed an increased fall risk with increasing benzodiazepine 
dosages.12-14 
 Drug metabolism is of importance for plasma drug concentrations. Metabolism of 
most benzodiazepines consists of two phases; first, oxidation and second, conjugation to 
glucuronide, which is excreted via the urine. The benzodiazepines oxazepam, temazepam 
and lorazepam can, however, be directly conjugated.15 The oxidation phase is primarily 
catalyzed by liver enzymes from the Cytochrome P450 (CYP) 3A family, isoenzyme 2C19,11,15,16 
and CYP2C9 may also be involved.11,17 Genetic polymorphisms encoding altered enzyme 
activity may thereby influence drug concentrations, and potentially, subsequent fall risk. 
Previously, in a pilot study we investigated the association between benzodiazepine-
related fall risk and genetic polymorphisms CYP3A4*1b, CYP3A5*3, CYP3A7*1c, CYP2C9*2, 
CYP2C9*3 and CYP2C19*2. Interestingly, only CYP2C9*2 and *3 allele carriership was 
associated with an increased benzodiazepine-related fall risk.18 These polymorphisms both 
result in a decreased enzyme activity.19,20 Therefore, our current objective was to confirm this 
finding by replication in two independent studies; B-PROOF (B-vitamins for the PRevention 
Of Osteoporotic Fractures) and LASA (Longitudinal Aging Study Amsterdam). Furthermore, 
we investigated replication within the Rotterdam Study (original discovery) cohort, but after 
a longer follow-up time. All three studies included community-dwelling older individuals. 
Methods
Study population and setting
Data from three independent Dutch studies were used, the Rotterdam Study, B-PROOF, and 
LASA. 
 The Rotterdam Study is an ongoing prospective population-based cohort, executed 
within Rotterdam. Previously, its design, objectives and methods have been described in 
detail.21,22 For the current study, participants with pharmacy dispensing data and validated 
fall data were included, covering a study period from May 1991 until December 2010, 
including up to five measurement rounds. 
 B-PROOF is a multi-centre, randomized, placebo-controlled, double-blind trial 
investigating the efficacy of vitamin B12 and folic acid supplementation on the prevention 
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of fracture incidence in persons aged ≥65 years and having homocysteine levels of 12 to 
50 μmol/L. The study was executed from 2008 until 2013, and participants participated for 2 
to 3 years.23 Previous results indicated no effect of the intervention on the time to the first or 
second fall, and on the number of falls encountered during the study.24 Therefore, a cohort 
study design was used in the current study.
 LASA is an ongoing prospective population-based cohort study started in 1991 and 
executed in the surrounding of Amsterdam, Zwolle and Oss. Its design, objectives and follow-
up measurement procedures have been described previously.25,26 For the current study, data 
from the fall follow-up study were used. This study was embedded within LASA and included 
those who participated from wave C (1995/1996) until wave D (1998/1999), and who were 
≥65 years on the first of January 1996, community-dwelling, and participated in the data 
examination visit.27 
 All three studies were approved by a Medical Ethics Committee and all participants gave 
written informed consent.21-23,25-27
Fall incidents
In the Rotterdam Study, ‘serious falls’ were defined as ‘a fall leading to a hospital admission 
or leading to a fracture’. Serious falls data were obtained from a computerized reporting 
system of the general practitioners within the Rotterdam Study. Additionally, participant 
data were linked to the Dutch National Morbidity Registration (LMR), containing information 
of all hospital admissions. Two members of the research team coded the serious falls and 
data were completed until 2010. The first serious fall date was defined as the index date and 
participants were followed until their first serious fall, death or the end of the study period, 
whichever came first. 
 In B-PROOF and LASA, a fall incident was defined as ‘an unintentional change in position 
resulting in coming to a rest at a lower level or on the ground’.28 Participants reported falls 
weekly on a calendar.29,30 In B-PROOF, the Thursday in the first fall week was defined as the 
index date. Participants were followed until their first fall-incident date, drop-out date or 
last calendar date, date of death, or the end of the study, whichever came first.30 In LASA, 
the first fall week was defined as the index date. Participants were followed until their first 
fall-incident week, first missing calendar, death, or the end of the study period (wave D, 
1998/1999), whichever came first.29
Benzodiazepine use
Benzodiazepine use was defined according to the Anatomical Therapeutic Chemical codes,31 
‘N05BA’ for anxiolytics, or ‘N05CD’ for hypnotics. 
 In the Rotterdam Study, benzodiazepine use was based on pharmacy dispensing records. 
These records from the regional pharmacies were available from January 1st 1991 onwards. 
Over 95% of the participants fill their drug prescriptions at one of these pharmacies. The 
records include date of dispensing, total number of drug units per dispensing, prescribed 
daily number of units, product name of the drugs and corresponding Anatomical Therapeutic 
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Chemical code. Current medication use was defined as use at the time of the fall (on the 
index date). Past use was defined as use ending prior to the index date, taking into account 
potential carry-over effects of one week. To investigate a dose-response relation, the average 
prescribed daily dose was expressed in standardized defined daily doses (DDDs).31 To avoid 
potential misclassification of exposure, we ensured that all participants had pharmacy 
dispensing records for at least four months prior to their study start.
 In B-PROOF, benzodiazepine use was also based on pharmacy dispensing records. These 
records were obtained from the Dutch Foundation for Pharmaceutical Statistics (SFK), as 
previously described.30 Data were available for participants throughout their study period. 
The same definition as in the Rotterdam Study for current and past use, and dosages was 
used.
 In LASA, benzodiazepine use was determined at the medical interview. Participants were 
asked to bring their medication containers to the interview.27 Current use was defined as use 
at the start of their fall follow-up. Past use was defined as use at the previous study visit and 
no current use. No specific dose information was available.
Covariables 
Characteristics including age, sex, walking aid use, fall history, smoking habits, alcohol 
consumption, and diabetes were assessed using a questionnaire.21,23,27 During study visits, 
various characteristics were measured including weight, height, blood pressure, depressive 
symptoms and cognitive status. Additionally, serum creatinine levels were determined.21,23,32 
As physical function measures, lower-limb disability scores were determined in the Rotterdam 
Study,33,34 whereas in B-PROOF and LASA physical performance scores and handgrip strength 
were assessed.27,35,36 Ethnicity was self-reported using a questionnaire in all three studies,22,23,25 
though in B-PROOF ethnicity was assessed using the genetic data when available. A detailed 
description of the covariable assessment is presented in the supplement.
Genotyping
In the Rotterdam Study, genotyping of CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) 
allele variants was done using a validated polymerase chain reaction and restriction enzyme 
digestion analysis.37,38 The reference group was defined as those being homozygous for the 
major allele (*1/*1), i.e., the absence of a CYP2C9*2 or CYP2C9*3 allele. 
 In B-PROOF, both variants were determined based on the Illumina-Omni express array and 
imputations to 1000 Genomes Project (PhaseIv3, March 2012) reference set.39 The imputation 
quality of both variants was >0.99. The imputations were only done for Caucasians. In LASA, 
the variants were directly genotyped using the Illumina HumanOmni2.5Exome- 8 BeadChip 
array.
 The three methods were validated in the Rotterdam Study, the concordances for 
CYP2C9*3 was >99%. For CYP2C9*2 exome chip data were lacking, but concordance between 
genotyping and imputation to 1000 Genomes Project data was >99%.
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Statistical analyses 
Baseline characteristics were determined for fallers and non-fallers. Differences between 
groups were tested using a t-test for continuous variables and a Chi-square test for 
categorical variables. Non-normally distributed variables were tested using a Mann-Whitney 
U test. Deviation from Hardy-Weinberg equilibrium was tested using a Chi-square test for the 
allele frequencies.
 Cox proportional hazards models were used to calculate the fall hazard ratios (HRs) for 
benzodiazepine use compared to non-benzodiazepine use. In the Rotterdam Study and 
B-PROOF the model compares the prevalence of exposure to benzodiazepines in the incident 
fall cases on the index date with the exposure prevalence in all other participants in the 
cohort on that date.40 The models were adjusted for age and sex (model 1). Covariables that 
significantly differed between fallers and non-fallers at baseline were included in the model 
when they changed the HR >10% (model 2). Additionally, subgroup analyses were done for 
anxiolytic and hypnotic drug use. In the Rotterdam Study and B-PROOF, a dose-response 
relation was also investigated. Dose categories were made according to median number 
of prescribed DDDs. We assessed the role of CYP2C9*1, *2 and *3 genotypes within the 
association between benzodiazepine use and fall risk, by stratifying on genotypes per study 
population. Furthermore, ‘the Synergy Index’ (SI) was calculated, which is a ratio measure 
for assessing relative excess risk due to interaction between two factors.41 Those without 
benzodiazepine use and without a variant allele functioned as reference group, and the risk 
for the presence of one of the factors (benzodiazepine use or carriership of an allele variant) 
or both factors (benzodiazepine use and carriership of an allele variant) was calculated, also 
using Cox proportional hazards models. In addition, the association between genotypes and 
fall risk was investigated within benzodiazepine users, to account for potential confounding 
by indication. To combine the results of the three studies, a meta-analysis was done. The 
effect estimates – beta’s – and their standard errors were used to calculate the overall effect, 
and to investigate the heterogeneity between the studies. Meta-analyses were done using 
the R package ‘rmeta’ applying a random effect model, R version 3.0.3. All other statistical 
analyses were done using the statistical software package SPSS version 21.0 (IBM, Armonk, 
NY, USA) and p-values <0.05 were considered to be statistically significant.
Additional analyses
We reassessed the negative findings of the other genetic variants – CYP3A4*1b, CYP3A5*3, 
CYP3A7*1c, CYP2C19*2 – applying the same method as for the other variants, but only 
within the Rotterdam Study and B-PROOF, since these variants were not available in LASA. 
The genotyping of these variants is described in the supplement.
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Results
Study population
In the Rotterdam Study, data on fall incidents and medication use was available for 7,662 
participants and of these, 6,368 participants had CYP2C9*2 and CYP2C9*3 data. In B-PROOF, 
fall and medication data were available for N= 2,407, and genetic data for N= 2,135. In LASA 
the numbers were N= 1,416 and N= 938, respectively (supplementary Figure 1). Some of the 
baseline characteristics between participants with and without genetic data differed slightly, 
which are depicted in supplementary Table 1 for all three study populations. In Table 1, the 
population characteristics of the three study populations (including those with medication 
and fall data) are depicted for fallers and non-fallers during follow-up. This indicated that 
fallers were more likely to be older, of female gender, have a history of falls, use a walking aid, 
have depressive symptoms, have poorer physical function parameters, and to have reduced 
kidney function. The total median follow-up time was 11.4 years with an inter quartile range 
(IQR) of 5.1 to 17.9 years (Rotterdam Study), 1.7 years (0.6-3.0 [LASA]) and 1.8 years (0.5-2.0 
[B-PROOF]).
Benzodiazepine use and fall risk
At baseline, 11.5% (Rotterdam Study), 4.2% (B-PROOF), and 14.9% (LASA) of the participants 
used a benzodiazepine. In all three studies, current benzodiazepine use – compared to non-
use – was associated with an increased fall risk, the combined risk of the studies was HR= 1.26 
(95% CI, 1.13; 1.40; p= 1.91*10-5) (Table 2). Past use of benzodiazepines was also associated 
with an increased fall risk, combined HR= 1.10 (95% CI, 1.00; 1.20; p= 0.04) (Table 2). In all three 
studies, the hazard ratios were adjusted for age and sex, as the other considered covariates 
(including the fall-risk factors described previously) did not change the HR by more than 
10%, and thereby did not act as a confounding factor. 
Dose-response relation
The meta-analyses indicated no dose-response associations for anxiolytic use (supplementary 
Table 2). For hypnotics, those using a dose below the median of 1.0DDD compared to non-use 
had a fall risk of HR= 1.14 (95% CI, 0.87; 1.48; p= 0.34), whereas those using a dose ≥1.0DDD 
had a risk of HR= 1.33 (95% CI, 1.10; 1.59; p= 0.003) (supplementary Table 2).
Genotypes and benzodiazepine-related fall risk 
Genotypes and allele frequencies of CYP2C9 *1, *2, and *3 variants are provided in 
supplementary Table 3. Genotypes for both variants were in Hardy-Weinberg equilibrium 
in the studies. Participants having one or two variant alleles (*2 or *3) were clustered, as 
the allele frequencies were relatively low, resulting in stratified analyses for those having no 
variant alleles (subjects homozygous for *1/*1) versus those having at least one variant allele. 
The results stratified for CYP2C9*2 and CYP2C9*3 genotypes are provided in supplementary 
Table 4. The meta-analysis indicated that the fall risk of those carrying a CYP2C9*2 allele 
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was similar to the fall risk of those carrying a CYP2C9*3 allele. Therefore, the genotypes for 
both variant alleles were combined into a “variant genotype” group (as compared to the 
homozygous *1/*1 “wild type” genotype group). Additionally, a heterozygous (i.e., *1/*2 and 
*1/*3 ) and homozygous (i.e., *2/*2, *2/*3, and *3/*3) group was composed of the genotypes. 
 The stratified results for the combined genotypes of CYP2C9*2 and *3 are provided in 
Table 3. The meta-analysis indicated that in those carrying no variant CYP2C9 alleles (*1/*1), 
the fall risk of current benzodiazepine use (n= 204) compared to non-use (n= 1,752) was 
HR= 1.14 (95% CI, 0.90; 1.45; p= 0.29). In comparison, the fall risk in those carrying at least 
one variant CYP2C9*2 or *3 allele of current benzodiazepine use (n= 150) compared to 
non-use (n= 1,224) was HR= 1.45 (95% CI, 1.21; 1.73; p= 4.98*10-5). When investigating allele 
dose effects we observed that the fall risk of benzodiazepine use compared to non-use in 
heterozygous CYP2C9 variant allele carriers was HR= 1.42 (95% CI, 1.17; 1.72; p= 3.80*10-4) 
and HR= 1.70 (95% CI, 0.85; 3.40; p= 0.13) in homozygous CYP2C9 variant allele carriers. 
 The results within benzodiazepine users are presented in Table 4 for the combined 
genotypes of CYP2C9*2 and CYP2C9*3. Carrying a variant *2 or *3 allele was significantly 
associated with an increased fall risk, HR= 1.35 (95% CI, 1.06; 1.72; p= 0.02). When investigating 
an allele dose effect, we observed an increased fall risk for heterozygous allele carriers, HR= 
1.30 (95% CI, 1.05; 1.61; p= 0.02), and for homozygous allele carriers HR= 1.91 (95% CI, 1.23; 
2.96; p= 0.004). Moreover, there was a linear trend in fall risk between heterozygous and 
homozygous allele carriers, HR=1.33 (95% CI, 1.07; 1.64; p=0.009).
 For calculation of the Synergy Index (SI), those without benzodiazepine use and without 
a variant CYP2C9*2 or *3 allele functioned as reference group, the combined fall risk 
for benzodiazepines users was HR= 1.14 (95% CI, 0.90; 1.44; p= 0.29), and the fall risk for 
carriers of a *2 or *3 allele was HR= 1.03 (95% CI, 0.95; 1.11; p= 0.54), whereas the fall risk for 
those using benzodiazepines and carrying a *2 or *3 allele was HR= 1.51 (95% CI 1.27; 1.79; 
p= 2.17*10-6). These risks resulted in a SI of 3.0 indicating an excess risk from exposure to both 
factors due to the interaction, relative to the excess risk from exposure – to both factors – 
without interaction.
 None of the meta-analyses indicated significant heterogeneity between the studies, I2 
varied between 0-19%.
Additional analyses
Regarding the other genetic variants, the genotype distribution for all alleles were in Hardy-
Weinberg equilibrium. Of the alleles analyzed only the stratification on CYP2C19*2 indicated 
significant differences. The meta-analyses indicated that the fall risk of benzodiazepine use 
compared to non-use in those carrying no variant CYP2C19 alleles (reference *1/*1 genotype) 
was increased: HR= 1.33 (95% CI, 1.14; 1.55; p= 3.42*10-4). In comparison, the fall risk in those 
carrying at least one variant CYP2C19 allele was HR= 0.85 (95% CI, 0.65; 1.12: p= 0.34). Within 
benzodiazepine users, carriership of CYP2C19*2 alleles was inversely associated with fall risk: 
combined HR= 0.65 (95% CI, 0.48; 0.88; p= 0.01).
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Discussion
Our study addresses an important and novel topic, namely the effect of genetic variation 
on medication-related falls. Benzodiazepine-related fall risk was significantly modified by 
CYP2C9 genotype. Carriers of at least one variant CYP2C9 *2 or *3 allele using benzodiazepines 
– compared to non-users – had a significantly increased fall risk, while users carrying no 
variant *2 or *3 alleles had no significantly increased fall risk. In addition, we observed an 
allele dose effect, since having more variant alleles was associated with a higher increased 
fall risk. 
 Both fall risk and CYP2C9 variant allele frequencies are relatively low and thus multiple 
and large samples are required. By including three large and independent study populations 
we were able to show replication and consistency of the association and gain power by 
performing meta-analyses, in line with a previous pilot study in one of the study populations.18 
This was not only indicated in the analyses comparing benzodiazepine users with non-users, 
but also within users stratified on CYP2C9 genotypes, and thereby accounting for potential 
confounding by indication. Moreover, we observed evidence for an allele dose effect 
comparing heterozygous and homozygous variant allele carriers, as the fall risk increased 
with increasing number of CYP2C9 variant alleles. Furthermore, the Synergy Index indicated 
a threefold excess risk for exposure to the combination of benzodiazepine use and *2 or *3 
allele carriership, due to the interaction between both factors. Additionally, carriership of a 
*2 or *3 allele on itself was not associated with fall.
 The percentage of benzodiazepine users differed between the three study populations 
(4-15%), which is probably due to the different points in time of the studies. In the Netherlands, 
the reimbursement policy changed in 2009 resulting in a decrease in benzodiazepine use.47
 The CYP2C9 gene is positioned on chromosome 10 with the *2 and *3 variants located 
in exon 3 and 7, encoding an arginine to cysteine (*2) and isoleucine to leucine (*3) amino 
acid substitution respectively. Both protein variants of the CYP2C9 enzyme result in a 
decreased enzyme activity, and the combination of having both variant alleles exhibits 
the most pronounced effect.19,20 The *2/*2 or *3/*3 genotypes are considered to result in 
a relatively poor metabolizer (PM) phenotype.19,20 In this phenotype, the metabolism rate 
of this oxidative pathway is approximately half compared to individuals having no variant 
alleles (*1/*1). Additionally, variant genotypes, both heterozygous and homozygous for 
CYP2C9*2 and *3 has been shown to affect drug clearance, with lower clearance observed 
up to 90% for, for example S-acenocoumarol, S-warfarin, phenytoin, tolbutamide, ibuprofen, 
or fluvastatin.19,20 Yet, the effect of the variant alleles on metabolism rate and/or total drug 
clearance depends on the relative contribution of the CYP2C9 dependent pathway for that 
particular compound. Furthermore, effect on metabolism and/or clearance could differ 
between CYP2C9*2 and *3 alleles and per substrate20. For benzodiazepines, it is yet unclear 
to what extent *2 and *3 alleles affect their total metabolism and/or in vivo clearance. To 
our knowledge, as of yet there is only limited evidence indicating that CYP2C9 plays a role 
in the metabolism of benzodiazepines, as CYP3A enzymes and 2C19 enzymes are currently 
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thought to be the main enzymes involved in benzodiazepine biotransformation.11,15,16 
However, in vitro studies using human liver microsomes indicated that CYP2C9 can catalyze 
the N-demethylation of diazepam,17,48,49 flunitrazepam,50 N-desmethyladinazolam51 and 
temazepam.17 Additionally, another study using human liver microsomes showed that 
CYP2C9 was involved in the oxidation and hydroxylation of quazepam.52 A complicating 
factor may be that some of these biotransformations can yield pharmacologically active 
metabolites. In addition, CYP2C9 may be inhibited by concomitantly used drugs including 
amiodarone, fluvastatin and fluconazole.19,20 We could not account for all these factors and, 
although we do not think that they affected our study results substantially, they should be 
considered in further research. Additionally, due to our sample size we were not able to 
perform subanalyses of different benzodiazepine classes – anxiolytics and hypnotics – or 
investigate individual benzodiazepines in order to assess a potential class or individual drug 
effect. Overall, additional research is needed to elucidate the exact role of CYP2C9 enzyme 
and its polymorphisms in the metabolism of benzodiazepines. 
 Remarkably, our additional analyses indicated an increased fall risk for subjects with 
benzodiazepine use in those not carrying a CYP2C19*2 allele (homozygous reference *1/*1). 
Like CYP2C9*2, CYP2C19*2 alleles encode for a decreased enzyme activity.53 We do not 
have a clear explanation for this finding, though we hypothesize that potentially different 
benzodiazepines are metabolized by CYP2C9 and CYP2C19, and for those metabolized 
by CYP2C19 active metabolites are of more importance in fall risk than the parent drug. 
However, further research is necessary to elucidate this finding.
 Our study has limitations: first, no benzodiazepine plasma levels were available to 
confirm our hypothesized mechanism. Future studies could investigate plasma levels across 
CYP2C9*2 and *3 genotypes, and preferably also in relation to therapeutic and adverse 
effects. Second, the number of fall cases per CYP2C9*2 and CYP29*3 genotype groups 
was limited, and the population frequency of the variant alleles is relatively low with the 
*3 allele being lower than the *2 allele (6% vs. 13%). We therefore combined genotypes for 
each variant allele since both alleles result in a decrease in enzyme activity.19,20 In addition, 
the observed effect size in subjects carrying the CYP2C9*3 allele was similar to that in 
subjects carrying the CYP2C9*2 allele. In future studies it would be interesting to investigate 
both variants: *2 and *3 separately. Third, as the majority of the study population was of 
Caucasian ethnicity, our results cannot be extrapolated to other ethnic groups. Fourth, in the 
Rotterdam Study, a fall definition was used that differed from the one in the other two studies 
(i.e., serious fall incidents). Thereby, the total number of incident falls is likely to higher, as 
the noninjurious falls were not included. This may have affected the association between 
benzodiazepine use and falls. However, the effect sizes were relatively similar across the 
three studies. Additionally, differences in fall definition could affect the association between 
benzodiazepine use and falls when the underlying mechanism for benzodiazepine-related 
falls would differ between serious and less serious falls. Nevertheless, we are not aware 
of potentially different underlying mechanisms. Fifth, in LASA, medication data were 
gathered during study visits and not ascertained at the moment of the fall; consequently, 
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misclassification of the exposure may have occurred. By using pharmacy dispensing records 
in the Rotterdam Study and B-PROOF, exposure at the moment of the fall could be assessed, 
although these records do not necessarily reflect actual use, thus misclassification may 
also have occurred. Last, the B-PROOF study population was selected on having a slightly 
elevated homocysteine level. However, we are not aware of a mechanism through which 
increased homocysteine levels could have interfered with benzodiazepine-related fall risk 
that is modified by CYP2C9 genetic variants.
Conclusion
Taken together, our results show that CYP2C9 genotype for *2 and *3 allele variants modify 
benzodiazepine-related fall risk. Those using benzodiazepines and having reduced CYP2C9 
enzyme activity (based on their genotype) are at increased fall risk. When the role of CYP2C9 
in benzodiazepine metabolism is further revealed and verified, this drug-gene interaction 
may also be relevant for other unintended benzodiazepine effects. Moreover, it will be 
interesting to investigate whether it also affects other age-groups. For now, in clinical practice, 
genotyping might be considered for elderly patients with an indication for benzodiazepine 
use. Further research on the additional value of genotyping  as a prognostic factor in the 
clinical-decision making process is warranted.
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Supplementary material
Methods 
Covariable assessment
In the Rotterdam Study, alcohol consumption was based on food frequency data and reported 
in grams per day.54 In B-PROOF and LASA, alcohol consumptions was categorized into ‘light’, 
‘moderate’ and ‘excessive’.55 Diabetes was based on self-report,21,23 though in LASA these data 
was validated with general practitioner data.32 From weight and height the body mass index 
(BMI, kg/m2) was calculated. Hypertension was defined as systolic blood pressure >140mmHg 
and/or diastolic blood pressure >90 mmHg.46 Depressive symptoms were measured using 
the Center for Epidemiological Studies Depression Scale (CES-D, score range 0-60)56 in the 
Rotterdam Study and LASA, and in a subsample of the Rotterdam Study also the Hospital 
Anxiety and Depression Scale (HADS-D, score range 0-21)57 was used. While in B-PROOF, 
the 15-item version of the geriatric depression scale (GDS) was used.58 Clinically relevant 
depressive symptoms were bases on CES-D scores ≥16,42,43 HADS-D scores ≥9,44 or GDS scores 
≥5.45 Cognitive status was measured by using the mini-mental state examination (MMSE).59 
Serum creatinine levels were used to calculate an age-adjusted estimate of the glomerular 
filtration rate (GFR) according to the chronic kidney disease epidemiology collaboration 
(CKD-EPI) formula.60 Lower-limb disability scores were assessed using a modified version 
of the Stanford Health Assessment Questionnaire.33,34 The score was based on answers to 
questions regarding rising, walking, bending, and getting in and out of a car. Disability was 
defined as a score of 3 or higher.34 A physical performance score was calculated from the 
results of three physical function tests: walking test, chair stand test, and the tandem stand 
test.36 The physical performance score ranged from 0 to 12 (low physical performance – high 
physical performance).27,35 The maximum handgrip strength (kg) was defined as the highest 
results of two maximum trials per hand using a dynamometer (B-PROOF: Takei TKK 5401, 
LASA: Takei TKK 5001, Takei Scientific Instrument CO. Ltd.,Tokyo, Japan). For the Rotterdam 
Study, baseline fall history and serum creatinine levels were used, and the use of a walking 
aid was not assessed at the second measurement round. In addition, depressive symptoms 
were available from the second visit onwards. Data of the other covariables were available 
for all follow-up visits, but to minimize the number of missing, the values from the preceding 
visit were used. 
Genotyping
In the Rotterdam Study, genotyping of CYP3A4*1b (rs2740574), CYP3A5*3 (rs776746), 
CYP3A7*1c (rs11568825), all located on chromosome 7, and CYP2C19*2 (rs4244285) located 
on chromosome 10, was done using a TaqMan allelic discrimination assays on a ABI Prism 
9700 HT sequence detection system, as previously described.61,62
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In B-PROOF, these variants were determined based on the Illumina-Omni express array and 
imputations to 1000 Genomes Project (PhaseIv3, March 2012) reference set.39  The imputation 
quality of all variants was >0.99.
 
Total exclusions
N = 904 
B-PROOF 
N = 2,919 
Exclusion criteria: 
No pharmacy data, N = 512 
 
 
Exclusion criteria: 
No fall follow-up, N = 71 
Not living in the community,  
N = 22 
Total no 2C9*2/*3  genetic 
data 
N = 2,044 
Participants with 
2C9*2/*3  
N = 9,441 
No 2C9*2/*3  genetic data 
N = 272 
No 2C9*2/*3  genetic data 
N = 478 
Participants with 
medication data & fall 
data 
N = 2,407 
Participants with 
medication data & fall 
data 
N = 1,416 
Participants with 
2C9*2/*3  
N = 2,135 
Participants with 
2C9*2/*3 
N = 938 
Exclusion criteria: 
No informed consent for follow-
up, N = 226 
End of follow-up before
 
01-05-1991, N = 73   
Case before 01-05-1991, N = 22 
No 2C9*2/*3  genetic data 
N = 1,294 
Participants with 
2C9*2/*3  
N = 6,368 
LASA 
N = 1,509 
The Rotterdam Study 
N = 7,983 
Total 
N = 12,411 
Total participants with 
medication data & fall 
data 
N = 11,485 
Participants with 
medication data & fall 
data 
N = 7,662 
Figure 1. Flowchart of the included study populations.
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Table 3. Genotypes and allele frequencies of CYP2C9*2 and *3 in the total population, split per study 
population. 
the Rotterdam Study 
N= 7,662
B-PROOF 
N= 2,407
LASA 
N= 1,416
CYP2C9*2/*3 Tot available: 6,368* Tot available: 2,135* Tot available: 938*
*1/*1† 4,230 (66.4) 1,399 (65.5) 597 (63.6)
*1/*2† 1,320 (20.7) 435 (20.4) 195 (20.8)
*1/*3† 596 (9.4) 218 (10.2) 104 (11.1)
*2/*3† 92 (1.4) 34 (1.6) 14 (1.5)
*2/*2† 104 (1.6) 41 (1.9) 26 (2.8)
*3/*3† 26 (0.4) 8 (0.4) 2 (0.2)
Allele frequency *2 (%) 13 13 14
Allele frequency *3 (%) 6 6 7
*Total number of participants with genotype data available. †Presented as N (%).
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Abstract 
Background
To investigate the association between use of beta-blockers and beta-blocker characteristics 
– selectivity, lipid solubility, intrinsic sympathetic activity (ISA), and CYP2D6 enzyme 
metabolism – and fall risk.
Methods 
Data from two prospective studies were used, including community-dwelling individuals, 
N= 7,662 (the Rotterdam Study) and 2,407 (B-PROOF), all aged ≥55 years. Fall incidents 
were recorded prospectively. Beta-blocker use was determined using pharmacy dispensing 
records. Cox proportional hazard models adjusted for age and sex were applied to determine 
the association between beta-blocker use, their characteristics – selectivity, lipid solubility, 
ISA, and CYP2D6 enzyme metabolism –, and fall risk. The results of the studies were combined 
using meta-analyses.
Results 
In total 2,917 participants encountered a fall during a total follow-up time of 89,529 years. 
Meta-analysis indicated no association between use of any beta-blocker, compared to non-
use, and fall risk, HR= 0.97 (95% CI 0.88; 1.06). Neither was use of a selective beta-blocker 
associated with fall risk, HR= 0.92 (95% CI 0.83; 1.01). Use of a non-selective beta-blocker 
was associated with an increased fall risk, HR= 1.22 (95% CI 1.01; 1.48). Other beta-blocker 
characteristics including lipid solubility and CYP2D6 enzyme metabolism were not associated 
with fall risk. 
Conclusion 
Our study suggests that use of a non-selective beta-blocker, contrary to selective beta-
blockers, is associated with an increased fall risk in an older population. In clinical practice, 
beta-blockers have been shown effective for a variety of cardiovascular indications. Though, 
fall risk should be considered when prescribing a beta-blocker in this age group, and the pros 
and cons for beta-blockers classes should be taken into consideration.
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What is already known about this subject
 • Beta-blocker use has been associated with fall risk, although literature is contradictory.
 • Pharmacological and adverse effects may vary between beta-blocker characteristics. 
 • Therefore, the association between beta-blocker characteristics – adrenergic receptor 
selectivity, lipid solubility, intrinsic sympathetic activity (ISA), and CYP2D6 enzyme 
metabolism – and fall risk should be evaluated.
What this study adds
 • Use of a non-selective beta-blocker, in contrast to selective beta-blockers, is associated 
with an increased fall risk in an older population.
 • Lipid solubility and CYP2D6 enzyme metabolism was not associated with fall risk.
 • The number of participants using a beta-blocker with ISA was limited and therefore an 
association with fall risk could not be examined. 
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Introduction
In the aging population, fall incidents form a growing healthcare problem.1 Of those above 
65 years of age, one in three encounters at least one fall annually.2 Falls lead to significant 
morbidity and even mortality. Moreover, falls are associated with reduced quality of life and 
increased health care costs.3-5 One of the risk factors for falls is the use of certain medication,6,7 
including beta-blockers, although literature is contradictory.7-10 Beta-blocker use is thought to 
result in fall risk by inducing bradycardia, reducing the cardiac output, inducing hypotension 
and dizziness.11 Pharmacological effects and occurrence of adverse effects may vary between 
different beta-blocking agents. Differences of beta-blocking agents relate for example to 
their selectivity for adrenergic receptors, lipid solubility, intrinsic sympathetic activity (ISA), 
and their elimination route.11,12
 Previously, we observed an increased fall risk with the use of non-selective beta-blocking 
agents.8 In addition, the more lipophilic beta-blockers may be associated with central nerve 
system side effects, such as dizziness and light-headedness.11,13 Furthermore, beta-blocking 
agents with ISA might be less susceptible to cause bradycardia.11 Regarding the elimination 
route, some beta-blockers are eliminated through liver metabolism – e.g., metoprolol and 
propranolol –, whereas others are predominantly eliminated by renal excretion – e.g., atenolol 
–.11,12 For those subjected to liver metabolism, the Cytochrome P450 (CYP) 2D6 enzyme plays 
an important role.14,15 The CYP2D6 gene displays multiple genetic variations, of which the 
*4 variant allele is suggested to be of main importance for Caucasians. The *4 variant results 
in a non-functional protein,16 and in Caucasians it is responsible for the majority of poor 
metabolizer (PM) phenotypes.14,15 Previous research indicated that metoprolol users with a 
poor metabolizers phenotype, according to their CYP2D6*4 genotypes, had a lower blood 
pressure and were at increased risk for bradycardia.17,18 Overall, varying pharmacological 
effects of beta-blocking agents or individual differences on clearance may underlie the 
contradictory literature results.
 Our objective was to investigate the association between use of beta-blocker and beta-
blocker characteristics – selectivity, lipid solubility, ISA, and CYP2D6 enzyme metabolism – 
and fall risk. We hypothesized that use of non-selective agents, lipid soluble agents and those 
without ISA are associated with an increased fall risk. In addition, we hypothesized that users 
of beta-blockers metabolized by CYP2D6 who carry a CYP2D6*4 variant are also at increased 
risk for fall incidents. These research questions were investigated in two independent studies 
involving community-dwelling older individuals.
Methods 
Study population and setting
Data were used from the Rotterdam Study and B-PROOF (B-vitamins in the PRevention 
Of Osteoporotic Fractures). The Rotterdam Study is an ongoing population-based cohort, 
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executed within a suburb of Rotterdam. Its design, objectives and methods have been 
described in detail.19,20 Briefly, the study was initiated in 1989 and 7,983 participants aged 
≥55 years were included. Subsequently, participants were interviewed and underwent an 
extensive set of examinations that were repeated during the follow-up visits every 4-5 years. 
For the current study, participants with pharmacy dispensing data and validated fall data 
were included, covering a study period from 1 May 1991 until 31 December 2010. The 
Rotterdam Study has been approved by the medical ethics committee according to the 
‘Wet Bevolkingsonderzoek ERGO’ (Population Study Act: Rotterdam Study), executed by the 
Ministry of Health, Welfare and Sports of the Netherlands. All study participants gave written 
informed consent to participate in the study and obtain information from their treating 
physicians.19,20
 B-PROOF has also been described in more detail.21 In short, it is a multi-centre, randomized, 
placebo-controlled, double-blind trial investigating the efficacy of vitamin B12 and folic acid 
supplementation on the prevention of fractures in persons aged ≥65 years. In total 2,919 
participants were included and followed for 2 to 3 years, covering a study period from 2008 
until 2013. Inclusion criteria were homocysteine levels of 12-50 μmol/L, serum creatinine 
≤150 μmol/L, and no reported malignancies in the past 5 years. For the current study, 
participants with pharmacy dispensing data were included. The Medical Ethics Committee of 
Wageningen University approved the study protocol, and the Medical Ethics committees of 
Erasmus Medical Centre and VU University Medical Center gave approval for local feasibility. 
Before entering the study, all participants gave written informed consent.21
 Previous B-PROOF results indicated that the intervention had no effect on the time to first 
or second fall, or the number of falls encountered during the study.22 For the current study 
we therefore used a cohort study design.
Fall incidents
In the Rotterdam Study, ‘serious falls’ were defined as ‘a fall leading to a hospital admission 
or leading to a fracture’. Data were obtained from a computerized reporting system of the 
general practitioners within the Rotterdam Study. Participant data was also linked to the 
Dutch National Morbidity Registration (LMR), which contains information of all hospital 
admissions. Serious fall data were coded by two members of the research team and were 
completed until 2010. The first serious fall date was defined as the index date. A participant 
was followed from the baseline date (date of study enrolment) until the first serious fall 
(index date), death or the end of the study period, whichever came first. 
 In B-PROOF, a fall incident was defined as ‘an unintentional change in position resulting 
in coming to a rest at a lower level or on the ground’.23 Participants reported fall incidents 
prospectively on a fall calendar on a weekly basis. The calendar was returned to the research 
team every 3 months. Participants with incomplete or unclear calendars were contacted 
by telephone. Participants were followed until their first fall incident, the Thursday in that 
particular week was defined as the index date. Participants were followed from baseline until 
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the index date, their drop-out date or the date of their last calendar, date of death, or the end 
of the study, whichever came first.
Beta-blocker use
Beta-blocker use was defined according to the Anatomical Therapeutic Chemical (ATC) code,24 
‘C07’. Selective beta-blockers were defined with the ATC codes; ‘C07AB’, ‘C07BB’, ‘C07CB’, 
‘C07DB’, ‘C07EB’, and ‘C07FB’. Non-selective beta-blockers were defined as ‘C07AA’, ‘C07BA’, 
‘C07CA’, ‘C07DA’, ‘C07EA’, ‘C07FA’, and ‘C07AG’. Table 1 depicts the characteristics of individual 
beta-blocking agent, according to lipid solubility, ISA, and CYP2D6 enzyme metabolism.11,12
 Five exposure definitions were used in the analyses: 1) beta-blocker use overall, 
2) selective- and non-selective beta-blocker use, 3) lipophilic and non-lipophilic beta-blocker 
use, 4) beta-blockers with and without ISA, and 5) use of beta-blockers with and without 
CYP2D6 enzyme metabolism. 
 In both studies, beta-blocker use was based on pharmacy dispensing records. In the 
Rotterdam Study, these records from the regional pharmacies were available from January 
1st 1991 onwards. More than 95% of the participants fill their drug prescriptions at one of 
these pharmacies. 
 In B-PROOF, pharmacy dispensing records were obtained from the Dutch Foundation for 
Pharmaceutical Statistics (SFK), as previously described.8 Data were available throughout the 
study period of a participant. 
 The dispensing records contain information regarding date of dispensing, total amount 
of drug units per dispensing, prescribed daily number of units, product name of the drugs 
and corresponding ATC code. Current medication use was defined as use at the time of the 
fall (on the index date). Past use was defined as use prior to, but no longer on, the index date. 
To investigate a dose-response relation, the average prescribed daily dose was expressed 
in standardized defined daily doses (DDDs). In the Rotterdam Study, we ensured that all 
participants had pharmacy dispensing records available for at least four months prior to their 
study start, to avoid potential misclassification of exposure.
Covariables 
Basis characteristics including age, sex, ethnicity, use of a walking aid, history of falls, smoking 
habits, alcohol consumption, and diabetes were ascertained using a questionnaire.19,21 During 
study visits, various characteristics were measured including weight, height, blood pressure, 
depressive symptoms and cognitive performance. Additionally, serum creatinine,19,21 and 
the use of concomitant medication was assessed. As a measure of physical function, lower 
limb disability scores were determined in the Rotterdam Study,25,26 in B-PROOF physical 
performance scores and hand-grip strength were assessed.27,28 In the Rotterdam Study, also 
orthostatic hypotension measures and dizziness were available.19
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Table 1. Depicts the characteristics of individual beta-blocking agent, according to lipid solubility, ISA, and 
CYP2D6 enzyme metabolism.
Beta-blocker agent Selectivity Lipophilicity ISA CYP2D6 metabolism
Acebutolol x x x
Alprenolol xx x x
Atenolol x
Betaxolol x x
Bevantolol x x
Bisoprolol x x
Carteolol x
Carvedilol xx x
Celiprolol x x
Labetalol x
Metoprolol x x x
Nebivolol x x x
Oxprenolol x x
Penbutolol xx x
Pindolol x x
Propranolol xx x
Sotalol
Timolol x x
A ‘x’ indicates the presence of a characteristic, and ‘xx’ indicates the highly lipophilic agents.
In the Rotterdam Study, alcohol consumption was based on food frequency data and reported 
in grams per day.29 In B-PROOF, alcohol consumptions was categorized into ‘light’, ‘moderate’ 
and ‘excessive’.30 Diabetes was based on self-report.19,21 Weight and height were measured 
and were used to calculate body mass index (BMI, kg/m2). Hypertension was defined as 
systolic blood pressure >140mmHg and/or diastolic blood pressure >90 mmHg.31 In the 
Rotterdam Study, depressive symptoms were assessed using the Center for Epidemiological 
Studies Depression Scale (CES-D, score range 0-60)32 or in a subsample the Hospital Anxiety 
and Depression Scale (HADS-D, score range 0-21).33 In B-PROOF, the 15-item version of the 
geriatric depression scale (GDS) was used.34 Clinically relevant depressive symptoms were 
based on CES-D scores ≥16,35,36 HADS-D scores ≥9,37 or GDS scores ≥5.38 Cognitive performance 
was assessed by the mini-mental state examination (MMSE).39 Serum creatinine levels were 
used to calculate an age-adjusted estimate of the glomerular filtration rate (GFR) according 
to the chronic kidney disease epidemiology collaboration (CKD-EPI) formula.40 Concomitant 
medication use was assessed with pharmacy dispensing records, and those considered 
as potential confounders were; antihypertensive medication ‘C02’, diuretics ‘C03’, calcium 
antagonist ‘C08’, renin-angiotensin agents ‘C09’ , benzodiazepines ‘N05BA’ or ‘N05CD’ , and 
antidepressants ‘N06A’. Lower-limb disability scores were assessed using a modified version 
of the Stanford Health Assessment Questionnaire.25,26 The score was based on answers to 
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questions regarding rising, walking, bending, and getting in and out of a car. Disability was 
defined as a score of 3 or higher.26 A physical performance score was calculated from the 
results of three physical function tests: walking test, chair stand test, and the tandem stand 
test.28 Physical performance score ranged from 0-12 (low physical performance – high physical 
performance).27,41 Maximum handgrip strength (kg) was defined as the highest results of two 
maximum trials per hand using a dynamometer (Takei TKK 5401, Takei Scientific Instrument 
CO. Ltd.,Tokyo, Japan). Orthostatic hypotension was defined as: a decrease of ≥20 mmHg in 
systolic and/or a decrease of ≥10 mmHg in diastolic blood pressure.42 Dizziness symptoms 
were assed using a questionnaire.19 
 For the Rotterdam Study, baseline fall history, dizziness and serum creatinine levels 
were used, and depressive symptoms were available from the second visit onwards. Data of 
the other covariables were available for all follow-up visits, but to minimize the number of 
missings, the values from the preceding visit were used. 
Genotyping
CYP2D6*4 (rs3892097) allele variants were determined based on the illumina 550 (+duo) 
(the Rotterdam Study), and the Illumina-Omni express array (B-PROOF), and imputation to 
1000 Genomes Project (PhaseIv3, March 2012) reference set.43 The imputation quality was 
0.99. In B-PROOF imputations were only done for Caucasians. For both studies, the reference 
group was defined as those with homozygous major allele carrier ship, i.e. the absence of a 
CYP2D6*4 allele.
Statistical analyses 
Baseline characteristics were determined for fallers and non-fallers. Differences between 
groups were tested using a t-test, a Chi-square test or a Mann-Whitney U test. Deviation from 
Hardy-Weinberg equilibrium was tested using a Chi-square test for allele frequencies.
 Cox proportional hazards models were used to calculate fall hazard ratios (HR) for 
users compared to non-users.44 The model compares the prevalence of exposure to beta-
blockers in the incident fall cases on the index date with the exposure prevalence in all other 
participants in the cohort on the same date of follow-up. In this way, cases are censored but 
non-cases can serve as a reference on multiple occasions until the end of the study period. 
This method for cohort analysis with a Cox proportional hazards analysis with drug use as a 
time-varying determinant is valid and has been described earlier.44 This analysis was done 
for the five exposure categories (i.e., beta-blocker use overall, selectivity, lipophilicity, ISA 
and CYP2D6 enzyme metabolism) separately. Per exposure category we stratified on beta-
blocker characteristic (e.g., non-use vs. selective- and non-selective beta-blocker use). Non-
use was defined as no current beta-blocker use. The models were adjusted for age and sex 
(model 1). Covariables were included in the models if they changed the hazard ratio of the 
association between beta-blocker use and falls by more than 10% (model 2). For the first 
exposure a dose-response relation was investigated. Dose categories were made according 
to median number of prescribed DDDs. In addition, the analysis of the fifth exposure was 
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 73
73Beta-blocker use and fall risk | 
1
2
3
4
5
stratified on CYP2D6 genotypes. Fall risk in current users was compared to non-users, within 
those carrying no variant CYP2D6*4 alleles. Likewise, within those carrying at least one 
variant CYP2D6*4 allele, fall risk in current users was compared to non-users. 
 The results of the two studies were combined using meta-analysis. The effect estimates 
– beta’s (log HR) – and their standard errors were used to calculate the overall effect, and to 
investigate the heterogeneity between the studies. Meta-analyses were done using the R 
package ‘rmeta’ applying a random effect model, R version 3.0.3. All other statistical analyses 
were done using the statistical software package SPSS version 21.0 (IBM, Armonk, NY, USA) 
and p-values <0.05 were considered statistically significant.
 Finally, sensitivity analyses were applied, in which we categorized the selectivity beta-
blocker group into; no beta-blocker use (reference), selective beta-blocker use, non-selective, 
and non-selective and also high lipophilic beta-blocker use. The lipophilic beta-blocker group 
was categorized into; no beta-blocker use (reference), non-lipophilic, medium lipophilic, and 
highly lipophilic. In addition, a dose-response relation was investigated for non-selective 
beta-blockers. Furthermore, an association with falls for past en current use was investigated 
for selective and non-selective beta-blockers.
Results
Study population
The total Rotterdam Study population comprised 7,983 participants. Of those, 7,662 had 
both medication and fall data, with 6,170 having also genetic data. B-PROOF included 2,919 
participants, of whom 2,407 had medication and fall data, and 2,135 also had genetic data 
(flow-chart supplementary figure 1). The Rotterdam population with medication, fall, and 
genetic data differed slightly from those without genetic data. Those without genetic data 
were slightly older, more likely to be of female gender, to have a positive fall history, use a 
walking aid, have a lower MMSE score, depressive symptoms, hypertension, self-reported 
diabetes, lower limb disabilities, and to be of non-Caucasian origin. In addition, there were 
fewer current smokers. In B-PROOF, those without genetic data were more like to have self-
reported diabetes. 
 In the Rotterdam Study the median follow-up time was 11.4 year with an inter quartile 
range (IQR) of 5.1-17.9 years, and in B-PROOF it was 1.8 years [0.5-2.0]. Table 2 presents the 
baseline characteristics for both study populations, separated on occurrence of a fall during 
follow-up.
Beta-blocker use and fall risk
In both studies, current and past use of beta-blockers was not associated with fall risk, Table 
3. For current use – compared to non-use – the combined HR was 0.97 (95% CI 0.88; 1.06). 
The use of selective beta-blockers was also not associated with fall risk, combined HR= 0.92 
(95% CI 0.83; 1.01). Use of non-selective beta-blockers was associated with an increased 
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fall risk, combined HR= 1.22 (1.01; 1.48). Use of a lipophilic or non-lipophilic beta-blocker 
was not associated with fall risk, combined HR was 0.99 (95% CI 0.71; 1.37), and HR= 0.99 
(95% CI 0.88; 1.09) respectively. In both studies the hazard ratios were adjusted for age and 
sex, as the other considered covariates did not change the HR by more than 10%. As, in total, 
there were only four fall cases who used a beta-blocker with ISA capacity, the association 
between beta-blockers with and without ISA could not be investigated. 
Dose response relation
In both studies, beta-blockers were used in relatively low dosages, the median number of 
prescribed DDDs was 0.50. No dose-response relation was observed. The combined analyses 
indicated that those using the median dose or less – compared to non-use – had a fall risk of 
HR= 1.03 (95% CI 0.92; 1.16). Those using a dose above the median had a fall risk of HR= 0.88 
(95% CI 0.72; 1.08). In addition, there was no significant linear trend for the dose categories, 
p= 0.159. Data of the individual studies is not shown.
Beta-blocker use, fall risk and CYP2D6*4 genotype
In the Rotterdam Study, CYP2D6*4 allele had a frequency of 20%, and in B-PROOF 22%. In 
both studies, the allele frequency was in Hardy and Weinberg-equilibrium.
 The association between use of beta-blockers, subjected to CYP2D6 enzyme metabolism 
or not, and fall risk, was stratified on CYP2D6*4 genotype. No significant associations were 
observed, Table 4.
 None, except one, of the meta-analyses indicated significant heterogeneity between the 
studies, I2 varried between 0-4%. The meta-analyses of non-lipophilic beta-blockers indicated 
significant heterogeneity, p= 0.04 and I2= 4%.
Sensitivity analyses
Additional categorization of the non-selective beta-blocker group into non-selective, and 
non-selective highly lipophilic beta-blockers, did not result in materially different results. Use 
of non-selective beta-blockers – compared to non-use – was non-significantly associated 
with an increased fall risk, combined HR= 1.22 (95% CI 0.97; 1.53). Use of non-selective 
highly lipophilic beta-blockers was non-significantly associated with fall risk, combined 
HR= 1.23 (95% CI 0.87; 1.74). Likewise, subdividing lipophilic beta-blockers into medium 
and highly lipophilic beta-blockers did not show substantially different results, combined 
HR= 0.99 (95% CI 0.85; 1.15), and HR= 1.22 (95% CI 0.86; 1.71), respectively. In addition, no 
dose-response relation was observed for non-selective beta-blocker use (data not shown). 
The combined analyses indicated that those using the median dose (0.50 DDD) or less – 
compared to non-use – had a fall risk of HR= 1.25 (95% CI 0.96; 1.62). Those using a dose 
above the median had a fall risk of HR= 1.22 (95% CI 0.87; 1.69). The results of the association 
between past and current use of selective and non-selective beta-blockers were not different 
when compared to the results for current users, supplemental Table 1. All these analyses 
were adjusted for age and sex.
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Table 2. Baseline characteristics of the Rotterdam Study and B-PROOF grouped on the basis of fall incidents 
during follow-up. 
the Rotterdam Study B-PROOF
Fallers 
N= 1,770
Non-fallers  
N= 5,892
Fallers 
N= 1,147
Non-fallers  
N= 1,260
Age, yearsa 71.6 (9.3) 69.7 (9.5)d 74.4 (6.7) 73.7 (6.1)d
Female genderb 1,360 (76.8) 3,270 (55.5)d 617 (53.8) 564 (44.8)d
Caucasian ethnicityb 1,640 (92.7) 5,477 (93.0) 1,080 (94.2) 1,186 (94.1)
BMIa 26.3 (3.7) 26.3 (3.7) 26.9 (4.0) 27.3 (4.0)
History of falls (yes)b,e 392 (22.6) 907 (15.7)d 399 (44.2) 217 (21.4)d
Walking aid use (yes)b 215 (13.2) 591 (10.7)d 172 (15.1) 153 (12.2)d
MMSE scorec 28 [26-29] 28 [26-29] 29 [27-29] 28 [27-29]d
Depressive symptoms (yes)b,f 153 (13.6) 339 (9.0)d 90 (7.9) 65 (5.2)d
Hypertension (yes)b,g 955 (58.2) 3077 (56.9) 599 (64.0) 670 (63.6)
Diabetes (yes)b 115 (6.7) 378 (6.6) 93 (10.3) 109 (10.7)
Alcohol intake 
 g/dayc
 lightb
 moderateb
 excessiveb
2.4 [0.1-13.2]
-
-
-
3.9 [0.2-15.2]d
-
-
-
-
778 (67.8)
327 (28.5)
42 (3.7)
-
842 (66.9)
371 (29.5)
46 (3.7)
Current smokingb 351 (20.4) 1345 (23.5)d 93 (8.1) 130 (10.3)
Lower limb disability (yes)b 601 (36.4) 1624 (29.4)d - -
Physical performance scorec - - 9 [6-11] 9 [7-11]d
Handgrip strength (kg)c - - 29 [24-40] 33 [25-42]d
Dizziness (yes)b 616 (35.8) 1792 (31.1)d - -
Orthostatic hypotension (yes)b 203 (13.9) 656 (13.5) - -
eGFR (ml/min/1.73m2)c 71.7 [61.7-81.5] 72.7 [62.2-82.7]d 70.8 [60.7-80.8] 72.2 [61.7-82.4]d
Selective beta-blockers (yes)b 161 (9.1) 623 (10.6) 235 (20.5) 247 (19.6)
Non-selective beta-blockers (yes)b 40 (2.3) 145 (2.5) 46 (4.0) 35 (2.8)
Antihypertensive use (yes)b 20 (1.1) 84 (1.4) 9 (0.8) 14 (1.1)
Diuretic use (yes)b 224 (12.7) 806 (13.7) 181 (15.8) 181 (14.4)
Benzodiazepine use (yes)b 236 (13.3) 648 (11.0)d 54 (4.7) 46 (3.7)
Antidepressant use (yes)b 35 (2.0) 128 (2.2) 57 (5.0) 38 (3.0)d
The numbers presented are based on the valid number of included fall cases and non-fallers. a Presented as mean (±SD). b Presented as N 
(%). c Presented as median [IQR]. d Differences between fall cases and non-fallers within a study population with a p-value <0.05. e Fall history 
concerns falls in the last month for the Rotterdam Study and falls in the preceding year in B-PROOF. f Clinically relevant depressive symptoms 
were bases on CES-D scores ≥16,35,36 HADS-D scores ≥9,37 or GDS scores ≥5.38 g Hypertension was defined as systolic blood pressure >140mmHg 
and/or diastolic blood pressure >90 mmHg.31
BMI= body mass index, MMSE= mini-mental state examination, the eGFR is based on the chronic kidney disease epidemiology collaboration 
formula.
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Discussion
In two large older populations, the use of non-selective beta-blockers was associated with 
an increased fall risk. Use of selective, lipophilic or beta-blockers overall, was not associated 
with fall risk. Furthermore, we did not observe an association between beta-blocker use and 
fall risk across genotypes of CYP2D6. 
 To our knowledge, our study group is the first to evaluate the association between 
beta-blocker characteristics and fall risk. We observed an increased fall risk for current use 
of non-selective beta-blockers, although there was no dose-response relation. Furthermore, 
no association was observed for selective beta-blocker use or beta-blocker use overall. These 
findings might be explained by the receptor binding profile and accompanying systemic 
effects of non-selective beta-blockers. Non-selective beta-blockers bind, in addition to 
binding to β1-receptors, also to β2-receptors and some also to α-receptors. β1-receptors are 
mainly located in the heart, while β2-receptors are also present in the lungs, smooth muscle 
cells of the peripheral circulation, liver and in skeletal muscle cells.11,12,45 As a consequence 
non-selective beta-blockers not only reduce heart rate and contractility, they also induce 
peripheral vasoconstriction, including in blood vessels towards and in skeletal muscle.11,12 
Contrarily, β- and α-blockers also exhibit vasodilating properties.11,12 In theory, β2-antagonist 
may as well have a direct negative effect on skeletal muscle and might thereby be related to 
fall risk, as β2-agonist are suggested to have a positive effect on muscle function.46,47 Thus, 
non-selective beta-blockers may be related to fall risk by their broader range in effects and 
their potential negative effect on skeletal muscle.
 Another aspect of selective and non-selective beta-blockers is that the indication for use 
can differ. Selective beta-blockers are mainly used for hypertension, although metoprolol, for 
example, is also used in patients with heart failure or those with angina pectoris or a previous 
myocardial infarction. Non-selective beta-blockers on the other hand are contraindicated 
for asthmatics and diabetics. Sotalol, a non-selective agent is used for arrhythmias and 
carvedilol is used for heart failure, but also for hypertension and angina pectoris.11,12,48 These 
potential indication differences of beta-blockers may be related to fall risk. Nevertheless, 
our sensitivity analyses did not indicate an association with fall risk for past use of selective 
or non-selective beta-blockers. If the association was spuriously caused by confounding by 
indication, we would expect a similar risk estimate in past users as in current users. 
 Within the B-PROOF population we previously observed an association between non-
selective beta-blocker use and fall risk, though then non-selective beta-blockers were slightly 
differently defined.8 Currently we also included in alfa- and beta-blockers, and excluded 
ocular administered beta-blockers.
 In previous studies, overall use of beta-blockers has been associated with fall risk,9,10 
but not consistently.7 In the studies that reported an association, an increased fall risk 
was observed during initiation of use, which was thought to be due the increased risk of 
hypotension.9,10 We investigated current use and not initiation of use, which may partly 
explain the discrepancy in results. 
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With respect to the lipophilicity of beta-blockers, some non-selective beta-blockers are 
highly lipophilic, such as carvedilol and propranolol.11,12 Because lipophilic agents can cross 
the blood-brain barrier,11,13 we hypothesized that their use was associated with more central 
adverse effects, including dizziness. Nevertheless, our sensitivity analyses investigating the 
use of beta-blockers, combining strong lipophilic and non-selective characteristics, in relation 
to fall risk did not result in a different association than for non-selective beta-blockers overall. 
Thus, our results do not confirm this hypothesis. 
 Regarding pharmacokinetic properties of beta-blockers, we hypothesized that users of 
beta-blockers that are subjected to 2D6 enzyme metabolism who carry a CYP2D6*4 variant 
are at increased risk for fall incidents, due to decreased metabolism and potentially increased 
drug concentrations. Previous studies indicated that the combination of metoprolol – a beta-
blocker predominantly metabolized by CYP2D6 – use and a poor metabolizer phenotype 
– based on genotype – was associated with a lower clearance, a longer half-life,49 and with 
lower blood pressure and, heart rate.17,18 Although we were not able to investigate these 
specific endpoints, our results do not indicate that these clinical effects – whether they 
occurred or not – were translated into fall risk. 
 Our study has strengths and limitations. Its strength is the combination of two large, 
independent, community-dwelling study populations, and thereby the possibility to 
investigate consistency of a potential signal (finding) across the two studies. Our study 
also has limitations, as the B-PROOF study participants were included according to their 
homocysteine levels. However, we do not think that this inclusion criterion would have 
interfered with a mechanism underlying a potential association between beta-blocker use 
and falls. In the Rotterdam Study, fall incidents were differently assessed than in B-PROOF, 
as serious fall incidents were gathered, and falls not leading to serious consequences were 
not included. This may lead to a different association if the underlying mechanism for beta-
blocker-related falls would differ between serious and less serious falls. However, we are 
not aware of different mechanisms, and the effect sizes were relatively similar across both 
studies. In addition, we investigated current use. Possibly, participants encountering side 
effects already stopped using, switched to another beta-blocker, or received lower doses. This 
may have resulted in underestimation of the association. Another limitation is the relatively 
low number of users carrying a CYP2D6*4 allele, consequently we clustered intermediate 
metabolizers (IMs) phenotype – carriers of one *4 allele – with PMs – carriers of two *4 alleles 
–. Although the clustering, the numbers were too low to draw conclusion. And lastly, we do 
not have information on actual plasma levels of the beta-blockers. 
Conclusion
Our study indicates an increased fall risk in older people during the use of non-selective 
beta-blockers, contrary to selective beta-blockers. In clinical practice, beta-blockers have 
been shown effective for a variety of cardiovascular indications. Though, fall risk should be 
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considered when prescribing a beta-blocker in this age group, and the pros and cons for 
beta-blockers classes should be taken into consideration. 
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Supplementary material 
Total exclusions 
N = 833 
B-PROOF 
N = 2,919 
 
Exclusion criteria: 
No pharmacy data, N = 512 
 
Total no 2D6*4 genetic data 
N = 1,764 
Participants with 
2D6*4  
N = 8,305 
No 2D6*4 genetic data 
N = 272 
Participants with 
medication data & fall 
data 
N = 2,407 
Participants with 
2D6*4  
N = 2,135 
Exclusion criteria: 
No informed consent for follow-
up, N = 226 
End of follow-up before 01-05-
1991, N = 73 
Case before 01-05-1991, N = 22 
No 2D6*4 genetic data 
N = 1,492 
Participants with 
2D6*4 
N = 6,170 
The Rotterdam Study 
N = 7,983 
Total 
N = 10,902 
Total participants with 
medication data & fall 
data 
N = 10,069 
Participants with 
medication data & fall 
data 
N = 7,662 
Figure 1. Flowchart of the included study populations.
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Abstract 
Objective 
To identify genetic variants that influence the association between benzodiazepine use and 
fall risk, applying a genome wide association study (GWAS) approach.
Design 
GWAS on two nested case-control studies; the Rotterdam Study and B-PROOF.
Setting 
Community-dwelling individuals living in or near three Dutch cities.
Participants 
Benzodiazepine users, 201 fall cases and 3,187 controls (the Rotterdam Study), and 57 fall 
cases, 241 controls (B-PROOF).
Measurements 
Fall incidents were prospectively recorded and benzodiazepine use was determined using 
pharmacy dispensing records. Only benzodiazepine users were included. Cases were 
defined as those who used a benzodiazepine at the date of the fall. All other participants 
were classified as control. GWAS was done for both studies separately, adjusting for age, sex, 
and the first four principal components. Results were combined with meta-analysis.
Results 
In the Rotterdam Study, a variant was associated with benzodiazepine-related falls, OR 
0.34 (95% CI 0.22; 0.52), p= 6.56*10-7. In B-PROOF this variant was also associated, OR 0.11 
(95% CI 0.03; 0.46) p= 2.51*10-3. This variant was genome wide significantly associated in 
the combined results, OR= 0.31 (95% CI 0.21; 0.47) with MAF= (minor allele frequency) 0.03, 
p= 2.15*10-8, and I2=  54.3%, p= 0.14. This indicates a 69% lower benzodiazepine-related 
fall risk per minor allele, compared to non-carriers. The variant is located in an intron on 
chromosome 9 within the FAM73B gene. 
Conclusions 
Within our study population, a genome wide significantly associated with benzodiazepine-
related falls was observed. Replication and functional studies are warranted to verify and 
support our observed finding.
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Introduction
Fall incidents are a growing health problem in the light of the aging population and their 
substantial impact on morbidity and mortality. Moreover, falls are associated with reduced 
quality of life and increased health care costs.1-4 Annually, one third of the older adults – aged 
≥65 years – encounters at least one fall.5 Fall risk is related to multiple factors, including, 
muscle weakness, problems with balance, vision and cognition, but also use of certain 
medication, in particular benzodiazepines.6-8 Benzodiazepines are frequently used in older 
individuals, mainly for sleeping problems and as anxiolytic.9,10 Their use is thought to affect 
fall risk by inducing sedation, dizziness and balance problems.11,12 
 It has been shown that response to benzodiazepines varies between individuals, which 
may be related to genetic variation.13,14 Previous studies investigated and indicated several 
candidate genes that may affect benzodiazepine response. Most of these genes coded 
for drug metabolizing enzymes (e.g., Cytochrome P450 enzymes),13,14 although genetic 
associations with drug receptors (e.g., GABA receptors) have also been investigated.14-16 
 However, candidate gene studies are generally biased towards existing knowledge, 
usually lack replication, and/or often only a few single nucleotide polymorphisms (SNPs) are 
investigated. In case of metabolizing enzymes different isoforms are usually investigated, 
but variants in enhancers or promotors of the gene are not always taken into account.17,18 
Such variants may influence the amount of protein present in the cell19 and thus potentially 
also the rate of drug metabolism. Here, we aimed to gain more insight into pathways and 
mechanisms underlying benzodiazepine-related falls. In this study, we therefore opted for 
a hypothesis-free approach, namely genome-wide association studies (GWAS) in order to 
identify any genetic variants that influence the association between benzodiazepine use and 
fall risk.
Methods
Study population and setting
Data from two independent study populations were used: the Rotterdam Study and 
B-PROOF (B-vitamins in the PRevention Of Osteoporotic Fractures). The Rotterdam Study 
is an ongoing population-based cohort study, executed within a suburb of Rotterdam. Its 
design, objectives and methods have been described in detail.20,21 In short, the study started 
in 1989 and 7,983 participants aged ≥55 years were included. Participants were interviewed 
and underwent examinations that were repeated every 4-5 years during the follow-up visits. 
Later, in 2002 and 2008 two other cohorts were enrolled. For the current study, participants 
with pharmacy dispensing data and validated fall data from the first cohort were included, 
covering a study period from 1 May 1991 until 31 December 2010. The Rotterdam Study has 
been approved by the medical ethics committee according to the ‘Wet Bevolkingsonderzoek 
ERGO’ (Population Study Act: Rotterdam Study), executed by the Ministry of Health, Welfare 
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and Sports of the Netherlands. All study participants gave written informed consent to 
participate in the study and obtain information from their treating physicians.20,21
 B-PROOF has also been described in more detail.22 Briefly, it is a multi-centre, randomized, 
placebo-controlled, double-blind trial investigating the efficacy of vitamin B12 and folic acid 
supplementation on the prevention of fractures. In total, 2919 participants aged ≥65 years 
were included and followed for 2 to 3 years, covering a study period from 2008 until 2013. 
Inclusion criteria were homocysteine levels of 12-50 μmol/L, serum creatinine ≤150 μmol/L, 
and no reported malignancies in the past 5 years. For the current study, participants with 
pharmacy dispensing data were included. The Medical Ethics Committee of Wageningen 
University approved the study protocol, and approval for local feasibility was obtained from 
the Medical Ethics committees of Erasmus Medical Centre and VU University Medical Centre. 
All participants gave written informed consent before entering the study.22
 B-PROOF results indicated that the intervention had no effect on the time to first or 
second fall, or the number of falls encountered during the study.23 
Benzodiazepine use
Benzodiazepine use was defined according to the Anatomical Therapeutic Chemical (ATC) 
codes,24 ‘N05BA’ for anxiolytics, or ‘N05CD’ for hypnotics, and was based on pharmacy 
dispensing records. In the Rotterdam Study, records from the regional pharmacies were 
available from January 1st 1991 onwards. Over 95% of the participants fill their drug 
prescriptions at one of these pharmacies. To avoid potential misclassification of exposure, 
we ensured that all participants had pharmacy dispensing records for at least four months 
prior to their study start. In B-PROOF, pharmacy dispensing records were obtained from the 
Dutch Foundation for Pharmaceutical Statistics (SFK), as previously described.25 Records 
were available for participants throughout their study period.
Fall incidents
In the Rotterdam Study, ‘serious falls’ were defined as ‘a fall leading to a hospital admission 
or leading to a fracture’. Data were obtained from a computerized reporting system of the 
general practitioners within the Rotterdam Study. Participant data were also linked to the 
Dutch National Morbidity Registration (LMR), which contains information of all hospital 
admissions. Serious fall data were coded by two members of the research team and were 
completed until 2010. The first serious fall date was defined as the index date and a participant 
was followed until the first serious fall, death or the end of the study period, whichever came 
first. 
 In B-PROOF, a fall incident was defined as ‘an unintentional change in position resulting 
in coming to a rest at a lower level or on the ground’.26 Participants reported fall incidents 
prospectively on a fall calendar on a weekly basis, as previously described.25 Participants 
were followed until the index date, their drop-out date or the date of their last calendar, date 
of death, or the end of the study, whichever came first.
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Case and control definition
From both studies only benzodiazepine users were selected, which were defined as those 
having at least one benzodiazepine dispensing record during the follow-up of the study 
period. For each participant, the usage period was calculated by dividing the total number 
of pills in a prescription by the prescribed daily number of pills, starting at the prescription 
filling date at the pharmacy.
 Cases were defined as those who used a benzodiazepine at the date of the first fall (index 
date), i.e. when the fall day fell in a usage period. All other participants were classified as 
controls. 
Genotyping and imputation
Genotyping was done using the illumina 550 (+duo) array (the Rotterdam Study), and the 
Illumina-Omni express array (B-PROOF). Standard QC was performed.27,28 Subsequently 
imputations were performed using the 1000 Genomes Project (PhaseIv3, March 2012) as a 
reference set.29 In both studies only samples of European Ancestry were taken into account.
Statistical analyses
Baseline characteristics were determined for cases and controls per study population. 
Differences between groups were tested using a T-test, a Chi-square test or a Mann-Whitney 
U test.
 GWAS was done for both studies separately applying logistic regression analysis, using 
an additive genetic model. Analyses were adjusted for age, sex and the first four principal 
components to account for any remaining population substructure. The analyses were 
done using GRIMP, a web-based tool for high-speed analysis of large-scale genome-wide 
association using imputed data.30 Quality control was conducted for both studies according 
to the EasyQC protocol.31 Finally, results were combined with meta-analysis using the 
software package METAL, applying a fixed-effect, inverse variance weighted approach and 
including genomic control correction.32 Visualization of the results was done using R, the R 
package ‘qqman’,33 and LocusZoom.34
Database lookups of the associated variants
To gain information about the location, linkage to other variants, and potential function of 
the associated variant – top hit – , the UCSC (University of Californa Santa Cruz) genome 
browser (Build hg19),35 dbSNP36 (human annotation release 107) ,OMIM (online mendelian 
inheritance in man),37 MGI (mouse genome information),38,39 and GeneCards40 were reviewed. 
These databases were also used to gain information on the function of the genes near the 
top hit.
 For further exploration of potential functional elements (e.g., gene regulatory elements, 
promotors, or transcripts) in various cell types and tissues of the top hit, and variants in high 
LD (R2 >0.8), HaploReg was used,41 which compiles data from ENCODE (Encyclopedia of 
DNA Elements), and the NIH Roadmap Epigenomics Mapping Consortium.42 UCSC genome 
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bowers was also used to access information from GTEX (genotype-tissue expression),43 
and ENCODE and Roadmap data directly. Additionally, to lookup whether the top hit was 
previously identified in other – published – GWAS studies, the GWAS catalog was consulted44. 
Results
Study population
In the Rotterdam Study 7,983 participants were included, of whom 6,170 had medication, 
fall and genetic data. Subsequently, 201 cases and 3,187 controls – participants with a 
benzodiazepine dispensing during follow-up – were available for the GWAS analysis. 
In B-PROOF, 2,919 participants were included of whom 2,135 had medication, fall and 
genetic data. Subsequently, 57 cases and 241 controls were available for the GWAS analysis, 
supplementary Figure 1. Table 1 depicts the baseline characteristics of both study populations 
separately for cases and controls.
Meta-analysis
Separate and combined analyses of the Rotterdam study and B-PROOF resulted in several 
suggestive hits, p ≤1.00*10-6, supplementary Table 1a, 1b and 1c. For the combined results, 
the QQ (quantile-quantile) plot, Figure 1, did not show evidence for strong inflation and 
showed some evidence for associations. The Manhattan plot (Figure 2) showed one genome-
wide significant signal on chromosome 9 as well as several suggestive loci. Figure 3 displays 
the regional plot. Table 3 depicts the combined results of the top hit, and those for both 
studies (the Rotterdam Study and BPROOF) separately. The top hit was negatively associated 
with benzodiazepine-related falls, OR 0.31 (95% CI 0.21; 0.47), with MAF= (minor allele 
frequency) 0.03 and P= 2.15*10-8. This indicates a 69% lower benzodiazepine-related fall risk 
per minor allele, compared to non-carriers (Table 2). The heterogeneity between the studies 
was, I2= 54.3%, p= 0.14. Figure 4 depicts a regional plot of for the genome-wide significant 
association.
Database lookups
The variant is located within an intron of FAM73B gene (homo sapiens family with sequence 
similarity 73 member B) with the alternative name of MIGA2 (mitoguardin 2). The gene 
encodes a protein involved in regulation of mitochondrial fusion. No pathway databases 
were available for the gene. With respect to the gene ontology, the protein of the gene is 
located in the cell membrane, and integral component of membrane, and it is involved in 
bone development. The OMIM database referred to research by Zang et al., indicating that 
malfunctioning of mitochondrial fusion is involved in neurodegenerative disorders and fat 
metabolism.50 Knock out models are present in MGI database, and the following associated 
phenotypes are reported; craniofacial, homeostasis/metabolism, immune system and 
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skeleton.51,52 With respect to skeleton phenotypes, a.o., decreased bone mineral content and 
density, and decreased bone strength have been reported.51,52 
Table 1. Baseline characteristics of the Rotterdam Study and B-PROOF separately for cases and controls.
the Rotterdam Study B-PROOF
Cases N= 201 Controls N= 3,187 Cases N= 57 Controls N= 241
Age (years)a 73.8 (9.0) 69.3 (8.9)d 77.5 (7.3) 74.8 (6.5)d
Sex (women, %)b 172 (85.6) 2085 (65.4)d 44 (77.2) 153 (63.5)d
BMI (Kg/m2)a 26.3 (3.8) 26.4 (3.8) 26.3 (3.3) 27.5 (4.0)d
History of falls (%yes)b,e 63 (32.5) 546 (17.4)d 25 (52.1) 58 (30.7)d
Walking aid (%yes)b 29 (16.0) 310 (10.2)d 19 (33.3) 44 (18.3)d
MMSE scorec 27 [26-29] 28 [27-29]d 28 [27-29] 28 [27-29]
Depressive symptoms (%yes)b,f 27 (24.1) 250 (11.8)d 12 (21.1) 26 (10.8)d
Hypertension (yes)b,g 119 (60.4) 1752 (56.3) 32 (68.1) 117 (56.0)
Diabetes (yes)b 15 (7.8) 179 (5.7) 5 (10.4) 21 (11.0)
Alcohol intake 
 g/dayc
 lightb
 moderateb
 excessiveb
0.8 [0.1-11.3] 3.2 [0.1-14.5]d
44 (77.2)
11 (19.3)
2 (3.5)
158 (65.6)
69 (28.6)
14 (5.8)
Current smokingb 46 (23.8) 728 (23.4) 11 (19.3) 24 (10)
Lower limb disability (%yes)b 92 (48.9) 917(30.2)d - -
Physical performance scorec - - 6.0 [3.0-9.0] 8.0 [6.0-10.0]d
Handgrip strength (kg)c - - 23.1 [18.5-27.6] 28.1 [23.0-36.0]d
eGFR (ml/min/1.73m2)c 71.1 [58.9-82.2] 72.2 [62.0-82.6] 69.2 [56.9-82.2] 72.3 [61.6-82.1]
The numbers presented are based on the valid number of included cases and controls. a Presented as mean (±SD). b Presented as N (%). 
c Presented as median [IQR]. d Differences between cases and controls within a study population with a p-value <0.05. e Fall history concerns 
falls in the last month for the Rotterdam Study and falls in the preceding year in B-PROOF. f Clinically relevant depressive symptoms were bases 
on CES-D scores ≥16,45,46 HADS-D scores ≥9,47 or GDS scores ≥5.48 g Hypertension was defined as systolic blood pressure >140mmHg and/or 
diastolic blood pressure >90 mmHg.49 
BMI= body mass index, MMSE= mini-mental state examination, the eGFR is based on the chronic kidney disease epidemiology collaboration 
formula.
HaploReg reports no regulatory features or regions for the variant. Additionally, none of 
the SNPs in high LD (linkage disequilibrium; R2 >0.8), had regulatory features or were in 
regulatory regions. 
 Using ENCODE, FAM73B appears to be expressed in various cell types; blood cell types, 
kidney cells, skeletal muscle cells, lung cells, and breast cells. Similarly, using the roadmap 
‘ChromHmm Primary Core Marks’ track FAM73B appears to be expressed in various cells 
types, e.g., blood, adipose, skeletal muscle, brain, liver and pancreas cells. GTEX, also 
reports expression in a variety of tissues, though with a highest median expression in brain 
– cerebellum. Likewise, expression patterns in GeneCard report expression in a variety of 
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(normal human) tissues – GeneCard also includes data from GTEX –. In addition, it reports 
overexpression in bone in embryonic tissue and stem cells.
Figure 1. QQplot for the GWAS meta-analysis (N= 3,686) on benzodiazepine-related fall risk. The p-values 
were generated using logistic regression analysis.
Figure 2. Manhattan plot for the GWAS meta-analysis (N= 3,686) on benzodiazepine-related fall risk. The 
p-values were generated using logistic regression analysis.
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Figure 3. Regional association plot for the genome-wide significant association with benzodiazepine-related 
falls.
Table 2. Genome-wide association of the top hit (meta-analyses) and separate results for the Rotterdam 
Study and B-PROOF.
Study Chr All 1 All 2 MAF Effect (β) SE OR (95% CI) p-value N
 Rotterdam Study 9 t c 0.036 -1.079 0.217 0.34 (0.22; 0.52) 6.56*10-7 3,388
 B-PROOF 9 t c 0.019 -2.208 0.731 0.11 (0.03; 0.46) 2.51*10-3 298
Combined 9 t c 0.035 -1.171 0.209 0.31 (0.21; 0.47) 2.15*10-8 3,686
Chr= chromosome, All= allele, MAF= minor allele frequency, SE= standard error, OR= odds ratio, 95% CI = 95% confidence interval.
Within the GWAS catalog, 2 studies are reported within a ±500kb distance from the variant, 
though both studies did not observe genome wide significant hits. One study investigated 
response to amphetamines (N= 381, no replication),53 the other systemic lupus erythematosus 
(N= 1,311 cases, N= 3,340 control with replication in N= 793 cases, N= 857 control).54
 The genes near (±500kb) the variant were also reviewed for their function, which is 
presented in supplementary Table 2.
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Discussion
The genome wide association analyses of benzodiazepine-related fall incidents in two 
independent study populations identified a less common variant located in FAM73B gene. 
This variant is associated with a 3-times lower risk of falling, OR= 0.31 (95% CI 0.21; 0.47), 
p= 2.15*10-8, MAF= 3%, N= 3,686 (N= 258 cases and N= 3,428 controls).
 To our knowledge, we are the first to use a GWAS approach to identify genetic variants 
that modify benzodiazepine-related fall incidents. The variant, is an intronic variant located 
on chromosome 9 within the FAM73B gene. Based on the narrow peak in the region plot and 
the functions of the surrounding genes, the FAM73B gene is probably the most likely gene 
underlying the observed association. FAM73B gene encodes a protein involved in regulation 
of mitochondrial fusion, and is involved in bone development. Moreover, mitochondrial 
fusion has been linked to neurodegenerative disorders.50 On the other hand, expression 
data from GTEX reports expression in a wide range of cell types and tissues,43 which is 
plausible with respect to the basic function of the gene. Nevertheless, in normal human 
tissue the highest median expression was in brain, cerebellum. This part of the brain plays 
a key role in motor control,55 thereby the FAM73B gene could be linked to our phenotype, 
benzodiazepine-related fall incidents. Benzodiazepines are thought to affect fall risk by 
inducing sedation, dizziness and balance problems, due to their effect on the central nervous 
system.11,12 Although the FAM73B gene has been linked to neurodegenerative disorders and 
is expressed in brain tissue, other information points towards its involvement in bone. Data 
from mouse models indicate that the gene is associated with skeletal phenotypes, including 
decreased bone mineral content and density, and decreased bone strength.51,52 
 Our phenotype, benzodiazepine-related falls, has been differently defined in both studies. 
Within the Rotterdam Study, falls resulting in a hospital admission or facture – serious falls 
– were assessed. Thereby, a connection to bone phenotypes may be plausible, especially 
as our observed association was mainly driven by the Rotterdam Study. However, there are 
more potential pathways, as mouse models also indicate that FAM73B is associated with 
other phenotypes including, craniofacial, homeostasis/metabolism, and immune system.51,52 
Overall, these potential explanations of our observed association remain speculative, 
because it is as of yet unknown whether the variant affects the function of FAM73B. Another 
option might be that the variant affects another gene – yet unknown –, as in the example of 
the obesity-associated variant, which was located in the intron of one gene but appeared to 
affect another gene.56 
 This study has strengths and limitations. Its major strengths is the detailed assessment 
of the phenotype, because of the prospective design of the study and because medication 
use could be determined at the time of the fall incident. Nevertheless, the heterogeneity 
between the study results could be caused by the different effect sizes, the Rotterdam 
study: OR 0.34 (95% CI 0.22; 0.52), p= 6.56*10-7, and B-PROOF OR 0.11 (95% CI 0.03; 0.46) 
p= 2.51*10-3. Otherwise, the heterogeneity is possibly due to the difference in fall definition 
used in both studies. In a previous epidemiologic study regarding the association 
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between benzodiazepine use and fall incidents, we had no indication that difference in fall 
definition would substantially affect the association.57 However, with respect to the genetic 
background of benzodiazepine-related falls, this may in fact have an effect and warrants 
further investigation. In this particular case, the variant might be more related to serious 
consequences of a fall, e.g., a fracture, than to the fall itself. However, within the large GWAS 
on bone mineral density and fracture loci from the GEFOS consortium this variant was not 
reported.58 It should be noted that this is still in the light of the above reported speculative 
explanation of our finding. Overall our study is limited with respect to its sample size. Another 
point to consider is the difference in exposure definition between the cases and the control. 
In cases, exposure at the time of the fall could be determined, while in controls exposure was 
defined as having at least one benzodiazepine dispensing record during the follow-up. This 
could have affected our observed outcome. 
 For future studies, it might be interesting to perform a replication study for both 
phenotypes, benzodiazepine-related falls and benzodiazepine-related serious falls. Thereby, 
a potential difference in underlying genetic mechanisms might be disentangled. 
 In conclusion, our study indicates that a specific variant significantly modifies 
benzodiazepine-related fall incidents, in a population of older individuals. Replication and 
functional studies are warranted to verify and support our observed finding.
Acknowledgments
We gratefully thank all study participants, and all dedicated co-workers who helped in the 
success of both studies. 
Conflicts of Interest: The authors have no potential conflicts of interest that are directly 
relevant to the content of this study.
Author contributions: Study concept and design: BHS, AGU, LB and NvdV. Acquisition, analysis, 
or interpretation of data: all authors. Drafting of the manuscript: ACH, LB, BHS, AGU, and 
NvdV.
Critical revision of the manuscript for important intellectual content: all authors. Statistical 
analysis and statistical expertise: LB. Obtained funding: BHS, AGU, and NvdV. 
Funding/Support: The Rotterdam Study is supported by the Erasmus MC and Erasmus 
University Rotterdam; the Netherlands Organisation for Scientific Research (NWO); the 
Netherlands Organisation for Health Research and Development (ZonMw); the Research 
Institute for Diseases in the Elderly (RIDE); the Netherlands Genomics Initiative (NGI); the 
Ministry of Education, Culture and Sciences; the Ministry of Health Welfare and Sports; the 
European Commission (DG XII); and the Municipality of Rotterdam. B-PROOF is supported 
and funded by The Netherlands Organisation for Health Research and Development 
(ZonMw, Grant 6130.0031 and 11-31010-06), the Hague; unrestricted grant from NZO (Dutch 
Dairy Association), Zoetermeer; NCHA (Netherlands Consortium Healthy Ageing) Leiden/ 
Rotterdam; Ministry of Economic Affairs, Agriculture and Innovation (project KB-15-004-003), 
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 98
98 | Chapter 2.4
the Hague; Wageningen University, Wageningen; VU University Medical Centre, Amsterdam; 
Erasmus Medical Center, Rotterdam. 
Sponsor’s Role: None of the funders had any role in design and conduct of this study; 
collection, management, analysis, and interpretation of the data; and review, or approval of 
the manuscript.
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 99
99Genetics of benzodiazepine-related falls | 
1
2
3
4
5
References
1. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the older population: injuries, 
healthcare costs, and long-term reduced quality of life. J Trauma. 2011;71(3):748-753.
2. Stel VS, Smit JH, Pluijm SMF, Lips P. Consequences of falling in older men and women and risk factors for health 
service use and functional decline. Age and Ageing. 2004;33(1):58-65.
3. Tinetti ME, Doucette J, Claus E, Marottoli R. Risk factors for serious injury during falls by older persons in the 
community. Journal of the American Geriatrics Society. 1995;43(11):1214-1221.
4. Roudsari BS, Ebel BE, Corso PS, Molinari N-AM, Koepsell TD. The acute medical care costs of fall-related injuries 
among the U.S. older adults. Injury. 2005;36(11):1316-1322.
5. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs & Aging. 
1998;12(1):43-53.
6. Woolcott JC, Richardson KJ, Wiens MO, et al. MEta-analysis of the impact of 9 medication classes on falls in 
elderly persons. Arch Intern Med. 2009;169(21):1952-1960.
7. Moreland JD, Richardson JA, Goldsmith CH, Clase CM. Muscle weakness and falls in older adults: a systematic 
review and meta-analysis. Journal of the American Geriatrics Society. 2004;52(7):1121-1129.
8. Panel on Prevention of Falls in Older Persons AGS, British Geriatrics S. Summary of the Updated American 
Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J 
Am Geriatr Soc. 2011;59(1):148-157.
9. Kurko TA, Saastamoinen LK, Tahkapaa S, et al. Long-term use of benzodiazepines: Definitions, prevalence and 
usage patterns - a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037-1047.
10. Gregg JA, Tyson RL, Cook D. Benzodiazepines and Geriatrics: What Clinical Practice Strategies Can Be Used to 
Reduce the Inappropriate Prescribing? Rehabil Nurs. 2016.
11. Hill K, Wee R. Psychotropic Drug-Induced Falls in Older People. Drugs & Aging. 2012;29(1):15-30.
12. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: 
meta-analysis of risks and benefits. Bmj. 2005;331(7526):1169.
13. Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the 
pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007;32(4):333-341.
14. Tiwari AK, Souza RP, Muller DJ. Pharmacogenetics of anxiolytic drugs. J Neural Transm. 2009;116(6):667-677.
15. Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; 
and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum Psychopharmacol. 
2012;27(3):262-269.
16. Choi YJ, Lee SY, Yang KS, Park JY, Yoon SZ, Yoon SM. Polymorphism rs4263535 in GABRA1 intron 4 was related to 
deeper sedation by intravenous midazolam. J Int Med Res. 2015;43(5):686-698.
17. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating 
science into practice. Clin Pharmacol Ther. 2012;92(4):467-475.
18. Peters BJ, Rodin AS, de Boer A, Maitland-van der Zee AH. Methodological and statistical issues in 
pharmacogenomics. J Pharm Pharmacol. 2010;62(2):161-166.
19. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters 
and enhancers in the human genome. 2007;39(3):311-318.
20. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: 
the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7(4):403-422.
21. Hofman A, Brusselle GG, Darwish Murad S, et al. The Rotterdam Study: 2016 objectives and design update. 
European Journal of Epidemiology. 2015;30(8):661-708.
22. van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, et al. Rationale and design of the B-PROOF study, 
a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture 
incidence. BMC Geriatrics. 2011;11:80.
23. Swart KM, Ham AC, van Wijngaarden JP, et al. A Randomized Controlled Trial to Examine the Effect of 2-Year 
Vitamin B12 and Folic Acid Supplementation on Physical Performance, Strength, and Falling: Additional Findings 
from the B-PROOF Study. Calcif Tissue Int. 2015.
24. ATC and DDD Index. http://www.whocc.no/atc_ddd_index/. Accessed March 15, 2015.
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 100
100 | Chapter 2.4
25. Ham AC, Swart KM, Enneman AW, et al. Medication-related fall incidents in an older, ambulant population: the 
B-PROOF study. Drugs Aging. 2014;31(12):917-927.
26. The prevention of falls in later life. A report of the Kellogg International Work Group on the Prevention of Falls 
by the Elderly. Dan Med Bull. 1987;34 Suppl 4:1-24.
27. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic 
case-control association studies. Nat Protoc. 2010;5(9):1564-1573.
28. Genetic Laboratory Erasmus MC Rotterdam. Human Genomics Facility (HUGE-F). 2016; http://glimdna.org/.
29. Pennisi E. Genomics. 1000 Genomes Project gives new map of genetic diversity. Science. 2010;330(6004):574-
575.
30. Estrada K, Abuseiris A, Grosveld FG, Uitterlinden AG, Knoch TA, Rivadeneira F. GRIMP: a web- and grid-based 
tool for high-speed analysis of large-scale genome-wide association using imputed data. Bioinformatics. 
2009;25(20):2750-2752.
31. Winkler TW, Day FR, Croteau-Chonka DC, et al. Quality control and conduct of genome-wide association 
meta-analyses. Nat Protoc. 2014;9(5):1192-1212.
32. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. 
Bioinformatics. 2010;26(17):2190-2191.
33. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. bioRxiv. 2014.
34. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. 
Bioinformatics. 2010;26(18):2336-2337.
35. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996-1006.
36. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 
2001;29(1):308-311.
37. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns 
Hopkins University (Baltimore, MD). http://omim.org/. Accessed June, 2016.
38. Smith CM, Finger JH, Hayamizu TF, et al. The mouse Gene Expression Database (GXD): 2014 update. Nucleic 
Acids Res. 2014;42(Database issue):D818-824.
39. Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE, Mouse Genome Database G. The Mouse Genome Database 
(MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res. 2015;43(Database 
issue):D726-736.
40. GeneCards. Crown Human Genome Center, Weizmann Institute of Science. http://www.genecards.org/. 
Accessed June 2016.
41. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif 
alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40(Database issue):D930-934.
42. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-
74.
43. Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-585.
44. Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. 
Nucleic Acids Res. 2014;42(Database issue):D1001-1006.
45. Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W. Criterion validity of the Center 
for Epidemiologic Studies Depression scale (CES-D): results from a community-based sample of older subjects 
in The Netherlands. Psychol Med. 1997;27(1):231-235.
46. Beekman AT, van Limbeek J, Deeg DJ, Wouters L, van Tilburg W. [A screening tool for depression in the elderly 
in the general population: the usefulness of Center for Epidemiological Studies Depression Scale (CES-D) Een 
screeningsinstrument voor depressie bij ouderen in de algemene bevolking: de bruikbaarheid van de Center 
for Epidemiologic Studies Depression Scale (CES-D). Tijdschr Gerontol Geriatr. 1994;25(3):95-103.
47. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An 
updated literature review. Journal of Psychosomatic Research. 2002;52(2):69-77.
48. Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for 
the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. Int J Geriatr Psychiatry. 
1999;14(10):858-865.
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 101
101Genetics of benzodiazepine-related falls | 
1
2
3
4
5
49. Whitworth JA, World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International 
Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-
1992.
50. Zhang Y, Liu X, Bai J, et al. Mitoguardin Regulates Mitochondrial Fusion through MitoPLD and Is Required for 
Neuronal Homeostasis. Mol Cell. 2016;61(1):111-124.
51. Bassett JH, Gogakos A, White JK, et al. Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 
9 new genes that determine bone strength. PLoS Genet. 2012;8(8):e1002858.
52. Podrini C, Koffas A, Chokshi S, et al. MacroH2A1 isoforms are associated with epigenetic markers for activation 
of lipogenic genes in fat-induced steatosis. Faseb J. 2015;29(5):1676-1687.
53. Hart AB, Engelhardt BE, Wardle MC, et al. Genome-wide association study of d-amphetamine response in 
healthy volunteers identifies putative associations, including cadherin 13 (CDH13). PLoS One. 2012;7(8):e42646.
54. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and 
ITGAM-ITGAX. N Engl J Med. 2008;358(9):900-909.
55. Koziol LF, Budding D, Andreasen N, et al. Consensus paper: the cerebellum’s role in movement and cognition. 
Cerebellum. 2014;13(1):151-177.
56. Smemo S, Tena JJ, Kim K-H, et al. Obesity-associated variants within FTO form long-range functional 
connections with IRX3. 2014;507(7492):371-375.
57. Ham AC, Ziere G, Broer L, et al. CYP2C9 Genotypes Modify Benzodiazepine-Related Fall Risk: Original Results 
From Three Studies With Meta-Analysis. J Am Med Dir Assoc. 2016.
58. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density 
loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44(5):491-501.
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 102
3.
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 103
MEDICATION, HOMOCYSTEINE 
AND BONE MINERAL DENSITY3.
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 104
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 105
3.1
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Abstract 
Background 
Elevated homocysteine levels are a risk indicator for cardiovascular disease, fractures and 
cognitive decline. Previous studies indicated associations between homocysteine levels and 
medication use, including antihypertensive, lipid-lowering and antidiabetic medication. 
However, results were often contradictory and inconclusive. Our objective was to study the 
associations established previously in more detail by sub-classifying medication groups, and 
investigate the potential mediating role of vitamin B12 and folate status.
Materials and methods
Baseline data from the B-PROOF (B-vitamins for the PRevention Of Osteoporotic Fractures) 
study were used. We included 2,912 participants aged ≥65 years, with homocysteine levels 
of 12-50 μmol/L, creatinine levels ≤150 μmol/L, for whom self-reported medication data 
were available. We used multivariable linear regression models and analysis of covariance 
to assess the association between medication use and plasma homocysteine levels, and the 
potential mediation by serum vitamin B12 and folate. 
Results 
The mean age was 74 years (standard dieviation 6.5), 50% were women, and median 
homocysteine levels were 14 µmol/L [inter quartile range: 13-17 µmol/L]. Higher mean 
homocysteine levels were observed in users vs. non-users for diuretics (15.2 vs. 14.9, p= 
0.043), high-ceiling sulphonamide diuretics (16.0 vs. 14.9, p <0.001), medication acting via 
the renin-angiotensin system (15.2 vs. 14.9, p= 0.029) and metformin (15.6 vs. 15.1, p= 0.006). 
Non-selective β-blocker use was associated with lower mean homocysteine levels (14.4 
vs. 15.0, p= 0.019). Only this association was mediated by an underlying association with 
vitamin B12 and folate levels.
Conclusion 
The associations between homocysteine levels and medication use appear to be fairly 
modest. Our results suggest that medication use is unlikely to contribute to clinically relevant 
changes in plasma homocysteine levels. 
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Key points
 • In a population of mildly hyperhomocysteinemic persons aged ≥65 years, use of diuretics 
(and the subgroup high-ceiling sulphonamide diuretics), medication acting via the renin-
angiotensin system, and metformin use was associated with higher plasma homocysteine 
levels.
 • Non-selective β-blocker use was associated with lower homocysteine levels, and this was 
the only association that was characterized by an underlying association with vitamin B12 
and folate levels.
 • The differences in homocysteine levels between medication users and non-users were 
relatively modest (ranging from 0.3 to 1.1 µmol/L), suggesting that medication use is 
unlikely to contribute to clinically relevant changes in plasma homocysteine levels.
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Introduction
Hyperhomocysteinemia, >15 µmol/L, is prevalent in 10-30% of older Dutch individuals1 and 
is one of the risk indicators of cardiovascular disease,2,3 fractures,4-6 and cognitive decline.7,8 
Homocysteine is an amino acid formed from methionine, an essential amino acid obtained 
from the diet.9 Important causes for elevated homocysteine levels are reduced intake or 
absorption of vitamin B12 and/or folic acid.
9 Therefore, homocysteine levels can be lowered 
by supplementation of B vitamins, thereby potentially reducing the negative outcomes 
mentioned above. Nevertheless, trials assessing the effect of B vitamin supplementation 
were not able to show a benefit in preventing cardiovascular events,10 whereas evidence for 
fractures11 and cognitive decline12,13 is still limited and inconclusive. In addition, homocysteine 
levels are affected by a genetic polymorphism in the methylenetetrahydrofolate reductase 
(MTHFR) gene, C677T. This polymorphism results in a reduced activity of the MTHFR enzyme 
that is required for the remethylation of homocysteine to methionine, thereby increasing 
homocysteine levels, especially in combination with low folate levels.14 Besides B vitamin status 
and the MTHFR polymorphism, homocysteine levels may also be influenced unintentionally 
by several medications. This is particularly a problem in older individuals, because they are 
more prone to unintended medication effects as a result of their age-related changes in 
pharmacokinetics and pharmacodynamics.15,16 Furthermore, the majority of older individuals 
have one or more chronic diseases and often multiple medicines are used concomitantly.16-18 
The use of antihypertensive, lipid-lowering, antidiabetic, antirheumatic, anticonvulsant 
and anti-Parkinson disease medication19-21 has been associated with homocysteine levels 
(Table 1). Nevertheless, limited evidence is available per medication group and the studied 
subgroups were small. Additionally, outcomes are partly contradictory and inconclusive. 
Another issue that has as yet received little attention is the potential mediating role of vitamin 
B12 and folate. More insight into possible medication-related changes in homocysteine levels 
and the role of these vitamins could help to create clinical awareness, and might suggest the 
monitoring of these levels during the use of specific medications.
 Overall, our objective is to study in more detail the associations suggested in the literature 
between medication use and homocysteine levels, by sub-categorising medication groups 
into therapeutic and chemical subgroups, in a large population of older community-dwelling 
individuals with mildly elevated homocysteine levels. By extending the models by adding 
vitamin B12 and folate levels, the potential mediation by these vitamins is also examined. 
Methods and materials
Study design and population
For this cross-sectional study, we used baseline data from the B-PROOF study. B-PROOF is an 
acronym for ‘B-vitamins for the PRevention Of Osteoporotic Fractures’, its study design has 
been described elsewhere in more detail.11 Briefly, it is a multi-centre, randomized, placebo-
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controlled, double-blind intervention study investigating the efficacy of vitamin B12 and folic 
acid supplementation on the prevention of fracture incidence in persons aged ≥65 years 
with mildly elevated homocysteine levels. In total, 2,919 participants were included from 
the surroundings of the three Dutch University study centres in Wageningen, Rotterdam 
and Amsterdam. All participants had mildly elevated homocysteine levels (12-50 μmol/L), 
sufficient renal function (creatinine ≤150 μmol/L), and had not received intramuscular 
injections of vitamin B12 or folic acid supplementation (>300 µg daily). Additionally, they had 
not reported malignancies in the past 5 years. The Medical Ethics Committee of Wageningen 
University approved the study protocol, and the Medical Ethics Committees of Erasmus 
Medical Centre and VU University Medical Center gave approval for local feasibility. Before 
entering the study, all participants gave written informed consent.
Medication and supplement use
Self-reported medication and supplement use was gathered at the beginning of the study 
by a structured questionnaire filled out at home. Participants were categorised as users or 
non-users per medicine. Medicines were coded and grouped according to the Anatomical 
Therapeutic Chemical (ATC)-code system.49 To investigate the main group effect we used 
ATC-2 levels (e.g. A01). To investigate the effect of therapeutic subgroups we used ATC-3 
levels (e.g. A01A) and for class effects the chemical subgroups were used, i.e. ATC-4 levels (e.g. 
A01AA). Identical chemical substrates used for different indications have different ATC codes, 
such codes were combined because they can be expected to have the same therapeutic 
and adverse effects. Thus, for example, β-blockers used for cardiovascular treatment were 
combined with β-blockers used in eye treatment. The selected medication groups of interest 
were based on the literature (Table 1) and categorised according to the above-described 
method.
Laboratory measurements
At baseline, blood samples were collected in the morning when participants were either in 
a fasting state or had consumed a restricted breakfast. Plasma homocysteine levels were 
assessed from blood collected in EDTA tubes, which was stored on ice after blood collection 
and processed within 4h. To determine homocysteine, Wageningen University used high-
performance liquid chromatography (intra assay coefficient of variation [CV]= 3.1%, inter 
assay CV= 5.9%), Erasmus MC used liquid chromatography-mass spectrometry/ mass 
spectrometry [LC-MS/MS] (intra assay CV= 5.5%, inter assay CV= 1.3%), and VU University 
Medical Center used the Architect i2000 RS analyzer (intra assay CV= 2%, inter assay CV= 4%). 
Cross calibration of the assays indicated no significant difference in outcome measures 
between the different methods. 
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Table 1. A summary of previous studies regarding the association between medication use on homocysteine, 
vitamin B12 and folate levels.
Medication groups Homocysteine Vitamin B12 Folate
Antihypertensive drugs
Diuretics ↑20,22 ↔20 ↓20 
Thiazides ↑23,24 ↔24 ↔24
β-blockers
Selective β-blockers ↓20,23
ACE inhibitors ↓23 ↔24,25 ↔24 ↔24
Dihydropyridine derivatives ↔23
Lipid-lowering drugs
Statins ↑26 ↓27 ↔20 ↑26
Fibric acid derivatives ↑20 ↔20 ↔20
Cholestyramine ↑19
Antidiabetic drugs
Biguanides ↑28-31 ↔32 ↓28-33 ↓29-31 ↔32
Sulphonylurea derivatives ↓34,35
Rosiglitazone ↓30 ↔30 ↔30
Insulin ↓19
Peptic ulcer and GORD drugs
Proton Pump Inhibitors ↓36,37 ↔38 ↔39
H2-receptor antagonist ↓37 ↔36
Antirheumatic drugs
Methotrexate ↑19 ↓19,40
Sulfasalazine ↑19 ↓19
Anticonvulsant drugs ↑41,42 ↔42 ↓42 ↔41
Phenytoin ↑42 ↔42 ↓42
Carbamazepine ↑43 ↔42,43 ↓43 ↔42
Valproic acid ↑43 ↓43 ↔42 ↔42,43
Anti-Parkinson drugs
L-dopa ↑44 ↔45,46 ↔45,46
Other drugs
Oestrogens ↓19
Tamoxifen/raloxifene ↓19 ↑19
Theophylline ↑19
Acetylcysteine ↓19
Acetylsalicylic acid ↔47 ↓48
A positive association is indicated as ↑, and negative association as ↓. When no association was observed a ↔ is used, and an open space 
indicated no reported results.
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Serum was used to determine folate, holotranscobalamin (HoloTC), methylmalonic acid 
(MMA) and creatinine. Folate was determined by immunoelectrochemiluminescence on 
a Roch Modular E170 (Roche, Almere, The Netherlands) (CV= 5.9% at 5.7 nmol/l and 2.8% 
at 23.4 nmol/l). A folate deficiency was defined as folate levels <10 nmol/L. HoloTC was 
measured using the AxSYM analyser (Abbott Diagnostics, Hoofddorp, The Netherlands) 
(C <8%) and MMA was measured using LC-MS/MS (CV <9%). HoloTC was used as measure 
of vitamin B12 status, because it has been shown to better reflect vitamin B12 status than 
serum total vitamin B12.
50 A vitamin B12 deficiency was defined as both HoloTC levels <32 
pmol/L and MMA levels >0.45 µmol/L.50 Creatinine was measured using the enzymatic 
colorimetric Roche CREA plus assay (CV= 2%) on a Modular P analyser (Roch, Almere, The 
Netherlands). It was used to calculate the modification of diet in renal disease (MDRD) for 
men using the formula: 186 * (serum creatinine (μmol/L) / 88.4)-1.154 * age-0.203 (years) in ml/
min/1.73m2, and for women: 186 * (serum creatinine (μmol/L) / 88.4)-1.154 * age-0.203 (years) * 
0.742 in ml/min/1.73m2. The MDRD is an age-adjusted estimate of the glomerular filtration 
rate (GFR).15
 Buffy coats were used to isolate DNA. The MTHFR genotypes, 677CC, 677CT or 677TT, 
were determined using the Illumina Omni-express array (Illumina Inc., San Diego, CA, USA).
Covariates
Demographic characteristics were ascertained using a questionnaire. The questions were on 
age, sex and health status variables, which included smoking habits, alcohol consumption, 
cardiovascular disease history, diabetes mellitus and hypercholesterolemia. A positive 
cardiovascular disease history was defined as having a history of at least one of the 
following disorders: heart problems (i.e. myocardial infarction, angina pectoris, heart failure, 
percutaneous coronary intervention), intermittent claudication, transient ischemic attack, 
stroke, thrombosis or embolism. During the baseline study visit, various characteristics were 
measured including weight, height and blood pressure.11 Weight was measured with the 
participant wearing light garments. Height was measured with the participant standing erect, 
wearing no shoes. From weight and height, the body mass index (BMI, kg/m2) was calculated. 
Blood pressure was measured twice, using an Omron M1 plus device (Omron Healthcare 
Europe, Hoofddorp, The Netherlands), and the lowest diastolic and corresponding systolic 
blood pressure readings were included in the analyses. Hypertension was defined as systolic 
blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.51
Statistical analyses
We assessed normal distribution for all variables, applying natural log transformation if 
necessary. Values were transformed back (ex) and results were presented as geometric beta, 
95% confidence intervals or means to facilitate the interpretation. Linear regression was 
used to determine associations between medication use and homocysteine levels (model 
1, crude). When the number of users in a medication group was less than 1% of the overall 
population, only the crude association with homocysteine levels was determined and no 
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further analyses were applied. Associations between covariates and homocysteine levels were 
assessed also using linear models. When a covariate had a p-value <0.2 it was considered as 
a potential confounder. Subsequently, age, sex and MDRD were added as fixed confounders 
while the other confounders were added using the forward-selection method (model 2). 
Medication use that was significantly associated with homocysteine levels according to 
the results of model 2, were added in model 3. Thereby we adjusted the associations for 
confounding effects of concomitantly used medication. To address the potential mediating 
effect of vitamin B12 and folate levels, these factors were subsequently added to model 3. 
When the point estimate of interest changed >10%, vitamin B12 and/ or folate levels were 
regarded as potential mediators. Thereafter, similarly as for homocysteine, models 1 and 2 
were formed, but now using HoloTC or folate as the dependent variable. Confounders for 
these associations were also determined in the same way as for homocysteine.
 To investigate whether the MTHFR genotype was an effect modifier, an interaction term 
was added to the fully adjusted model. When the p-value of the interaction term was <0.1, 
the results were stratified.
 Analysis of covariance was used to calculate the estimated means for homocysteine levels 
in users and non-users, only for the significant findings based on model 3. Additionally, it was 
used to investigate whether there was an additive effect of combined use of significantly 
associated medication groups. Then, the estimated means for homocysteine levels were 
calculated for non-users and users of, respectively, one significantly associated medication 
group, two significantly associated medication groups and three or four significantly 
associated medication groups. Statistical analyses were done using the statistical software 
package SPSS version 21.0 (SPSS Inc., Chicago, IL, USA) and p-values <0.05 were considered 
to be statistically significant.
Results
Population characteristics
Self-reported medication use was available for 2,912 participants. The mean age of the 
study population was 74 years (± standard deviation 6.5) and 50% were women (Table 2). 
The median homocysteine level was 14 µmol/L [inter quartile range: 13-17] and a small 
percentage was deficient in vitamin B12 (4%) or folate (3%). A positive cardiovascular disease 
history was present in 38%, and 84% used at least one medicine. 
Antihypertensive medication
The use of diuretics in general was positively associated with homocysteine levels (Table 
3, model 3), users had a 0.3 µmol/L higher mean homocysteine than non-users , 15.2 vs. 
14.9 µmol/L, p= 0.043 (Figure 1). Adding vitamin B12 and folate to the model changed 
the association slightly, resulting in mean homocysteine levels of 15.3 vs. 14.9 µmol/L, 
p= 0.004. Diuretic use was associated with both vitamin B12, β= 5.58, p= 0.002 (adjusted 
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Table 2. Population characteristics.
N= 2,912
Age (years)a 74 (6.5)
Sex (women, %) 50
BMI (kg/m2)a 27 (4.0)
Smoking (%)
 Never
 Former
 Current
34
56
10
Alcohol consumption (%)
 Light
 Moderate
 Excessive
 Very excessive
67
29
3
<1
Cardiovascular disease history (% yes) 38
Diabetic (% yes) 10
Vitamin B12 supplement use (% yes) 15
Folate supplement use (% yes) 14
Hypertension 64
MDRD (ml/min/1.73m2)b 74 [64-84]
Homocysteine (µmol/L)b 14 [13-17]
Vitamin B12 (pmol/L)
b 285 (116)
Folate (nmol/L) 21 (12)
MMA (µmol/L)b 0.23 [0.18-0.30]
HoloTC (pmol/L)a 72 (43)
Vitamin B12 deficiency (%)
c 4
Folate deficiency (%)d 3
MTHFR genotype(%)
 CC
 CT
 TT
45
42
13
Medication use (%) 84
a Presented as mean (± standard deviation). b Presented as median [inter quartile range]. c 43as1Defined as: HoloTC levels <32 pmol/L and MMA 
levels >0.45 µmol/L.50 dDefined as: folate levels <10nmol/L.
BMI= body mass index, MDRD= modification of diet in renal disease, MMA= methylmalonic acid, HoloTC= holotranscobalamin, MTHFR= 
methylenetetrahydrofolate reductase.
for age, sex, MDRD and study centre), and folate levels, β= 1.06, p= 0.024 (adjusted for age, 
sex, MDRD, study centre, BMI, smoking and diabetes). High-ceiling sulphonamide diuretic 
use, i.e. furosemide or bumetanide, was also positively associated with homocysteine levels 
(Table 3, model 3). Users had a 1.1 µmol/L higher mean homocysteine than non-users, 
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16.0 vs. 14.9 µmol/L, p <0.001 (Figure 1). Extending the model with vitamin B12 and/or folate 
did not substantially alter the results. Furthermore, no association between high-ceiling 
sulphonamide use and vitamin B12 or folate was observed (data not shown). The use of other 
diuretic subgroups including thiazides, low-ceiling sulphonamides, aldosterone antagonists 
and potassium-sparing agents was not associated with homocysteine levels. Similarly, the 
use of β-blockers in general and selective β-blockers was not associated with homocysteine 
levels. In contrast, non-selective β-blocker use was associated with lower homocysteine 
levels, β= -1.04, p= 0.019 (Table 3, model 3, Figure. 1), but the association lost significance 
after adding vitamin B12 and folate to the model, β= -1.03, p= 0.115. Non-selective β-blocker 
use was associated with both vitamin B12, β= 9.14, p= 0.011 (adjusted for age, sex, MDRD 
and study centre), and folate levels, β= 1.89, p= 0.035 (adjusted for age, sex, MDRD, study 
centre, BMI, smoking and diabetes). Use of medication acting via the renin-angiotensin 
system was positively associated with homocysteine levels (Table 3, model 3). Users had a 
0.3 µmol/L higher mean homocysteine level than non-users, 15.2 vs. 14.9 µmol/L, p= 0.029 
(Figure 1). Adding vitamin B12 to the model changed the association slightly, resulting in 
mean homocysteine levels of 15.2 vs. 14.8 µmol/L, p= 0.005, while adding folate had no 
effect. Use of medication acting via the renin-angiotensin system was positively associated 
with vitamin B12 levels, β= 5.44, p= 0.005 (adjusted for age, sex, MDRD, study centre and 
cardiovascular disease history). In contrast, the use of renin-angiotensin subgroup ACE 
inhibitors and angiotensin II inhibitors was not associated with homocysteine levels. Similarly, 
no association was seen between the use of calcium antagonists and, more specifically, 
dihydropyridine derivatives and homocysteine levels.
Lipid lowering medication
The use of statins was not associated with homocysteine levels (Table 3, model 2). None of 
the participants reported nicotinic acid use. 
Peptic ulcer and gastro-oesophageal reflux disease medication
Neither proton pump inhibitor use nor histamine H2-receptor antagonist use was associated 
with homocysteine levels (Table 3, model 2). 
Antidiabetic mediation
Metformin, a biguanide, was positively associated with homocysteine levels (Table 3, model 
3). Users had a 0.5 µmol/L higher mean homocysteine level than non-users, 15.6 vs. 15.1 
µmol/L, p= 0.006 (Figure 1). Adding folate to the model changed the association slightly, 
resulting in mean homocysteine levels of 15.7 vs. 15.0 µmol/L, p=0.001. Metformin use was 
associated with folate levels, β= 1.76, p= 0.034 (adjusted for age, sex, MDRD, study centre, 
BMI and smoking). The use of sulphonylurea derivatives, and insulin was not associated with 
homocysteine levels (Table 3, model 3). 
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Table 3. Linear regression results for natural logarithm (ln) homocysteine per medication group, presented 
as geometric β (p-value). 
Number of  
users (%)
Model 1  
Crude
Model 2 Model 3
Antihypertensive drugs
 Diuretics 774 (26.6) 1.05 (<0.001) 1.03 (0.001)a* 1.02 (0.043)c*
 Thiazides 520 (17.9) 1.02 (0.047) 1.01 (0.175)a
 Low-ceiling sulphonamides 75 (2.6) 1.03 (0.216) 1.04 (0.156)a
 High-ceiling sulphonamides 146 (5.0) 1.14 (<0.001) 1.08 (<0.001)a* 1.07 (<0.001)c*
 Aldosterone antagonist 50 (1.7) 1.09 (0.004) 1.03 (0.286)a
 Potassium-sparing agents 75 (2.6) -1.00 (0.933) -1.01 (0.689)a
 β-blockers 797 (27.4) 1.02 (0.089) -1.00 (0.712)a
 Non-selective β-blockers 145 (5.0) -1.03 (0.096) -1.04 (0.032)a* -1.04 (0.019)c*
 Selective β-blockers 652 (22.4) 1.03 (0.011) 1.01 (0.428)a
 α & β blockers 20 (0.7) 1.00 (0.937)
 Renin-angiotensin agents 966 (33.2) 1.04 (<0.001) 1.02 (0.009)a* 1.02 (0.029)c*
 ACE inhibitors 475 (16.3) 1.04 (0.021) 1.02 (0.023)a* 1.02 (0.083)c
 Angiotensin II antagonist 507 (17.4) 1.03 (0.004) 1.01 (0.247)a
 Calcium antagonists 410 (14.1) 1.03 (0.014) 1.02 (0.176)a
 Dihydropyridine derivatives 334 (11.5) 1.03 (0.015) 1.02 (0.106)a
Lipid-lowering drugs
 Statins 724 (24.9) 1.02 (0.033) -1.00 (0.759)a
 Fibric acid derivatives 7 (0.2) 1.06 (0.472)
 Cholestyramine 3 (0.1) -1.11 (0.365)
Antidiabetic drugs
 Metformin 215 (7.4) 1.04 (0.002) 1.05 (0.001)b* 1.04 (0.006)d*
 Sulphonylurea derivatives 104 (3.6) 1.06 (0.006) 1.04 (0.037)b* 1.01 (0.583)d
 Thiazolidinediones 11 (0.4) 1.06 (0.365)
 Insulin 50 (1.7) 1.05 (0.101) 1.06 (0.034)b* 1.03 (0.276)c
Peptic ulcer and GORD drugs
 Proton Pump Inhibitors 612 (21) 1.01 (0.618) -1.01 (0.617)a
 H2 antagonists 36 (1.2) -1.03 (0.430) -1.04 (0.241)a
Antirheumatic drugs
 Selective immunosuppressants 2 (0.1) 1.41 (0.014)
 Other immunosuppressants 34 (1.2) 1.05 (0.149) 1.05 (0.165)a
Anticonvulsant drugs 52 (1.8) -1.02 (0.623) -1.01 (0.753)a
 Barbiturates 2 (0.1) -1.03 (0.847)
 Phenytoin 3 (0.1) 1.21 (0.095)
 Carbamazepine 4 (0.1) -1.06 (0.549)
 Valproic acid 10 (0.3) -1.07 (0.266)
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Table 3. (Continued)
Number of  
users (%)
Model 1  
Crude
Model 2 Model 3
Anti-Parkinson drugs
 L-dopa & L-dopa derivatives 21 (0.7) 1.01 (0.896)
Other drugs
 Oestrogens 26 (0.9) -1.01 (0.735)
 Androgens 1 (<0.1) 1.20 (0.359)
 Raloxifene 7 (0.2) -1.08 (0.321)
 Theophyline 49 (1.7) 1.45 (0.052) 1.20 (0.323)a
 Acetylcysteine 11 (0.4) 1.01 (0.811)
 Acetylsalicylic acid 726 (24.9) 1.02 (0.031) -1.01 (0.355)a
Model 1: crude model. a adjusted for age, sex, MDRD, smoking, diabetes. b adjusted for age, sex, MDRD, smoking. c confounders of a, plus the 
other significantly associated drugs from model 2. d confounders of b, plus the other significantly associated drugs from model 2. *P-value 
<0.05. 
GORD= gastro-oesophageal reflux disease, MDRD= modification of diet in renal disease.
Antirheumatic, anticonvulsant, anti-Parkinson disease and other medication 
No association was observed between the use of the immunosuppressive agent methotrexate 
and homocysteine levels (Table 3, model 2). Methotrexate use was always combined with 
folate supplements; therefore, a correction for folate supplement use could not be made. 
We did not observe an association between the use of anticonvulsants and homocysteine 
levels (Table 3, model 2). Similarly, the use of acetylsalicylic acid and theophylline was not 
associated with homocysteine levels.
Additive effects and interaction with MTHFR
Medication groups that were positively associated with homocysteine levels were combined, 
and comprised of the use of diuretics in general (excluding high-ceiling sulphonamide 
diuretics), high-ceiling sulphonamide diuretics, medications acting via the renin-
angiotensin system and metformin. Compared with those using none of these medicines 
(mean homocysteine level of 14.7 µmol/L), users of one of these medicines had a higher 
mean homocysteine level (15.2 µmol/L, p= 0.001), users of two medicines also had a higher 
mean homocysteine level ( 15.2 µmol/L, p= 0.003), and similarly those using three or four 
medicines had a higher mean homocysteine level (15.7 µmol/L, p= 0.011) (Figure 2). Because 
only six participants used all four medicines, this group was combined with the use of three 
medicines. 
 None of the interaction terms of a medication group with MTHFR was significant (data 
not shown).
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Figure 1. Estimated geometrical mean (95% confidence interval) plasma homocysteine levels in users vs. 
non-users of diuretics, high-ceiling sulphonamide diuretics, renin-angiotensin agents, metformin, and non-
selective β-blockers.
Figure 2. Estimated geometrical mean (95% confidence interval) plasma homocysteine levels in users of 
none, one, two, three or four of the significantly associated medication groups, which consisted of diuretics 
(excluding high-ceiling sulphonamide diuretics), high-ceiling sulphonamide diuretics, renin-angiotensin 
agents, metformin, and non-selective β-blockers.
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Discussion
In this large population of older individuals, we demonstrated a small but significant positive 
association between plasma homocysteine levels and the use of diuretics in general, 
high-ceiling sulphonamide diuretics, agents acting via the renin-angiotensin system and 
metformin, which was largely independent of vitamin B12 and folate levels. When medication 
use of these drug groups was combined, no additive effect of the association was observed. 
In addition, an inverse significant association between non-selective β-blocker use and 
homocysteine levels was observed, which was characterised by an underlying association 
with vitamin B12 and folate levels. No association was observed between homocysteine 
levels and the use of thiazides, selective β-blockers, statins, sulphonylurea derivatives or 
anticonvulsants. 
 Diuretic use has previously been shown to be associated with higher homocysteine 
levels,20,23 possibly through decreasing folate levels.20 In our study, diuretic use in general 
was significantly associated with higher homocysteine levels, but this was independent of 
folate levels. From the diuretic subgroups, high-ceiling sulphonamides, i.e. furosemide or 
bumetanide, were strongly associated with higher homocysteine levels. To our knowledge, 
this association has not been reported before. Although the mechanism behind this elevation 
is unknown, high-ceiling sulphonamides are known as potent inhibitors of the reabsorption 
of electrolytes in the kidneys, resulting in reduced water reabsorption into the blood and 
thus increased water excretion.52 This alteration in fluid status, or mild dehydration, might 
cause the observed relative increase of the plasma homocysteine level in the blood. This 
potential mechanism merits further investigation. 
 Other investigators observed a negative association between the use of β-blockers 
and homocysteine levels, especially metoprolol, which is a selective β-blocker.20 However, 
we found no associations for selective β-blocker use, but did observe an association with 
homocysteine levels for non-selective β-blocker use, which depended on the mediating 
association with vitamin B12 and folate levels. How non-selective β-blockers may affect 
vitamin B12 and folate levels is still unknown. 
 The use of medication acting on the renin-angiotensin system was associated with 
slightly higher homocysteine levels. Previous studies only investigated the association with 
its subgroup ACE inhibitors, reporting a negative23 or no24,25 association with homocysteine 
levels. The mechanism behind our finding remains to be determined.
 Our finding of higher homocysteine levels in metformin users is in agreement with 
findings of earlier studies.28-31 It has been suggested that metformin reduces the absorption 
of vitamin B12
21 and negatively affects folate status through an unknown mechanism.28-31 
However, this contradicts our finding of a relationship between metformin and homocysteine 
levels that was independent of vitamin B12 and which became slightly stronger after including 
folate levels into the model. This indicates that metformin might affect homocysteine levels 
through other mechanisms. Metformin increases insulin sensitivity,21 and potentially insulin 
levels are involved. Nevertheless, the literature reports contradictory findings, as both insulin 
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sensitivity53 as well as insulin resistance54 were associated with higher homocysteine levels. 
More research is needed to elucidate the potential involvement of insulin levels.
 A surprising result was the lack of association between peptic ulcer and gastro-
oesophageal reflux disease (GORD) medication use and homocysteine levels. Because the 
literature consistently reports an association between lower levels of vitamin B12 and the use 
of peptic ulcer and GORD medication,36,37,39,55 we hypothesised that users would also have 
higher homocysteine levels. It has been suggested that prolonged proton pump inhibitor 
use in particular results in lower vitamin B12 status and higher homocysteine levels.
36 The 
discrepancy in results might be caused by the fact that we were unable to distinguish 
between short- and long-term users, since our data were cross-sectional. 
 Although statin use has previously been associated with both an increase26 and a decrease 
in homocysteine levels,27 it is most frequently reported not to be associated.20 Our results are 
in line with this absence of an association. 
 We did not observe a positive association between anticonvulsant drug use and 
homocysteine levels, while this has been consistently reported in the literature.41-43 
Anticonvulsant drugs may reduce folate levels and particularly in combination with the 
MTHFR TT genotype this may result in elevated homocysteine levels.56,57 The discrepancy 
between our findings and other studies may be explained by the non-significant interaction 
with the MTHFR polymorphism and the low frequency of folate deficiency in our population.
 The anti-Parkinson disease medication L-dopa has also been associated with increased 
levels of homocysteine;44 however, because of the low frequency of users we could not test 
this association and a potential association therefore cannot be ruled out.
 When the use of medication groups that were significantly associated with a higher 
homocysteine level was combined, no additive effect of the association was observed. To 
our knowledge, there is no literature regarding a potential additive effect of a combination 
of medication use on homocysteine levels. Nevertheless, because of multiple drug use, older 
individuals are more prone to unintended drug effects16,18 of which increased homocysteine 
levels might have been one.
 This study has some limitations. First, all participants had mildly elevated homocysteine 
levels, which may have reduced the contrast of the effect, because of the smaller range 
in homocysteine levels. Conversely, the observed associations may result in even greater 
differences in the overall population. Furthermore, despite the homocysteine cut-off value 
of 12 µmol/L, our study population represents approximately 30% of the general Dutch 
older population, as this percentage is known to have an increased homocysteine level.1 
Second, self-reported medication data were used, for which accuracy relies on the memory 
of the participant and recall bias might subsequently result in misclassification of exposure. 
In that respect, pharmacy supplied reports would have been a possible solution and would 
also have provided information about dose and duration of use, although they represent 
prescription data and not actual use, and over-the-counter medication still may be missed. 
Nevertheless, none of these two methods has been considered to be the ‘gold standard’ 
for measuring medication use,58 and various studies have reported a high agreement 
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between both methods.58-61 Third, pharmaco-epidemiological studies in general are prone 
to confounding by indication. We, however, do not think this would explain our significant 
results, as in addition to associations with diuretics in general and more specifically high-
ceiling sulphonamides, and metformin use, associations with the use of other diuretic 
subgroups and diabetic medication would have also been expected, while these were 
not observed. Fourth, based on the number of medication groups investigated, a chance 
finding could have occurred. Finally, because this is a cross-sectional study, we cannot 
draw any conclusions about cause or effect. Despite the limitations, our study also has its 
strengths; it was conducted in a large population and addressed hyperhomocysteinemia 
as an unintended drug effect in an important target group, namely older persons. We also 
investigated whether the association between medication use and homocysteine levels 
was mediated by an underlying association with vitamin B12 and/or folate, as levels of these 
vitamins are key determinants for homocysteine levels.62 
Conclusion
In a population of mildly hyperhomocysteinemic older persons, we have confirmed that 
diuretic use in general and metformin use is indeed associated with higher homocysteine 
levels. In addition, we have shown that users of the diuretic subgroup high-ceiling 
sulphonamides, and users of agents acting via the renin-angiotensin system had higher 
homocysteine levels than non-users. The difference in homocysteine levels between users 
and non-users had a range of 0.3-1.1 µmol/L. However, the question is whether these small 
differences are clinically relevant. Non-selective β-blocker users had lower homocysteine 
levels than non-users. Only the association with non-selective β-blocker use was mediated by 
an underlying association with vitamin B12 and folate levels, so additional research is needed 
to elucidate underlying mechanisms for metformin, diuretics and medication acting via the 
renin-angiotensin system. Other medications, belonging to the group of antihypertensives, 
lipid lowering agents, antidiabetic drugs, peptic ulcer and GORD medications, antirheumatic 
drugs, anticonvulsant drugs and anti-Parkinson medication were not associated with 
homocysteine levels.
Taken together, in this study, the associations between medication use and homocysteine 
levels appear to be fairly modest, suggesting that medication use is unlikely to contribute to 
clinically relevant changes in plasma homocysteine levels. 
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Abstract 
Background
Longitudinal studies showed conflicting results regarding the association between use of 
SSRIs and bone mineral density (BMD). Therefore, we investigate the association between – 
duration of – SSRI use and BMD, and change in BMD. 
Methods
Data from the population-based Rotterdam Study cohort (1991-2008) were used. In total, 
4,915 men and 5,831 post-menopausal women, aged ≥45 years were included, having 
measurement visits at 4-5 year intervals. Multivariable linear mixed models were applied to 
examine the association between SSRI use, based on pharmacy records, duration of SSRI use, 
and repeated measures of BMD, and changes in BMD, compared to non-use. Femoral neck 
BMD (g/cm2) was measured at 4 visits, comprising 19,861 BMD measurements. Three delta 
BMD periods were examined, comprising 7,897 delta BMD values. Delta BMD was expressed 
in the annual percentage change in BMD between 2 consecutive visits. 
Results
In men and women, we observed no association between SSRI and BMD when compared to 
non-use (women: mean difference 0.007 g/cm2, 95% CI -0.002; 0.017, p-value= 0.120). We did 
not find an association between duration of SSRI use and change in BMD (women: annual 
percentage change -0.081, 95% CI -0.196; 0.033, p-value= 0.164). 
Conclusion
In conclusion, use of SSRIs is not associated with BMD or change in BMD – after taking 
duration of treatment into account – in middle-aged and elderly individuals. Therefore, our 
results question previously raised concerns on the adverse effects of SSRIs on BMD.
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Introduction
Loss of bone mass is associated with an increased risk of osteoporosis and fractures, and is 
a major problem in older individuals, particularly in women. It has serious consequences for 
quality of life, health outcomes and related costs.1,2 Important risk factors for loss of bone 
mass include advanced aging, low body weight, reduced physical activity, poor nutritional 
status, smoking and alcohol use.3 In addition, multiple drugs are suspected to negatively 
affect bone mass (e.g., glucocorticoids and thyroid hormones).4-6 Selective serotonin 
reuptake inhibitors (SSRIs), a frequently used drug group in elderly, are also suspected to 
have a direct negative effect on bone health.3,7,8 SSRIs modulate serotonin levels, and major 
bone cell types such as osteoblasts, osteoclasts and osteocytes carry serotonin receptors 
and transporters, therefore, SSRIs could play a regulatory role in bone turnover.7,8 Peripheral 
serotonin could reduce osteoblast proliferation, and consequently negatively affect bone 
formation.8
 The association between SSRIs and bone mineral density (BMD) has been investigated 
in various observational studies. Cross-sectional studies almost consistently reported an 
association between use of SSRIs and low BMD.9-14 However, these results are not supported 
by longitudinal observational studies, conducted in women only, which reported conflicting 
results.15-17 Moreover, in previous cross-sectional and longitudinal studies, use of SSRIs was 
assessed through interview data and limited information was available regarding duration of 
use at the study visit or in-between study visits.9-17 Since bone remodeling is a slow process,18 
we expect that longer duration of SSRI use is an important risk factor for low BMD. 
 The present study aims to investigate the association between use of SSRIs (yes/no) 
and duration of treatment – assessed with pharmacy records over 4 year periods – with 
BMD, and change in BMD in a population-based cohort of middle-aged and older men and 
postmenopausal women. 
Methods
Study setting
The Rotterdam Study is a prospective population-based cohort study, its design, objectives 
and methods have been described in more detail,19 In short, the study was initiated in 1989 and 
in total 7,983 participants, aged ≥55 years, were included between 1989-1993 (78% response 
rate, cohort I). In 2000, the study was extended with a second cohort of 3,011 participants, 
aged ≥55 years (67% response rate, cohort II). Additionally, in 2006 a second extension of the 
cohort was initiated, including 3,923 participants aged 45 years or older (65% response rate, 
cohort III). From baseline onwards, follow-up examinations were conducted every 4-5 years 
including interviews and an extensive set of examinations.
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the 
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“Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study)”. All participants 
provided informed consent to participate in the study and to obtain information from their 
treating physicians.
Study population
We included participants with available pharmacy dispensing data and at least 1 BMD 
measurement during the follow-up period between 1991 and 2008. We restricted our 
population to men and postmenopausal women, thereby excluding measurements of 
pre- and peri-menopausal women, because of increased BMD loss around menopause.1,2 
Postmenopausal state was defined as previously described, in short: natural menopause – 
after 12 continuous months or amenorrhea –, surgical menopause, or assumed menopause 
after the age of 65 if detailed data were missing.20 To avoid potential misclassification of 
exposure, we ensured that all participants had pharmacy dispensing records available for at 
least 5 months prior to their baseline measurement. Moreover, we excluded measurements of 
participants who used or initiated use of drugs affecting bone structure and mineralization, 
notably bisphosphonates (Anatomical Therapeutic Chemical [ATC]-code: ‘M05B’), or used 
other antidepressant drugs than SSRIs or tricyclic antidepressants (TCAs) in six months 
before the BMD measurement or at time of the BMD measurement. 
Exposure assessment 
Pharmacy dispensing records from regional pharmacies were available from January 1st 
1991 onwards. More than 95% of the participants fill their drug prescriptions at one of these 
pharmacies. Dispensing records include date of dispensing, total amount of drug units per 
dispensing, prescribed daily number of units, product name of the drug and corresponding 
Anatomical Therapeutic Chemical (ATC) code. Duration of a dispensing was calculated by 
dividing the total number of dispensed units by the prescribed daily number of units. The 
average prescribed daily dose was expressed in number of standardized defined daily doses 
(DDDs).
 SSRIs were defined based on the 4th-level (chemical subgroup) ATC-code: ‘N06AB’. To 
consider potential confounding by indication (i.e. depression), TCAs (ATC-code: ’N06AA’) were 
also studied as exposure of interest. SSRI and TCA use was defined in multiple ways (Figure 1). 
First, current use (yes/no) was defined as a SSRI or TCA dispensing in the six months prior to 
the BMD measurement or at time of the BMD measurement. Non-use in the six months before 
and at the measurement round was considered as reference population. In addition, duration 
of treatment between two measurement rounds was taken into account to categorize 
current users in 1-364 days and 365 days or longer of current antidepressant use. Second, 
for the longitudinal analyses, duration of SSRI and TCA exposure was defined based on the 
sum of all prescription lengths (in years) between two consecutive BMD measurements. This 
exposure definition includes all use of SSRIs or TCAs between the measurement visits if there 
was at least one dispensing in the half year prior to or at the BMD measurement, otherwise 
exposure was coded as non-use. Our assumption was that any effect on BMD by SSRI would 
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vanish in 6 months after discontinuation of intake. Therefore, we assessed use of SSRI in 
the 6 months before BMD measurement in the cross-sectional assessment and calculated 
cumulative exposure to SSRI between two BMD measurements only for those patients who 
had used SSRI within 6 months before the second BMD measurement in the delta BMD 
assessment.
Outcome
BMD (g/cm2) of the right proximal femur neck was assessed with Dual-energy X-ray 
absorptiometry (DXA) scanning.21 Per participant one to four BMD measurements were 
available (between 1991 – 2008, Figure 1). On the first three BMD measurement visits – i.e. 
the first 3 visits of the first cohort and the first visit of the second cohort – a Lunar DPX-L 
densitometer was used, while from 2002 and onwards a Lunar Prodigy densitometer 
was used (Lunar Radiation Corp., Madison, WI, USA). Cross-calibration between the two 
devices showed no significant differences in BMD levels with a negligible slope.22 We used 
femoral neck (FN) BMD instead of lumbar spine BMD, as this measurement is not affected 
by degenerative changes (i.e. osteophytes) increasingly seen with aging.21 Our outcome 
measures are the BMD values (g/cm2) at the visits, and the annual percentage change in BMD 
between two consecutive visits. The percentage change in BMD (∆BMD) was calculated by 
subtracting the previous BMD value from its subsequent BMD value, divided by the previous 
BMD value and multiplied by 100. The percentage change was further divided by the 
number of years between the two consecutive BMD measurements resulting in the annual 
percentage change in BMD. In formula: (((BMDi+1 - BMDi)/BMDi)*100)/ (date BMDi+1 - date 
BMDi in years). Up to three ∆BMD measurements were available per participant (Figure 1).
Covariables
We considered several covariables that could confound the association between use of 
SSRIs or TCAs and BMD.2,4,23,24 These were; age, body mass index (BMI), lower-limb disability, 
depressive symptoms, smoking, alcohol intake, cognitive status, age at menopause, 
hypertension, diabetes mellitus and drugs known to be associated with BMD (i.e. thiazides, 
statins, glucocorticoids, thyroids, sex hormones, anticonvulsants, psycholeptics, and calcium 
and vitamin D supplements).2,4,23,24 All covariables were time-dependent and determined at 
the time of the BMD measurement. Change in BMI and change in lower-limb disability over 
time were also considered as potential confounders in the analyses regarding delta BMD. 
BMI was defined as weight (in kilograms) divided by height (in meters squared). Lower-
limb disability was assessed using a modified version of the Stanford Health Assessment 
Questionnaire. The score was based on answers to questions regarding rising, walking, 
bending, and getting in and out of a car.25 Disability was defined as a score of 3 or higher.25 
The Center for Epidemiological Studies Depression Scale (CES-D),26 and the Hospital Anxiety 
and Depression Scale (HADS-D)27 in a subsample of the population, were used to screen 
for depressive symptoms. On both questionnaires, higher scores indicate more depressed 
feelings. The CES-D results in a score ranging from 0 to 60, with a score of 16 or higher being 
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Figure 1. Definitions of antidepressant exposure (e.g. selective serotonin reuptake inhibitors and tricyclic 
antidepressants) and bone mineral density or change in bone mineral density. 
1 = current antidepressant use – in the six months before or at time of – the bone mineral density measurement. 
2 = duration of antidepressant use (in years) assessed between two consecutive bone mineral density 
measurements. This exposure definition includes all use of SSRIs or TCAs between the measurement visits if 
there was at least one dispensing in the half year prior to or at the BMD measurement, otherwise exposure 
was coded as non-use.
Three examples of duration of antidepressant use are given in the form of an arrow. The arrow with a ‘x’ 
represents a duration of antidepressant exposure that was coded as non-use. The other two arrows, with a 
‘ ’, represent duration periods that are included in ‘duration of antidepressant use’.
BMD 1: Participants from cohort I, visit 1
BMD 2: Participants from cohort I, visit 2
BMD 3: Participants from cohort I, visit 3 and cohort II, visit 1
BMD 4: Participants from cohort I, visit 4, cohort II visit 2 and cohort III, visit 1
Abbreviations: BMD = bone mineral density, ∆BMD = change in bone mineral density
indicative of clinically-relevant depressive symptoms. The HADS-D consists of 7 items, and its 
score ranges from 0 to 21, with 9 points or higher being indicative of depressive symptoms. 
These cut-offs have a high sensitivity for detecting relevant depressive symptoms in the 
general and older adult population.28,29 Cognitive status was assessed with the Mini Mental 
State Examination (MMSE).30 Smoking behavior (current, former or never) was determined 
based on interview data. When data on a round was missing, the results from the preceding 
round were imputed to minimize the number of missing values. Alcohol intake was assessed 
based on interview or food frequency questionnaire data.31 Age at menopause was also 
based on interview data, and validated as previously described.20 Hypertension was defined 
as a systolic blood pressure of 140 mmHg or higher, a diastolic blood pressure of 90 mmHg 
or higher, or the use of blood pressure lowering medication for the indication hypertension. 
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Diabetes mellitus status was based on the use of any glucose lowering drugs (ATC-code= 
‘A10’). Other potential confounding drug use was assessed with pharmacy records: thiazides 
(‘C03A’, ‘C03EA’), statins (‘C10A’), sex hormones (‘GO3’), glucocorticoids (‘H02AB’ or ‘R03BA’), 
thyroid therapy (‘H03’), anticonvulsants (‘N03A’) and psycholeptics (‘N05’). Besides, calcium 
and vitamin D supplementation use (‘A12’) was assessed at home interview. Here, if data on 
a round was missing, the results from the preceding round were imputed to minimize the 
number of missing values.
Statistical analyses
Baseline characteristics were defined based on data from the first eligible BMD measurement. 
We used linear mixed models to examine the association between current use of SSRIs or 
TCAs (yes/no) and repeated measurements of BMD. Linear mixed models take the within-
person correlation between multiple visits into account. We selected the unstructured 
correlation matrix based on the lowest Akaike’s Information Criterion (AIC).32 Additionally, 
current use was stratified on duration of use (1-364, ≥365 days) between the measurements 
of BMD. Furthermore, we studied a possible dose-response relationship between the average 
number of prescribed DDDs, split on the median prescribed DDD, and BMD. Non-use of any 
antidepressant was the reference in all abovementioned analyses. Linear mixed models were 
also used to study the association between duration of SSRI and TCA exposure between 2 
visits and repeated measurements of the change in BMD. All analyses were stratified by sex, 
and adjusted for age (model 1). With aging the decline in BMD differs between men and 
women,1,2 and SSRIs could have different effects in men and women.33 The full model was 
additionally adjusted for covariables that were associated with BMD, and changed the age-
adjusted point estimate of the association between SSRIs and BMD by more than 10% (model 
2). Menopausal age was added as an extra covariable to the full model in the postmenopausal 
female population. In additional analyses, we studied potential confounding by presence 
of depressive symptoms (model 3). These analyses were conducted in a subsample of the 
population since depressive symptoms were only assessed from the second measurement 
round onwards. 
 Moreover, additional sensitivity analyses were adjusted instead of stratified for sex and 
conducted in the complete study population to investigate overall associations. Furthermore, 
we defined current use as a dispensing at the time of the BMD measurement. SSRI or TCA use 
in the six months before the BMD measurement was classified as non-use. 
 All statistical analyses were performed with IBM SPSS statistics (version 21.0, IBM Corp., 
Somers, NY, USA). A two-sided p-value below 0.05 was considered statistically significant. 
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Results
Baseline characteristics
The flowchart in Figure 2 depicts the selection of our study population. The study population 
included 10,746 participants, with a total of 19,861 BMD measurements with a median of 
1 BMD measurement per participant, 5,291 participants (49.2%) had more than 1 BMD 
measurement. There were 4,926 participants with a delta BMD measurement, as not 
all BMD measurements were in a consecutive order. In total, there were 7,897 delta BMD 
measurements during follow-up, with a median period of 4.0 years (interquartile range: 
1.95-4.6) between two consecutive visits. Of these 4,926 participants, 1,913 (38.8%) had more 
than 1 delta BMD measurement. Baseline characteristics, using data from the first eligible 
BMD measurement, are depicted in Table 1. In short, the mean age of the study population 
was 64.1 years (standard deviation [SD] 8.7) in men, and 65.8 years (SD 8.7) in women. 
 
Total number of BMD measurements 
N= 22,122 measurements 
N= 11,698 participants 
N= 9,081 measurements delta BMD 
N= 5,452 participants 
Final number of participants and BMD 
measurements  
N= 19,861 measurements BMD  
N=10,746 participants 
N= 7,897 measurements delta BMD 
N= 4,926 participants 
Exclusion criteria and number of (BMD / delta BMD) 
measurements:   
 – less than 6 months of pharmacy records available 
(N=1,057 / N= 759) 
 –  pre- or perimenopausal women  
(N= 594 / N= 62) 
– use of drugs that aect the bone structure and mineralization 
(N= 534 / N= 296) 
 – other antidepressant drug use 
(N= 76 / N= 67) 
Figure 2. Flow-chart of the study population.  Abbreviations: BMD = bone mineral density.
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Antidepressants and BMD 
Current SSRI and TCA use was not associated with BMD, when compared to non-use, in either 
men or women (in women, SSRI: mean difference 0.007 g/cm2, 95% CI -0.002; 0.017, TCA: 
mean difference 0.003 g/cm2, 95% CI: -0.007; 0.012). Additional adjustment for BMI, MMSE 
score, hypertension, and age at menopause (in women only) did not significantly change the 
results (Table 2). When categorized by duration of current use, neither short nor long term 
SSRI or TCA use between the visits was associated with BMD (Supplemental Table 1a and 1b). 
Additionally, we observed no dose-response relationship between the average number of 
prescribed DDDs of SSRIs or TCAs and BMD in men and women (data not shown). Additional 
Table 1. Baseline characteristics of the study population.
Men (N= 4,915) Women (N= 5,831)
Age (years) 64.1 (8.7) 65.8 (8.7)
Body mass index (kg/m2) 26.6 (3.4) 27.1 (4.3)
Lower-limb disability score 0 [0-1] 1 [0-3]
Lower-limb disableda 656 (14.5) 1,418 (26.4)
Presence of depressive symptomsb 153 (5.5) 389 (13.0)
Alcohol intake (g/day) 16.5 [1.7-25.6] 6.9 [0.0-10.3]
Smoking status
Never
Current
Former
787 (16.1)
1,247 (25.5)
2,864 (58.5)
2,676 (46.1)
1,183 (20.4)
1,951 (33.6)
Hypertensionc 2,776 (57.2) 3,369 (58.4)
Number of BMD measurements 1 [1-2] 1 [1-2]
Number of delta BMD measurements 1 [1-2] 1 [1-2]
Drug use
Glucose lowering drugs 244 (5.0) 234 (4.0)
Thiazides 243 (4.9) 530 (9.1)
Statins 445 (9.1) 365 (6.3)
Sex hormones 11 (0.2) 233 (4.0)
Glucocorticoids 241 (4.9) 231 (4.0)
Thyroid therapy 26 (0.5) 220 (3.8)
Antiepileptics 54 (1.1) 65 (1.1)
Psycholeptics 385 (7.8) 1,082 (18.6)
Calcium and vitamin D supplements 46 (0.9) 249 (4.3)
Characteristics are presented as mean (standard deviation), median [interquartile range] or number (valid percentage).  Abbreviations: BMD 
= bone mineral density. a Disability was defined as a score of 3 or higher based on a modified version of the Stanford Health Assessment 
Questionnaire.25 b Number and percentages were defined at the second measurement round, and depressive symptoms were based on a 
Center for Epidemiological Studies Depression Scale (CES-D) score of 16 or higher,26 or a Hospital Anxiety and Depression Scale (HADS-D) score 
of 9 or higher.27 c Hypertension was defined as a systolic blood pressure of 140 mmHg or higher, a diastolic blood pressure of 90 mmHg or 
higher, or the use of blood pressure lowering medication for the indication hypertension.
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adjustment for depressive symptoms did not substantially change the associations between 
current use of SSRIs or TCAs, and BMD in men and women (in women, SSRI: mean difference 
0.007 g/cm2, 95% CI: -0.004; 0.018, TCA: mean difference 0.005 g/cm2, 95% CI -0.007; 0.017). 
Antidepressants and change in BMD (∆ BMD) 
Duration of SSRI or TCA use between two consecutive visits was not associated with the 
annual percentage change in BMD over time in men and women (in women, SSRI: -0.081, 
95% CI -0.196; 0.033, TCA: 0.003, 95% CI -0.113; 0.119, Table 3). Additional adjustment for 
other covariates and, in a subsample of the population for depressive symptoms, did not 
result in different results (Table 3, model 2 and 3). In men, the median duration period of SSRI 
use was 1.05 year [IQR: 0.32-3.07], and of TCAs 0.95 year [0.21-3.82]. In women, the median 
duration period of SSRI use was 1.59 year [0.35-3.34], and of TCAs 1.18 year [0.32-2.97].
Sensitivity analyses
Results on the association between SSRI or TCA use and BMD or delta BMD were not different 
when data from men and women were combined (results not shown). Moreover, restriction 
of the definition of current use – to dispensings at time of the BMD measurement – did not 
substantially change our results (results not shown). 
Discussion
Our results indicate that use of SSRIs was neither associated with a lower BMD, nor with change 
in BMD, in a population-based cohort of middle-aged and older men and postmenopausal 
women. 
 Our main results are in line with findings reported by Spangler et al.16 and Diem et al.17 
who did not observe an association between use of SSRIs and change in BMD. Contrarily, 
another study by Diem and colleagues reported an association between SSRIs and reduction 
in BMD in an older female population.15 However, they observed similar effects in bone loss for 
intermittent and continuous SSRI users (interval of 4.9 years), which does not support a real 
drug effect or might indicate lack of power. Antidepressant use was based on interview data 
and limited information regarding duration of use between the study visits was available.15-17 
This could have resulted in misclassification of exposure. A potential association between 
SSRIs and change in BMD is unlikely to be the result of an acute effect of SSRIs, as bone 
remodeling is a relative slow process.18 In our study, pharmacy records were available on 
a day-to-day basis so we took duration of treatment between visits over a four year period 
into account. Nevertheless, we did not observe an association between duration of SSRI use 
between the visits and decline in BMD. 
 Furthermore, we did not observe an association between SSRIs and repeated cross-
sectional measures of BMD, while most previous cross-sectional studies did.9-14 The main 
differences between these studies and the present study are the design and exposure 
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assessment. We assessed SSRI exposure and BMD at multiple points in time and took duration 
of SSRI use into account. Also, we did not observe an association between TCAs and BMD, 
or decline in BMD. TCAs can also to some extent modulate serotonin levels,34 and thereby 
potentially influence BMD. However, the expected effects would be smaller than with SSRIs. 
Therefore, we included TCAs in our analyses as a negative control and additionally to rule out 
possible confounding by indication. 
 It is hypothesised that SSRIs influence bone health via modulation of serotonin levels.3,7,35 
The major part of serotonin is synthesized in the gut (>95%), and the remainder is synthesized 
in the brainstem.8 Since serotonin cannot cross the blood-brain barrier, it mainly exhibits local 
functions. Both the peripherally and centrally acting serotonin appear to modulate bone, 
although in an opposing manner. Peripheral serotonin can reduce osteoblast proliferation 
and thereby negatively affect bone formation.3,7,8 On the other hand, central serotonin can 
increase bone mass, by decreasing the sympathetic output, which is an inhibitor of bone 
mass accumulation.3,7,8 In the majority of rodent and in-vitro studies, but not consistently, the 
biological mechanism of the peripheral serotonin mechanism appears to surpass the central 
acting mechanism.3,7,36-38 In addition, results from human studies investigating the effect of 
serotonin reuptake inhibitors on bone turnover markers – which may give insight into the 
effect on bone resorption or bone formation – are not uniform and only encompass two 
studies.35 So, the exact role of serotonin on bone remains unclear, but our data suggests that 
use of SSRIs has no strong effects on BMD in the middle-aged and elderly. 
 Our results are important in the context of fracture risk. SSRI use has been associated with 
fracture risk, including within this study population of the Rotterdam Study,39 and a potential 
association between SSRIs and BMD has been proposed as an underlying mechanism.3,7,35 
Nevertheless, our results do not confirm this potential underlying mechanism. This is in line 
with the finding of Spangler et al.,16 as they did not observed an association between SSRI 
use and change in BMD, but did observe an association with fracture risk. The association 
between SSRIs and an increased fracture risk might by related to other aspects, such as 
sedative properties of SSRIs that might increase fall risk, or changes in other markers of bone 
quality.3,7,35 
 This study has strengths and limitations. Strengths of our study are the population-based 
character, availability of pharmacy dispensing records, time-dependent covariables, and 
repeated measurements of BMD. A limitation may be confounding by indication because 
depression itself has been associated with bone loss.35 However, we did not observe an 
association with BMD, and additional adjustment for depressive symptoms, based on the 
CES-D or HADS-D, did not alter our results substantially. Therefore, it is unlikely that our 
negative results are the result of confounding by indication for use. Another important 
consideration is the use of two densitometers (and accompanied change in software) during 
follow-up, which may have an effect on the degree of change in BMD that can be assessed 
in our study setting. Within our study, the precision error and least significant change (LSC) 
have not been determined. Yet, assuming similar precision errors to those reported in the 
literature,40 we can estimate the precision of the DPX-L and Prodigy devices in our study 
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to be 0.028 g/cm2 and 0.009 g/cm2, respectively, and the mean expected LSC value for 
both densitometers is calculated to be ~0.0513 g/cm2 (DPX-L: 0.028*2.77= 0.0776 g/cm2 
and Prodigy 0.009*2.77= 0.0249 g/cm2).40 This way, the small and non-significant change in 
BMD observed across duration of SSRI use does not exceed the calculated LSC. Our study 
had a sufficient long follow-up to detect effects on BMD change greater than the LSC.40 Yet, 
minimal true effects of drug use on change in BMD (which are smaller than the LSC) might 
still go unnoticed. Moreover, we also lacked serum markers of bone resorption, which could 
be more sensitive to detect changes associated with SSRIs use than those observed on BMD 
levels. Nevertheless, we do not expect big differences compared to the analysis of BMD 
levels, considering the long follow-up with multiple BMD assessments in time. Furthermore, 
drug exposure was based on dispensing records over four year periods between the BMD 
measurements rounds. As in this way long term users (>4 years) were classified as being 
exposed for a maximum of 4 years, this may have introduced slight random misclassification 
of exposure. Nevertheless, we think the effect will be minimal as the number of such long-
term users was low compared to the complete study population. Finally, drug exposure 
was based on dispensing records, and not on actual intake. However, non-adherence to 
antidepressant use would probably not be different for users with a low or high BMD, and 
therefore misclassification of exposure would probably be random in this setting.
 In conclusion, our results suggest that use of SSRIs is not associated with lower BMD or 
a greater loss in BMD in men and postmenopausal women, or if there is an actual effect 
on BMD, it is minimal and unlikely to be clinically relevant. Although previous studies 
hinted at a potential role of serotonin in bone metabolism, its exact function remains to be 
demonstrated. 
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Supplementary material
Table 1a. Association between duration of current SSRI and TCA use and mean femoral neck bone mineral 
density in men.
Model 1 Model 2
Na Mean  
difference  
(g/cm2)
95% CI p-valueb Na Mean  
difference  
(g/cm2)
95% CI p-valueb
Non-use 8,748 ref 8,498 ref
SSRI use 
1-364 days 51 -0.007 -0.024; 0.010 0.407 50 -0.005 -0.022; 0.012 0.543
≥365 days 79 0.008 -0.011; 0.028 0.395 76 0.005 -0.015; 0.025 0.596
TCA use 
1-364 days 72 0.006 -0.008; 0.020 0.418 69 0.007 -0.008; 0.022 0.341
≥365 days 59 0.016 -0.007; 0.039 0.164 57 0.017 -0.005; 0.039 0.136
Na represents number of measurement and not number of unique participants. Number of measurements are different for the different models 
as we performed a complete caseset analysis. b Significance level of the association between SSRI or TCA use compared to non-use. Model 1: 
adjusted for age. Model 2: adjusted for age, body mass index, Mini-Mental State Examination score and hypertension. 
Abbreviations: SSRI= selective serotonin reuptake inhibitor, TCA= tricyclic antidepressant, 95% CI= 95% confidence interval. 
Table 1b. Association between duration of current SSRI and TCA use and mean femoral neck bone mineral 
density in women.
Model 1 Model 2
Na Mean 
difference  
(g/cm2)
95% CI p-valueb Na Mean 
difference  
(g/cm2)
95% CI p-valueb
Non-use 10,250 ref 9,719 ref
SSRI use 
1-364 days 96 0.010 -0.003; 0.022 0.125 90 0.012 -0.001; 0.025 0.071
≥365 days 190 0.005 -0.008; 0.018 0.462 176 -0.002 -0.015; 0.011 0.785
TCA use 
1-364 days 116 <0.0001 -0.011; 0.011 0.989 107 0.0001 -0.011; 0.012 0.984
≥365 days 150 0.007 -0.007; 0.021 0.323 147 0.001 -0.013; 0.014 0.930
Na represents number of measurement and not number of unique participants. Number of measurements are different for the different models 
as we performed a complete caseset analysis. b Significance level of the association between SSRI or TCA use compared to non-use. Model 1: 
adjusted for age. Model 2: adjusted for age, body mass index, Mini-Mental State Examination score, hypertension, and age at menopause. 
Abbreviations: SSRI= selective serotonin reuptake inhibitor, TCA= tricyclic antidepressant, 95% CI= 95% confidence interval.
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Fall incidents are an important health problem in older individuals, which has multiple risk 
factors including; a history of falling, muscle weakness, impaired balance, gait, vision and 
cognition, but also hazards in the environment, and medication use.1-3 In this thesis, we 
addressed the association between medication use and fall incidents, and their potential 
underlying pathways. For this, we examined the role of genetic variants, homocysteine and 
bone mineral density. We focused on the following objectives:
Objective 1: Which medication is associated with fall risk in the B-PROOF study population? 
(Chapter 2.1)
Objective 2: Are there genetic variants that modify the association between medication use 
and fall risk? (Chapter 2.2, 2.3 and 2.4)
Objective 3: Is medication use associated with homocysteine levels? (Chapter 3.1)
Objective 4: Is use of SSRIs associated with BMD and change in BMD over time? (Chapter 3.2)
In this last chapter, we first discuss our main findings, thereafter we outline methodological 
considerations that are of importance in our research, and finally we discuss medication-
related falls in a broader perspective, ending with suggestions for clinical implications and 
future directions of research.
Main findings of this thesis
Benzodiazepine-related falls
In chapter 2.1 we observed an association between benzodiazepine use and an increased 
fall risk, which is in line with previous literature where this association has consistently been 
reported.4-7 We further investigated this association in chapter 2.2 and 2.4. Benzodiazepines 
are a group of medications mainly used for anxiolytic and hypnotic purposes, and sometimes 
as anticonvulsants.8-10 In chapter 2.2, it appeared that the association seemed to be driven 
by hypnotic use. Although the various benzodiazepines are chemically very much alike, their 
pharmacodynamics effects can differ. Onset and duration of effects depend, among others, 
on the lipophilic properties and half-life.8-10 Additionally, the dosing regimens for anxiolytic 
and hypnotic properties differ, as for anxiolytic purposes benzodiazepines are often used 
multiple times per day to induce and sustain a stable plasma level. Moreover, they may be 
used for a longer period of time, as tolerance to the anxiolytic effect develops more slowly 
than tolerance to the hypnotic effects.10 Benzodiazepines for hypnotic purposes are mainly 
used in the evening and its use is only recommended for a short period,8,9,11 although this 
is not always the case in clinical practice. Whether these differences may contribute to a 
potential difference in fall risk is unclear, but it might be possible that differences in clinical 
effects are also reflected in adverse effects. On the other hand, there is also a study indicating 
that both anxiolytic and hypnotic use increased the risk of a hip fracture, which is in majority 
caused by a fall12 and literature suggest that the adverse reaction profile is grossly similar.13 
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Taken together, anxiolytic and hypnotic benzodiazepines may have a different frequency 
and magnitude of (adverse) effects, but more research is needed to quantify these effects 
and their underlying mechanisms.
 Another aspect we examined is the role of genetic variants on benzodiazepine-related 
falls, by applying a candidate gene study and a genome wide association study. In chapter 
2.2, we observed that the association between benzodiazepine use and fall incidents was 
modified by CYP2C9*2 and *3 allele variants. Participants using benzodiazepines and having 
reduced CYP2C9 enzyme activity – based on their genotype – had an increased fall risk. So, 
by having a reduced CYP2C9 enzyme activity, the benzodiazepine metabolism is reduced, 
potentially leading to increased blood and tissue levels and thereby more adverse effects. 
This is an interesting finding, because up to now only limited evidence indicated that CYP2C9 
plays a role in the metabolism of benzodiazepines, as CYP3A enzymes and 2C19 enzymes are 
currently thought to be the main enzymes involved in benzodiazepine biotransformation.9,14-21 
In future research, the role of CYP2C9 has to be elucidated and our findings should be verified. 
Furthermore, it would be interesting to separately investigate anxiolytics and hypnotics, 
and also take into account benzodiazepines with pharmacologically active metabolites 
after biotransformation. Currently, we could not account for all these factors because of our 
limited sample size.
 In addition to CYP2C9 genotypes, we identified genetic variants that influence the 
association between benzodiazepine use and fall risk in chapter 2.4. In the discovery cohort 
of 2 studies, N= 3,686 (N= 258 cases and N= 3,428 controls), we identified a less common 
variant, having a minor allele frequency of ~3% and an effect size of OR= 0.31 (95% CI 0.21; 
0.47), p= 2.15*10-8. This intronic variant is located on chromosome 9 within the FAM73B 
gene. This gene encodes a protein involved in mitochondrial fusion, while dysregulation 
of mitochondrial fusion has been related to neurodegenerative disorders in humans.22 
Furthermore, expression data reports the highest median expression in brain- cerebellum.23 
This part of the brain plays a key role in motor control,24 thereby the FAM73B gene could be 
linked to our phenotype, benzodiazepine-related fall incidents. On the other hand, FAM73B 
gene has been associated with bone phenotypes in mice.25,26 Overall, these potential 
explanations of our observed association remain speculative, because it is still unknown 
whether the genetic variant affects the function of FAM73B. Therefore, additional replication 
and functional studies are needed to verify and support our finding.
 Taken together, use of benzodiazepines is associated with fall incidents and potentially 
there are class or individual drug effects. Moreover, genetic variants can influence this 
association and more research is needed to verify our findings and identify other variants 
and their function. Thereafter, research should evaluate the additional value of genotyping 
as a prognostic factor for prescribing benzodiazepines to older individuals with respect to 
fall risk.
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Key points: future directions
 • Investigate the role of CYP2C9 and its genetic variants in benzodiazepine metabolism, 
and accordingly associate it with benzodiazepine (adverse) effects.
 • How? In vitro studies, using human liver microsomes to investigate if and to what 
extent CYP2C9 plays a role in the metabolism of various benzodiazepines. In addition, 
in vivo studies can be used to measure benzodiazepine/metabolite levels across 
genotypes. Furthermore, with population-based studies (adverse) effects of genetic 
variants in CYP2C9 can be investigated.
 • Replicate the association between our observed genetic variant and benzodiazepine-
related falls, and accordingly further investigate the functionality of the genetic variant.
 • How? Replication in population-based studies where falls and medication use are 
prospectively gathered. Functionality, could be investigated with in animal models, 
such as knockout mouse models, and in vitro studies.
Beta-blocker-related falls
Use of beta-blockers has been associated with fall risk, but literature is contradictory.4,27-29 
Previous studies investigated all beta-blockers as one medication group and did not 
distinguish between different characteristic of beta-blockers. We hypothesised that 
characteristics of beta-blockers regarding their selectivity for adrenergic receptors, lipid 
solubility, intrinsic sympathetic activity (ISA), and their elimination route, differed in their 
association with fall incidents. In chapter 2.3, we observed that non-selective beta-blockers in 
specific were associated with an increased fall risk, while selective or lipophilic beta-blockers 
were not. Additionally, we did not observe an association between beta-blocker use and fall 
risk across genotypes of CYP2D6. CYP2D6 is an enzyme, which is of major importance in the 
metabolism of some beta-blockers, such as metoprolol.30,31 Although no significant association 
between selective beta-blocker use and fall risk was observed, our results point towards 
a slightly decreased fall risk (HR= 0.92, 95% CI 0.83; 1.01). These apparently contradictory 
results – a potentially decreased fall risk for selective beta-blockers and an increased fall 
risk for non-selective beta-blockers – are noteworthy. We have no clear explanation for this 
other than their differential binding to β1-, β2- and α-receptors and resulting clinical and 
potential adverse effects,32-34 as discussed in chapter 2.3. In comparison to selective beta-
blockers, non-selective beta-blockers not only reduce heart rate and contractility, they also 
induce peripheral vasoconstriction, including in afferent blood vessels in skeletal muscle.32,33 
Nevertheless, a drug class review on the differences in effectiveness and safety for various 
indications, reported no substantial differences in adverse effects between various beta-
blockers, all with their own characteristics.35 Thus, potential differences in adverse effects are 
plausible based on their working mechanism, though they are not uniform in literature. In 
addition, beta-blockers have been shown effective for a variety of cardiovascular diseases.35 
So, with respect to fall risk, additional research is needed to confirm a potential positive 
effect for selective beta-blockers, and negative effect of non-selective beta-blockers. For 
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clinical practice, this stresses the importance of a well-balanced decision – based on patient 
characteristics and indication – regarding beta-blocker prescriptions. 
Key points: future directions
 • Further investigate the association between beta-blocker selectivity and fall risk, and 
accordingly formulate clinical recommendations.
 • How? A similar (epidemiologic) study for verification of our finding, potentially also 
investigating new users and the effect of duration of use.
Medication, bone mineral density and fractures
SSRI use has been associated with fracture risk, including in the population-based cohort 
of the Rotterdam Study.36-39 This has been attributed to an increase in fall risk and/or a 
potential direct effect on bone.37-39 In chapter 3.1, we did not observe an association with 
BMD or change in BMD when taking into account duration of treatment. So, our study did 
not confirm an association between SSRI use and BMD, and the exact role of serotonin on 
bone remains unclear.37,38,40 Furthermore, literature evidently indicates an association of 
SSRIs with fall risk.41-43 Thereby the most probable mechanism underlying the association 
between SSRIs and fracture risk appears to be their association with fall incidents rather than 
a potential effect on bone, as measured with BMD. However, SSRIs may affect bone in another 
way than is reflected in BMD, as other determinants of bone strength, bone remodeling or 
bone matrix/geometry might be affected.44,45
Key points: future directions
 • Investigate the role of serotonin in bone, and accordingly investigate the association 
between use of SSRIs and bone characteristics, e.g. bone strength (other than BMD), 
bone geometry, and bone markers. 
 • How? Animal and in vitro studies to investigate the mechanism, and population-based 
studies to investigate the association between use of SSRIs and bone characteristics.
Methodological considerations
Overall, we observed some medication groups to be associated with fall risk, but in our study 
many other groups which have been suggested to increase that risk were not associated 
with it. Why did we not observe an association? The exact answer is obviously unknown, 
but it can be distinguished into the following 2 options: 1) there may be a true association, 
but we did not observe it, or 2) the association is false, despite results from other studies. 
Considering option 1, there are multiple factors playing a role that probably all relate to 
methodological issues, including study design, study population, assessment of outcome, 
exposure and covariables, and sample size, separately or in combination. These factors are 
separately discussed in more detail below. 
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Study population and design
Data from three population-based studies were used, B-PROOF,46 The Rotterdam Study47 
and LASA,47 though for some research questions only one or two of these study populations 
were used. Although all studies included community dwelling older individuals, B-PROOF 
concerned a more selected population. Participants were primarily included on the basis of 
their homocysteine levels, thereby results from this study are not completely generalizable 
to the general population. Nevertheless, the generalizability of study results also depends on 
whether the studied association is related to homocysteine levels. With respect to medication-
related falls, we are not aware of a mechanism whereby homocysteine could be expected 
to affect this association. Additionally, the B-PROOF study population was subjected to an 
intervention with vitamin B12, folic acid and vitamin D, or only vitamin D (placebo). However, 
the intervention did not affect the time to the first or second fall, and the total number of 
incident falls.48 Thus, for the B-PROOF study population, we do not expect that the inclusion 
based on homocysteine levels or the intervention affected the generalizability of the results 
– regarding medication-related falls – described in this thesis. Nevertheless, the B-PROOF 
study population is used as a cohort, and cohort studies also do not completely represent 
the general population, as the healthy volunteer effect and differential loss to follow-up are 
inevitable.49,50 These limitations are, however, inherent to epidemiological studies and should 
be kept in mind when translating study results to clinical practice. 
Measuring the outcome: falls
Fall data can be gathered in various ways. In this thesis, we used prospectively gathered fall 
data, which better reflect the actual fall incidents than retrospective fall data, as they are not 
subjected to ‘recall bias’. Fall incidents were self-reported (B-PROOF and LASA) or defined as 
‘serious falls’ (the Rotterdam Study). Self-reported falls were gathered using a fall-calendar,51,52 
and defined as ‘an unintentional change in position resulting in coming to a rest at a lower 
level or on the ground’.53 Serious fall data were obtained from computerized reporting 
systems and are defined as ‘a fall leading to a hospital admission or leading to a fracture’.54 
By definition – falls and serious falls – represent a somewhat different type of outcome, that 
may affect the generalizability of the study results. Nevertheless, the effect sizes observed for 
benzodiazepine-related falls and beta-blocker related falls in B-PROOF, the Rotterdam Study 
and LASA were similar (chapter 2.2 and 2.3). Indicating that these medications are similarly 
associated with falls and serious falls.
Measuring the exposure: medication use
Like fall data, medication use can be assessed in various ways. In this thesis, we made use 
of self-reported data and pharmacy dispensing records.46,47,55 Unfortunately there is no ‘gold 
standard’ for assessing medication use in observational studies and both methods have 
pro’s and con’s.56,57 Self-reported medication data could be relatively easily assessed using 
a questionnaire and or a medication interview to gather information regarding prescribed 
and over the counter (OTC) medications. However, the accuracy relies on the memory of 
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the participant and recall bias might subsequently result in misclassification of exposure.56-59 
Obtaining pharmacy dispensing records in a population-based setting is logistically more 
complex and cumbersome. However, when possible, a large amount of detailed data, 
regarding dose, frequency and duration information, can be obtained. Nevertheless these 
data will not include OTC’s and does not necessarily imply actual use, and could thereby also 
result in misclassification of the exposure.57,59,60 Both types of misclassification are most likely 
not random, and may accordingly affect the outcome. Overall, the applicability of a method 
depends on the research question and the resources available, though the limitations of the 
method should be taken into account. For the study of falls, pharmacy dispensing records 
are probably favored, as it is important to determine which medication is used at the time of 
the fall or prior to the fall. 
Covariables and confounding factors
Although, the outcome and the exposure – when pharmacy dispensing records were used 
– were assessed at a certain point in time, covariables – including potential confounders – 
were not, and thereby we rely on priory assessed determinants. These determinants will not 
always capture the health status at the time of the outcome and consequently could have 
affected the risk estimate. This may have led to under- or overestimation of the association. 
 Another important item is confounding by indication, which refers to the phenomenon 
that the reason for use itself or the severity of the disease is independently associated with 
the outcome instead of the exposure.61 In this thesis, we used various ways to investigate 
whether confounding by indication may have played a role. We examined associations in 
past users of certain medications (Chapter 2.1, 2.2, 2.3), we examined the association in users 
of certain medications (Chapter 2.2), we investigated dose-response relations (Chapter 2.1, 
2.2, 2.3, and 3.2), and we examined the association with another medication group, used for 
the same indication (Chapter 3.2).
 Our observed association between antidepressant use and fall incidents (Chapter 2.1), 
could have been confounded by indication, as both depression and antidepressant use has 
been associated with falls.41,42,62 Therefore, we also examined the association in past users 
(who of course had had the same indication), which did not indicate a significant association. 
However, this does not completely rule out potential confounding by indication, as the 
indication depression varies over time, and because it is difficult to separate the effect of 
antidepressants from depression itself. Though, two self-controlled case-series studies also 
reported an association between antidepressant use and fall risk, and this method is less 
subject to confounding by indication,42,63 unless the indication varies over time. Furthermore, 
a cohort study investigating the association with both depression and antidepressants 
concluded that both aspects contributed to fall risk.41 So, our observed association may 
be confounded by indication, but based on literature it is likely that there is also a true 
association between antidepressant use and fall incidents.
 In addition, it may be possible that factors related to benzodiazepine use influenced 
the modifying effect of CYP2C9 genotype on benzodiazepine-related falls (Chapter 2.2). 
509950-L-bw-Ham
Processed on: 2-5-2017 PDF page: 150
150 | Chapter 4
However, to investigate whether this modifying effect was ‘truly’ due to CYP2C9 genotypes 
we examined an allele-dose association. This indicated that homozygous *2 or *3 versus 
heterozygous allele carriers have a higher increased fall risk. Furthermore, we assessed 
the association between CYP2C9 genotype and falls within benzodiazepine users. This 
analysis showed that also within benzodiazepine users carrying a CYP2C9*2 or *3 allele 
was significantly associated with an increased fall risk. Moreover, an allele-dose association 
was observed. Overall, these results indicated that factors, which are potentially related to 
benzodiazepine use, did not substantially influence the modifying effect of CYP2C9 genotype 
on the association between benzodiazepine use and falls. 
 Regarding dose-response relations, when an association is potentially caused by the use of 
a certain medicine, one would expect a dose-response relation. Only for the use of hypnotics 
we observed a dose-response relation (Chapter 2.2). Nevertheless, for benzodiazepines 
overall, literature reports a dose-response relation for fall risk and/or hip fractures.12,64-67
 A potential association between use of SSRIs and BMD may also be confounded 
by indication, as depression has been associated with BMD.37,39 Within the analyses we 
adjusted the models for presence of depressive symptoms, which did not change the results 
substantially. Furthermore, we investigated the associations between tricyclic antidepressant 
(TCA) use and BMD, as TCAs are also used for depressive symptoms. However, like SSRIs, TCAs 
can modulate serotonin levels, though to a lesser extent, thereby TCAs may also be related 
to BMD. Nevertheless, a potential effect would be smaller than with SSRI use. Overall, we 
did not observe an association between use of SSRIs or TCA’s and BMD. This suggests that 
confounding by indication did not substantially affect our results.
Sample size and exposure window
To study adverse effects of medication use, such as falls, large populations are needed. A fall 
incident is relatively common, as one third of those ≥65 years encounters a fall every year.68 
In an older population medication is also frequently used, although use varies between 
medication groups. Benzodiazepines use varied between 4-15% (The Rotterdam Study, 
B-PROOF and LASA), and beta-blocker use, 13% and 26% (The Rotterdam Study, B-PROOF). 
However, the combination of exposure and outcome is less frequent, and therefore we could 
not study all medication (sub)groups in for example chapter 2.1. For genetic studies sample 
size is even more important.69-72 Although we investigated ‘common’ genetic variants – those 
with a minor allele frequency ≥5%72 – large populations are needed to study the combination 
of exposure and a genetic variant on an outcome.
 Another important factor when studying adverse effects is timing of exposure. Within 
our studies we used prevalent users, which may be those who tolerate the drug well and 
are less susceptible to adverse effects. New users, might be better to study,73,74 however 
it also depends on the type of adverse effect. With respect to the association between 
antihypertensive medication and fall risk, initiation of antihypertensive medication is 
thought to increase fall risk by inducing a hypotensive effect that stabilizes over time.28,75 
Therefore it might be better to study this association within new users. On the other hand, 
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antihypertensive are often used for many years and it is of clinical value to examine if use – 
prevalent use – is associated with fall incidents.76 For an association between SSRI use and 
BMD, prevalent users are probably very suitable to study, because we hypothesized that a 
longer duration of use would affect BMD, as bone remodeling is a slow process.77 For both 
initiation and a longer duration of use, large sample sizes are needed. Therefore, we were 
not able to properly study initiation of use, and as the number of antidepressant users was 
limited, duration of SSRI use could not be studied in B-PROOF. 
Implications and future directions
Personalized medicine and medication-related falls
Personalized medicine, precision medicine or stratified medicine,71,78 irrespective of the 
name, have the common goal to optimize medication effects – efficacy and toxicity – based 
on patient characteristics, including age, gender, health status, lifestyle and genetic factors. 
With respect to genetic factors, it is probably too early to incorporate genetic testing to 
reduce medication-related fall incidents. Because, there are only few studies done,79,80 and 
their results need to be replicated, and their underlying mechanism need to be elucidated 
(chapter 2.2 and 2.4). However, these studies do indicate that genetic variants play a role 
in medication-related falls, and may form a first step towards pharmacogenetics testing in 
clinical practice. More research is needed to identify additional genetic variants that may 
play a role in medication-related falls. Thereby, it may be interesting to focus on medication 
groups that have a well-established relation with fall incidents, such as benzodiazepines 
and antidepressants. For antidepressants there are various pharmacogenetics studies,14,81 
so it would be interesting to investigate whether variants identified in those studies also 
influence fall incidents. On the other hand, one could also investigate medication groups of 
which the relation with fall incidents is less certain. It might be that only those with a specific 
genetic predisposition are at increased risk, while others are not.
 Medication-related falls is a complex outcome for the determination of genetic factors 
involved, as falls by itself is multifactorial. Therefore, it could be of value to also investigate 
the role of pharmacogenetics in the pathways associated with medication-related fall, such 
as muscle weakness, balance and dizziness, although these are also outcomes in which 
multiple factors are involved. 
 More information on the role of genetics in medication-related falls, and their underlying 
path-ways could help discriminate those persons at (increased) risk and provide clinicians 
with valuable information that help them with appropriate prescribing of medication.
Medication use and fall risk from a broader perspective
In this thesis we investigated medication-related falls, as medication use is a potentially 
modifiable risk factor. However, stopping or adjusting medication use has been shown to be 
very difficult. Studies have tried to reduce fall risk and fall rate, but results are not uniform.79,82-84 
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So, can we prevent falls by withdrawing or reducing the dose of fall-risk increasing drug, 
and/or should we focus on other fall-risk factors? Fall incidents have multiple risk factors, 
including fall history, muscle weakness, impaired balance, gait, vision and cognition, and also 
environmental hazards such as uneven surfaces or slippery floors. In older people, especially 
those with multiple morbidities, it is most likely that a combination of factors contributes 
to their fall risk. There are various fall prevention guidelines and literature reviews6,83,85-88 
and overall they recommend an individualized multifactorial approach, focusing on fall risk 
assessment and accordingly on intervention to reduce fall risk and fall rate. All assessing and 
targeting factors including, fall history, medical history (osteoporosis, depression, cognitive 
disorders and cardiovascular disease), physical and functional disabilities (strength, balance, 
gait, vision, urinary function, fear of falling), environmental factors, and medication review 
(psychoactive drugs and polypharmacy).6,83,86-88 However, these fall prevention guidelines 
might benefit from well-established fall risk prediction tools that help to better identify 
individuals at risk and the most important risk factors per individual. Accordingly a more 
personalized and effective multifactorial approach could be initiated.89,90 However, although 
various fall risk prediction tools have been developed, most have not been validated and 
their predictive accuracy is only modest.90-92 So, in further research, fall risk prediction 
tools should be investigated, in which the complex interaction of different risk factors and 
covariables are taken into account, as well as the subsequent interventions to reduce fall risk. 
With respect to the results of this thesis, we would recommend to include medication use 
in the prediction tools and especially benzodiazepine and antidepressant use. Regarding 
cardiovascular medication, we only observed an increased fall risk for non-selective beta-
blockers, but this association needs verification. Furthermore, antihypertensive medication 
has been associated with fall risk,4,28,76 though not consistently.27,93,94 So, this medication 
group also needs further investigation and should be evaluated in risk prediction tools. For 
studies investigating these tools it is of importance to use prospectively gathered fall and 
medication data. Furthermore, when the role of genetic variants in medication-related falls 
is evident, these genetic variants should also be evaluated in prediction tools. For now, for 
clinical practice, medication reviews are important and we would recommend to give special 
attention to use of antidepressants and/or benzodiazepines, based on our results27,95 and 
those from literature.4-7,41-43 There are various tools that can help a clinician to judge whether 
a prescription is appropriate.96 The key points in all are that it should be well evaluated if 
prescription is necessary, contraindicated, has the right doses, whether the benefits outweigh 
the potential negative effects, and if there are better substitutes.96 
Key points: clinical implications of the key findings
 • Use of benzodiazepines, antidepressants, anti-arrhytmics and non-selective beta-blockers 
was associated with increased fall risk.
 • Clinicians should prescribe medication associated with fall risk with caution and if 
possible choose safer alternatives for older patients.
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 • The differences in homocysteine levels between medication users and non-users were 
relatively modest, suggesting that medication use is unlikely to contribute to clinically 
relevant changes in plasma homocysteine levels in our population.
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5.1  Summary
Fall incidents are a major problem in older individuals, because approximately one third 
encounters at least one fall yearly. Of all falls, 5 to 12% result in serious injuries or fractures 
requiring medical attention, which lead to reduced quality of life and substantial health care 
costs. Medication use is one of the risk factors for falling, however literature is inconclusive 
on the medication groups that are associated with an increased fall risk. Moreover, the 
pathways underlying the association between medication use and fall incidents need to 
be further examined. In this thesis we addressed the association between medication use 
and fall incidents, and their potential underlying pathways. For this, we examined the role of 
genetic variants, homocysteine and bone mineral density (BMD).
 In chapter 2.1, using the B-PROOF study population, we observed several medications 
to be associated with an increased fall risk, namely; benzodiazepines, antidepressants, 
non-selective beta-blockers, and anti-arrhythmics. On the other hand, statin use was 
associated with a lower fall risk. We further investigated the potential underlying pathways 
of the associations between benzodiazepine and beta-blocker use, and fall incidents. For 
benzodiazepine-related falls we examined the role of genetic variants, by applying a candidate 
gene study and a genome wide association study. We observed that the association between 
benzodiazepine use and fall incidents was modified by CYP2C9*2 and *3 allele variants 
(chapter 2.2). Individuals using benzodiazepines and having reduced CYP2C9 enzyme 
activity – based on their genotype – were at increased fall risk. So it seems that by having 
a reduced CYP2C9 enzyme activity, the benzodiazepine metabolism is reduced, potentially 
leading to increased blood levels and thereby more adverse effects. However, it should be 
noted that the exact role of CYP2C9 in benzodiazepine metabolism is still unclear. In future 
research the role of CYP2C9 has to be elucidated and our findings should be verified. 
 In addition to CYP2C9 genotypes, we identified a genetic variant that influenced the 
association between benzodiazepine use and fall risk in chapter 2.4. We identified a less 
common variant within the discovery cohort of 2 studies, N= 3,686 (N= 258 cases and N= 
3,428 controls). The variant has a minor allele frequency of ~3% and an effect size of OR= 0.31 
(95% CI 0.21; 0.47), p= 2.15*10-8. It is an intronic variant – with unknown effect on protein 
– located on chromosome 9 within the FAM73B gene. This gene encodes a protein involved 
in mitochondrial fusion, and dysregulation of mitochondrial fusion has been related to 
neurodegenerative disorders in humans. Furthermore, FAM73B gene has been associated 
with bone phenotypes in mice. Overall, the effect of the variant on the gene is unknown and 
therefore additional replication and functional studies are needed to verify and support our 
finding.
 Use of beta-blockers overall was not associated with fall risk (chapter 2.3). Interestingly 
use of non-selective beta-blockers was associated with an increased fall risk, while selective 
or lipophilic beta-blockers were not. Additionally, we did not observe an association between 
beta-blocker use and fall risk across genotypes of CYP2D6. The CYP2D6 enzyme is of major 
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importance in the metabolizing pathway of some beta-blockers, such as metoprolol. A 
potential explanation for the contradictory findings between selective and non-selective 
beta-blockers is their differential binding to β1-, β2- and α-receptors and the resulting 
differences in clinical and potential adverse effects. In comparison to selective beta-blockers, 
non-selective beta-blockers not only reduce heart rate and contractility, they also induce 
peripheral vasoconstriction, including in blood vessels towards and in skeletal muscle. 
Nevertheless, literature does not report substantial differences in adverse effects between 
various beta-blockers. Therefore, additional research is needed to confirm a negative effect 
of non-selective beta-blockers use on fall risk.
 We investigated the relation between medication use and homocysteine levels in chapter 
3.2. Our results indicated that users of diuretics in general, high-ceiling sulphonamide 
diuretics, agents acting via the renin-angiotensin system and metformin had slightly 
higher homocysteine levels. The association were, however, fairly modest suggesting that 
medication use is unlikely to contribute to clinically relevant changes in plasma homocysteine 
levels within our study population.
 Selective serotonin reuptake inhibitor (SSRI) use has been associated with fracture risk in 
several studies, including the Rotterdam Study. This has been attributed to an increase in fall 
risk and/or a potential direct effect on bone. However, we did not observe an association with 
BMD or change in BMD – when taking into account duration of treatment – (chapter 3.3). So, 
our study did not indicate an association between SSRI use and BMD, and the exact role of 
serotonin on bone remains unclear. Furthermore, literature evidently indicates an association 
with fall risk. Thereby the most probable mechanism underlying the association between 
SSRIs and fracture risk appears to the be their association with fall incidents. However, SSRIs 
may affect bone in another way than is reflected in BMD, as other determinants of bone 
strength, bone remodeling or bone geometry might be affected.
 In the discussion (chapter 4) we conclude that based on our results and those form 
literature, benzodiazepines and antidepressants are two of the most important medications 
groups that are associated with increased fall risk. When evaluating fall risk in older persons, 
clinicians should give special attentions to these groups during the medication review. In 
addition, genetics variants appeared to play a role in benzodiazepine-related fall risk, but 
further research is needed to elucidate its exact role.
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5.2 Dutch summary – samenvatting
Voor oudere mensen zijn valincidenten een groot probleem, aangezien ongeveer één derde 
van de ouderen op zijn minst één keer per jaar valt. Van alle vallen resulteert 5 tot 12% in 
ernstig letsel of fracturen, wat leidt tot een verminderde kwaliteit van leven en hoge kosten 
voor de gezondheidszorg. Medicijngebruik is één van de risicofactoren voor vallen, alhoewel 
de literatuur niet eenduidig is over welke medicatiegroepen gerelateerd zijn aan valrisico. 
Verder moeten de mechanismes, onderliggend aan de relatie tussen medicatiegebruik 
en vallen, verder onderzocht worden. In dit proefschrift kijken we naar de relatie tussen 
medicatiegebruik en vallen. Tevens kijken we naar de onderliggende mechanismen, hiervoor 
onderzoeken we de rol van genetische variatie, homocysteïne en botmineraaldichtheid 
(BMD).
 In hoofdstuk 2.1, in de B-PROOF studiepopulatie, vonden we een relatie tussen het gebruik 
van verschillende medicijnen en een verhoogd valrisico, namelijk voor benzodiazepines, 
antidepressiva, niet-selectieve bètablokkers en anti-aritmica. Daarentegen was het gebruik 
van statines gerelateerd aan een verlaagd valrisico. De relatie tussen benzodiazepines, niet-
selectieve bètablokkers en valrisico hebben we verder onderzocht. Voor benzodiazepine-
gerelateerde valincidenten onderzochten we de rol van genetische varianten door middel 
van een kandidaatgen studie en een genoomwijde associatiestudie. Daarbij vonden we dat 
de relatie tussen benzodiazepines en valincidenten gemodificeerd werd door CYP2C9*2 
en *3 allel varianten (hoofdstuk 2.2). Personen die benzodiazepines gebruikten én een 
verminderde CYP2C9 enzymactiviteit hadden, gebaseerd op hun genotype, hadden een 
verhoogd valrisico. Dit zou kunnen impliceren dat door middel van een verminderde 
CYP2C9 enzymactiviteit het benzodiazepinemetabolisme verminderd is, wat mogelijk 
kan leiden tot verhoogde bloedspiegels en daardoor meer bijwerkingen veroorzaakt. 
Hierbij moet wel in gedachten worden gehouden dat de precieze rol van CYP2C9 in het 
benzodiazepinemetabolisme nog niet geheel duidelijk is. In vervolgonderzoek moet de 
precieze rol opgehelderd worden en onze resultaten bevestigd worden.
 Naast de CYP2C9 genotypen identificeerden we een genetische variant die de associatie 
tussen benzodiazepinegebruik en valincidenten beïnvloede (hoofdstuk 2.4). Deze niet 
veel voorkomende variant vonden we in een begin-cohort bestaande uit twee studies, N= 
3,686 (N= 258 cases en N= 3,428 controles). De variant heeft een minor allelfrequentie van 
~3% en een effectgrootte van OR= 0.31 (95%BI 0.21; 0.47), p= 2.15*10-8. Het betreft een 
intron variant, met een onbekend effect op het eiwit, op chromosoom 9 in het FAM73B 
gen. Dit gen codeert voor een eiwit wat betrokken is bij mitochondriale fusie. Disregulatie 
van mitochondriale fusie kan gerelateerd zijn aan neurodegeneratieve ziektes in mensen. 
Verder zijn er aanwijzingen dat het FAM73B gen gerelateerd is aan botfenotypes in muizen. 
Samenvattend, omdat het effect van de variant op het gen onbekend is, hebben we replicatie 
en functionele studies nodig om onze bevinding te bevestigen. 
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Het gebruik van bètablokkers was niet gerelateerd aan valrisico (hoofdstuk 2.3). Maar het 
gebruik van de subgroep niet-selectieve bètablokkers was gerelateerd aan een verhoogd 
valrisico, terwijl selectieve en lipofiele bètablokkers niet gerelateerd waren aan valrisico. Verder 
vonden we geen relatie tussen bètablokkergebruik en valrisico binnen CYP2D6 genotypen. 
Het CYP2D6 enzym is belangrijk voor het metabolisme van een aantal bètablokkers, zoals 
metoprolol. Een mogelijke verklaring voor de tegenstrijdige bevindingen tussen selectieve- 
en niet-selectieve bètablokkers kan komen door het verschil in bindingscapaciteit voor 
β1-, β2- en α-receptoren, wat resulteert in verschillende klinische effecten en mogelijke 
bijwerkingen. In vergelijking met selectieve bètablokkers, verminderen niet-selectieve 
bètablokkers niet alleen de hartslag en het samenknijpen van het hart, maar induceren ze ook 
perifere vasoconstrictie, inclusief van de bloedvaten in en naar de skeletspieren. Desondanks 
is er vanuit de literatuur bekend dat er geen substantiële verschillen in bijwerkingen zijn 
tussen de verschillende bètablokkers. Daarom is er meer onderzoek nodig om een mogelijk 
negatief effect van niet-selectieve bètablokkers op valrisico te bevestigen.
 Naast medicatie-gerelateerd vallen onderzochten we de relatie tussen medicatiegebruik 
en homocysteïne waardes (hoofdstuk 3.2). De resultaten laten zien dat gebruikers van 
diuretica, medicatie welke aangrijpt op het renine-angiotensine systeem, en metformine 
licht verhoogde homocysteïne waardes hadden. Voor diuretica was dit specifiek te zien bij 
sulfonamiden loop-diuretica (‘high-ceiling’ sulfonamiden diuretica). De verhoging was echter 
zeer beperkt, wat suggereert dat het onwaarschijnlijk is dat medicatiegebruik bijdraagt aan 
klinische relevante veranderingen in plasma homocysteïne-waardes in de bestudeerde 
populatie. 
 Vanuit de literatuur is een relatie tussen selectieve serotonine-heropnameremmer (SSRI) 
gebruik en fractuurrisico bekend. Deze relatie is ook gevonden in de populatie van de 
Rotterdam Studie. De relatie zou kunnen komen door een verhoogd valrisico en/of door een 
direct negatief effect op de botten. Echter, in ons onderzoek vonden we geen relatie tussen 
SSRI gebruik en BMD of verandering in BMD, ook niet wanneer er rekening gehouden werd 
met de duur van het SSRI gebruik (hoofdstuk 3.3). Ons onderzoek liet zien dat er geen relatie 
is tussen SSRI gebruik en BMD. Verder is het onduidelijk welke rol serotonine precies speelt 
in botten. Daarentegen is er vanuit de literatuur duidelijk bewijs voor een relatie tussen SSRI 
gebruik en valrisico. Daarom denken we dat de relatie tussen SSRI en valrisico het meest 
logische onderliggende mechanisme is voor de relatie tussen SSRI gebruik en fractuurrisico. 
Hoewel SSRI’s ook op een andere manier effect zouden kunnen hebben op bot dan wordt 
aangeduid met BMD. Zo zouden ze effect kunnen hebben op andere determinanten van 
botsterkte, botmodellering of botgeometrie.
 In de discussie (hoofdstuk 4) concluderen we dat, gebaseerd op onze eigen resultaten en 
de literatuur, benzodiazepines en antidepressiva de twee belangrijkste medicatiegroepen 
zijn die gerelateerd zijn met een verhoogd valrisico. Wanneer clinici het valrisico van een 
ouder individu evalueren is het belangrijk dat er op deze twee medicatiegroepen gelet 
wordt. Aangezien genetische variatie een rol bleek te spelen in benzodiazepine-gerelateerd 
valrisico, maar de exacte rol onduidelijk is, is het belangrijk dat dit verder onderzocht wordt. 
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5.5 Acknowledgment – dankwoord
Promoveren, het is niet zomaar iets, maar wel heel leerzaam op allerlei vlakken en zeker ook 
leuk. Hoewel er natuurlijk ook minder leuke dingen waren, maar dat hoort er ook bij. De 
behoorlijk lange tijd die ik nodig heb gehad om dit boekje te schrijven, heb ik niet alleen 
doorgebracht en dat is maar goed ook. Want zonder alle hulp van alle mensen om mij heen 
had ik het nooit gered! Daarom wil ik iedereen die mij op welke manier dan ook geholpen 
heeft heel hartelijk bedanken!
André en Bruno, als eerste wil ik jullie graag bedanken voor de mogelijkheid die ik heb 
gekregen om bij jullie mijn onderzoek te doen. Ik heb heel veel van jullie geleerd. Beiden 
hebben jullie een specifiek vakgebied waarvan ik helemaal niets wist toen begon. Maar 
gedurende de jaren hebben jullie mij geduldig alles uitgelegd en kritische vragen gesteld. 
Daarnaast hadden jullie altijd zeer nuttig commentaar over de opzet van de studies en de 
manuscripten. Dit heeft mij echt geholpen. Verder waren de afspraken altijd gezellig, soms 
iets te gezellig, en werd er uitgeweid over allerlei onderwerpen waardoor we niet veel tijd 
over hadden om de agendapunten te bespreken. Maar het is altijd goed gekomen. 
Nathalie, ik kan natuurlijk niet alleen André en Bruno bedanken voor de onderzoeks-
mogelijkheid. Jij bent namelijk degene die het project mogelijk heeft gemaakt waaraan ik al 
die jaren heb gewerkt. Dus hartelijk dank daarvoor! Ik heb veel van je geleerd en niet alleen 
op het gebied van onderzoek maar ook over mijzelf en mijn houding. Ik weet dat ik nogal 
koppig ben en dat is niet altijd makkelijk, maar gelukkig zijn we er samen uitgekomen. 
Mijn promotiecommissie, Dr. M.C. Zillikens, Prof.dr. R.J. van Marum, Prof.dr. P.M.L.A. van den 
Bemt, Prof.dr. R. van Schaik en Prof.dr. L.C.P.G.M. de Groot, wil ik hartelijk danken voor het 
opponeren en de moeite die jullie hebben genomen om mijn proefschrift te beoordelen en 
naar Rotterdam af te reizen (voor hen die daar niet vandaan komen). In het speciaal wil ik jou, 
Carola, bedanken, want tijdens mijn promotie heb je mij bij veel manuscripten geholpen. 
Ondanks dat je vaak druk was/bent nam je altijd rustig de tijd voor me om analyses of 
manuscripten te bespreken en te bediscussiëren. Lisette de Groot, u wil ik ook heel hartelijk 
danken, want naast dat u onderdeel bent van mijn promotiecommissie maakte u ook deel 
uit van het B-PROOF team. 
Daarbij wil ik ook alle andere mensen van het B-PROOF team bedanken; Rosalie, Janneke, 
Elske, Nikita, Paul, Natasja, Karin, Evelien, André, Nathalie, Anke, Suzanne, Sadaf en Sandra. 
En natuurlijk ook alle studenten die ons geholpen hebben. In Rotterdam waren ook Joyce en 
Carola betrokken en het was erg fijn dat jullie met ons mee dachten. Met z’n allen hebben we 
een behoorlijke studie opgezet, draaiende weten te houden en goed afgesloten. Het heeft 
heel wat uurtjes gekost om de mensen te meten, bloed af te nemen, pillen te versturen, 
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vragenlijsten af te nemen en in te voeren, kalenders te verzamelen, datasets te maken en 
op te schonen, maar het was ontzettend leuk. Dus hartelijk dank dat ik onderdeel mocht 
uitmaken van jullie team! In het speciaal wil ik het Rotterdam B-PROOF team bedanken, 
Anke, Sandra, Suzanne en Sadaf jullie waren een geoliede machine toen ik er bij kwam. Alles 
was geordend en draaide prima, waardoor ik op het begin wat moeite had om mijn plek te 
vinden, maar uiteindelijk ging dat prima. Helaas kwam ik jullie team niet alleen versterken 
maar bracht ik, samen met Sadaf ook nog een hele nieuwe taak mee; het verzamelen van de 
medicatiedata. Nou, dat hebben we geweten, het invoeren van al de medicatievragenlijsten 
en de medicatie op de kalenders kwam boven op alle andere praktische taken en nam dus 
ook behoorlijk wat tijd in beslag. Maar eigenlijk hebben jullie nooit geklaagd en ons altijd 
super goed geholpen, top! Verder dachten jullie altijd mee en hielpen ons bij het organiseren, 
ordenen en het maken van de database. Naast al het werk hadden we gelukkig ook nog 
tijd voor leuke dingen: koffie drinken, taart eten en kletsen. Later zijn we ook etentjes gaan 
invoeren en ik vind het super leuk dat we dat nog steeds doen. Anke, het is jammer dat jij 
wat veder weg woont en we daardoor wat minder contact hebben. Ik wil je bedanken voor 
je nuchterheid, intelligentie, geduld en duidelijke uitleg. Menigmaal heb je me geholpen 
met analyses en het schrijven van manuscripten. Altijd dacht je kritisch over stukken na, wat 
mij ook aan het denken zette. Suzanne, jou wil ik bedanken voor al je energie, je vrolijkheid 
en vooral je aanpak mentaliteit. Als er wat geregeld moest worden had je dat in een mum 
van tijd gedaan, zonder te klagen. Verder heb ook jij mij menigmaal geholpen met analyses 
en datasets, echt heel fijn! Sadaf, jou wil ik bedanken voor je gezelligheid, geordendheid en 
je doorzettingsvermogen. Je had altijd het overzicht over de medicatielijsten, wat er nog 
moest gebeuren en je bent heel wat apotheken langs geweest om data te verzamelen, super. 
Zonder jou hadden we nooit alle medicatiedata bij elkaar kunnen krijgen. Sandra, je wilt 
niet de B-PROOF moeder genoemd worden, maar je was het wel. Je zorgde voor ons hele 
team. Altijd stond je voor iedereen klaar, of het nou ging om werk of privé. Verder werkte je 
heel hard en vond je het nooit erg om extra uren te maken (net als ieder ander trouwens). 
Maar ik hoorde jou nooit klagen als er om 8 uur ’s ochtends bloed geprikt moest worden 
in bijvoorbeeld Maassluis, het DXA programma uitliep en we daarna nog brieven moeten 
versturen, ach dan was je wat later thuis zo was het dan maar…. Verder zorgde je altijd voor 
goede koffie, taarten en heerlijke recepten. Ik vind het super leuk dat je mijn paranimf bent, 
want waar het ook over gaat, ik kan altijd bij je terecht! Nadat de B-PROOF afgelopen was 
en Anke, Suzanne en Sadaf vertrokken waren zaten wij samen in een kelder, maar dat was 
altijd gezellig en nu ik niet meer op de donderdagen kom ga ik dat zeker ook missen. Dus 
we moeten maar wat vaker gaan lunchen en etentjes plannen met Suzanne, Sadaf en Anke, 
als je kunt.
Naast ons ‘eigen’ team waren er in het Erasmus MC nog een aantal mensen die hielpen bij de 
studie, zoals de dames van de apotheek voor de pillen en Monique de Waardt en de andere 
medewerkers van het Tiallab. Jullie wil ik ook hartelijk bedanken. Monique, het was fijn dat je 
met ons meedacht en ons hielp om alle samples in de vriezer te vinden.
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Renger, jou wil ik bedanken voor het meedenken over al mijn manuscripten en je kritische 
commentaar. Daar was ik erg blij mee. 
Uiteraard wil ik ook alle deelnemers en apothekers bedanken.
Ook wil ik graag alle collega’s bedanken van de genetica groep, jullie hebben me wegwijs 
gemaakt ik geneticaland. Altijd kon ik bij jullie terecht voor vragen en jullie legde mij de 
voor jullie o zo simpele dingen rustig en keer op keer uit, erg fijn! Verder heb ik veel geleerd 
van de werkbesprekingen en was het gezellig op lab- en wetenschapsdagen. Linda, jou 
wil ik heel erg bedanken voor al je hulp en je gezelligheid. Je maakte altijd tijd voor mij en 
m’n dummy-vragen en verder was het gezellig om even te kletsen en je prachtige foto’s te 
bekijken. Jeroen, jou wil ik bedanken voor alle gezellige werkonderbrekingen met koffie. 
Voor ik het weet zitten we een uur te kletsen over van alles en nog wat en is het toch echt 
weer tijd om aan het werk te gaan. Maar daarna ben ik weer gefocust en kan ik goed aan de 
slag, dus wat mij betreft houden we ze er in. Fernando, hartelijk dank voor alle hulp bij het 
BMD manuscript. Het was erg fijn dat je de tijd nam om samen naar de data, resultaten en het 
manuscript te kijken. Eline, jou wil ook heel erg bedanken voor al je hulp met het plannen 
van afspraken, André achter z’n broek aan zitten als hij mijn manuscript al weken op z’n 
bureau had liggen en alle regel dingen omtrent mijn proefschrift en promotie. Je bent echt 
mijn held, ik vind het echt super fijn dat je me overal bij wilt helpen en alles zo strak regelt.
Naast de geneticagroep wil ik ook mijn collega’s bij de pharmaco-epi groep bedanken. Ik heb 
heel veel van jullie geleerd tijdens de werkbesprekingen/discussies. Verder kon ik altijd met 
analyse- en datasetvragen bij jullie terecht en vond ik het fijn dat ik even kon komen kletsen 
op de meidenkamer!
Iedereen van het ERGO team wil ik ook graag bedanken voor de hulp en de mogelijkheden 
die ik heb gekregen. In het speciaal wil ik Jolande en Frank bedanken. Frank voor het 
aanleveren en het wegwijs maken in alle datasets en Jolande voor het helpen coderen. Voor 
het helpen coderen wil ik Bert ook hartelijk danken, het was erg fijn dat je al zo veel vallen 
had gecodeerd en dat we samen de vervolgset hebben kunnen doen.
De afdeling Geriatrie wil ik ook bedanken voor alle hulp. Caroline, bij jou kon ik altijd 
binnenlopen als ik vragen had of gewoon voor een praatje.
Uiteraard wil ik ook mijn ‘nieuwe’ collega’s op de 22ste bedanken. Jullie zijn een super leuke 
groep en ik voel me heel erg thuis bij jullie. Bedankt dat jullie naar al mijn promotie-sores 
hebben geluisterd en mij er bij geholpen hebben. Régine en Wendy, naast dat ik heel veel 
van jullie leer op het gebied van gynaecologie en verloskunde vind ik het ook erg fijn dat 
jullie mij de ruimte hebben gegeven om mijn promotieonderzoek af te maken, heel veel 
dank daarvoor. 
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Nikkie en Josje, wat had ik zonder jullie gemoeten…. Voor alle praktische en inhoudelijke 
promotie/werk dingen kan ik bij jullie terecht en ook voor alle andere dingen trouwens. 
Ik vind het heel leuk dat we alle drie nog in het EMC werken en dat we nog een koffietje, 
lunch of dinertje kunnen doen. Maar ook alle dagjes en weekendjes weg met of zonder de 
mannen zijn erg gezellig. Laten we die er zeker inhouden! Het zal nu wel allemaal een beetje 
veranderen met de komst van de baby’s maar dat komt vast wel goed.
Voedingsmiepjes; Josje, Rianne, Pauline, Nanine, Eva, Esther, Hanneke en Emmy, ik vind het 
ontzettend leuk dat we nog steeds contact hebben en we jaarlijks een weekendje weg gaan. 
Het is heerlijk om gezellig met jullie thee te leuten en koekjes te eten!
Lieve Emmy, Linda en Denise, jullie kennen mij al heel lang en hebben veel verschillende 
fases in m’n leven meegemaakt. Mijn promotiefase was niet de makkelijkste en ik wil jullie 
bedanken voor jullie interesse en ook voor het soms niet vragen hoe het er mee is! Gelukkig 
hebben jullie voor heel veel afleiding gezorgd, etentjes, (stap)avondjes, dagjes, weekendjes 
en vakanties, het is altijd gezellig en ik voel me helemaal thuis bij jullie. Het is erg fijn dat ik 
alles met jullie kan delen. Hopelijk blijft onze vriendschap bestaan tot dat we oud en kreupel 
zijn en we achter de geraniums om de foto’s van vroeger zitten te lachen.
Ook wil ik alle andere Trekvogels bedanken, het is heel fijn om met jullie te trainen, wedstrijden 
te spelen, spelletjes avondjes, bbq’s en teamuitjes te doen. 
Lieve (schoon)familie, ik ben super blij dat ik jullie allemaal heb. Pappa en mamma, bedankt 
voor alle mogelijkheden die jullie mij hebben gegeven en dat jullie altijd geïnteresseerd 
zijn en mij gestimuleerd hebben. Ik wil jullie allemaal bedanken voor alle hulp en gezellige 
familie-uitjes. Iedereen staat altijd voor elkaar klaar en dat vind ik heel bijzonder en fijn! 
Martijn, je bent mijn alles! Je helpt mij met alles en daar ben ik je ongelofelijk dankbaar voor. 
Samen zijn we een topteam en je geeft mij het gevoel dat we alles aankunnen en overal wel 
uitkomen. Ik houd heel veel van jou!!
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